Climate change and mental illness: What psychiatrists can do

Article Type
Changed
Fri, 09/01/2023 - 01:15
Display Headline
Climate change and mental illness: What psychiatrists can do

Hope is engagement with the act of mapping our destinies.” 1

—Valerie Braithwaite

Why should psychiatrists care about climate change and try to mitigate its effects? First, we are tasked by society with managing the psychological and neuropsychiatric sequelae from disasters, which include climate change. The American Psychiatric Association’s position statement on climate change includes it as a legitimate focus for our specialty.2 Second, as physicians, we are morally obligated to do no harm. Since the health care sector contributes significantly to climate change (8.5% of national carbon emissions stem from health care) and causes demonstrable health impacts,3 managing these impacts and decarbonizing the health care industry is morally imperative.4 And third, psychiatric clinicians have transferrable skills that can address fears of climate change, challenge climate change denialism,5 motivate people to adopt more pro-environmental behaviors, and help communities not only endure the emotional impact of climate change but become more psychologically resilient.6

Most psychiatrists, however, did not receive formal training on climate change and the related field of disaster preparedness. For example, Harvard Medical School did not include a course on climate change in their medical student curriculum until 2023.7 In this article, we provide a basic framework of climate change and its impact on mental health, with particular focus on patients with serious mental illness (SMI). We offer concrete steps clinicians can take to prevent or mitigate harm from climate change for their patients, prepare for disasters at the level of individual patient encounters, and strengthen their clinics and communities. We also encourage clinicians to take active leadership roles in their professional organizations to be part of climate solutions, building on the trust patients continue to have in their physicians.8 Even if clinicians do not view climate change concerns under their conceived clinical care mandate, having a working knowledge about it is important because patients, paraprofessional staff, or medical trainees are likely to bring it up.9

Climate change and mental health

Climate change is harmful to human health, including mental health.10 It can impact mental health directly via its impact on brain function and neuropsychiatric sequelae, and indirectly via climate-related disasters leading to acute or chronic stress, losses, and displacement with psychiatric and psychological sequelae (Table 111-29).

Impact of climate change on mental health

Direct impact

The effects of air pollution, heat, infections, and starvation are examples of how climate change directly impacts mental health. Air pollution and brain health are a concern for psychiatry, given the well-described effects of air deterioration on the developing brain.11 In animal models, airborne pollutants lead to widespread neuroinflam­mation and cell loss via a multitude of mechanisms.12 This is consistent with worse cognitive and behavioral functions across a wide range of cognitive domains seen in children exposed to pollution compared to those who grew up in environments with healthy air.13 Even low-level exposure to air pollution increases the risk for later onset of depression, suicide, and anxiety.14 Hippocampal atrophy observed in patients with first-episode psychosis may also be partially attributable to air pollution.15 An association between heat and suicide (and to a lesser extent, aggression) has also been reported.16

Worse physical health (eg, strokes) due to excessive heat can further compound mental health via elevated rates of depression. Data from the United States and Mexico show that for each degree Celsius increase in ambient temperature, suicide rates may increase by approximately 1%.17 A meta-analysis by Frangione et al18 similarly concluded that each degree Celsius increase results in an overall risk ratio of 1.016 (95% CI, 1.012 to 1.019) for deaths by suicide and suicide attempts. Additionally, global warming is shifting the endemic areas for many infectious agents, particularly vector-borne diseases,19 to regions in which they had hitherto been unknown, increasing the risk for future outbreaks and even pandemics.20 These infectious illnesses often carry neuropsychiatric morbidity, with seizures, encephalopathy with incomplete recovery, and psychiatric syndromes occurring in many cases. Crop failure can lead to starvation during pregnancy and childhood, which has wide-ranging consequences for brain development and later physical and psychological health in adults.21,22 Mothers affected by starvation also experience negative impacts on childbearing and childrearing.23

Indirect impact

Climate change’s indirect impact on mental health can stem from the stress of living through a disaster such as an extreme weather event; from losses, including the death of friends and family members; and from becoming temporarily displaced.24 Some climate change–driven disasters can be viewed as slow-moving, such as drought and the rising of sea levels, where displacement becomes permanent. Managing mass migration from internally or externally displaced people who must abandon their communities because of climate change will have significant repercussions for all societies.25 The term “climate refugee” is not (yet) included in the United Nations’ official definition of refugees; it defines refugees as individuals who have fled their countries because of war, violence, or persecution.26 These and other bureaucratic issues can come up when clinicians are trying to help migrants with immigration-related paperwork.

Continue to: As the inevitability of climate change...

 

 

As the inevitability of climate change sinks in, its long-term ramifications have introduced a new lexicon of psychological suffering related to the crisis.27 Common terms for such distress include ecoanxiety (fear of what is happening and will happen with climate change), ecogrief (sadness about the destruction of species and natural habitats), solastalgia28 (the nostalgia an individual feels for emotionally treasured landscapes that have changed), and terrafuria or ecorage (the reaction to betrayal and inaction by governments and leaders).29 Climate-related emotions can lead to pessimism about the future and a nihilistic outlook on an individual’s ability to effect change and have agency over their life’s outcomes.

The categories of direct and indirect impacts are not mutually exclusive. A child may be starving due to weather-related crop failure as the family is forced to move to another country, then have to contend with prejudice and bullying as an immigrant, and later become anxiously preoccupied with climate change and its ability to cause further distress.

Effect on individuals with serious mental illness

Patients with SMI are particularly vulnerable to the impact of climate change. They are less resilient to climate change–related events, such as heat waves or temporary displacement from flooding, both at the personal level due to illness factors (eg, negative symptoms or cognitive impairment) and at the community level due to social factors (eg, weaker social support or poverty).

Recognizing the increased vulnerability to heat waves and preparing for them is particularly important for patients with SMI because they are at an increased risk for heat-related illnesses.30 For example, patients may not appreciate the danger from heat and live in conditions that put them at risk (ie, not having air conditioning in their home or living alone). Their illness alone impairs heat regulation31; patients with depression and anxiety also dissipate heat less effectively.32,33 Additionally, many psychiatric medications, particularly antipsychotics, impair key mechanisms of heat dissipation.34,35 Antipsychotics render organisms more poikilothermic (susceptible to environmental temperature, like cold-blooded animals) and can be anticholinergic, which impedes sweating. A recent analysis of heat-related deaths during a period of extreme and prolonged heat in British Columbia in 2021 affirmed these concerns, reporting that patients with schizophrenia had the highest odds of death during this heat-related event.36

COVID-19 has shown that flexible models of care are needed to prevent disengagement from medical and psychiatric care37 and assure continued treatment with essential medications such as clozapine38 and long-acting injectable antipsychotics39 during periods of social change, as with climate change. While telehealth was critical during the COVID-19 pandemic40 and is here to stay, it alone may be insufficient given the digital divide (patients with SMI may be less likely to have access to or be proficient in the use of digital technologies). The pandemic has shown the importance of public health efforts, including benefits from targeted outreach, with regards to vaccinations for this patient group.41,42Table 2 summarizes things clinicians should consider when preparing patients with SMI for the effects of climate change.

Preparing vulnerable patients with serious mental illness for climate change

Continue to: The psychiatrist's role

 

 

The psychiatrist’s role

There are many ways a psychiatrist can professionally get involved in addressing climate change. Table 343-53 outlines the 3 Ps of climate action (taking actions to mitigate the effects of climate change): personal, patient (and clinic), and political (advocacy).

The 3 Ps of climate action

Personal

Even if clinicians believe climate change is important for their clinical work, they may still feel overwhelmed and unsure what to do in the context of competing responsibilities. A necessary first step is overcoming paralysis from the enormity of the problem, including the need to shift away from an expanding consumption model to environmental sustainability in a short period of time.

A good starting point is to get educated on the facts of climate change and how to discuss it in an office setting as well as in your personal life. A basic principle of climate change communication is that constructive hope (progress achieved despite everything) coupled with constructive doubt (the reality of the threat) can mobilize people towards action, whereas false hope or fatalistic doubt impedes action.43 The importance of optimal public health messaging cannot be overstated; well-meaning campaigns to change behavior can fail if they emphasize the wrong message. For example, in a study examining COVID-19 messaging in >80 countries, Dorison et al44 found that negatively framed messages mostly increased anxiety but had no benefit with regard to shifting people toward desired behaviors. The best public health messages are brief, repeated, and delivered by a trusted person.45 Good messages are targeted to a concrete concern and where action would pay off now and not in some distant future.

In addition, clinicians can learn how to confront climate disavowal and difficult emotions in themselves and even plan to shift to carbon neutrality, such as purchasing carbon offsets or green sources of energy and transportation. They may not be familiar with principles of disaster preparedness or crisis communication.46 Acquiring those professional skills may suggest next steps for action. Being familiar with the challenges and resources for immigrants, including individuals displaced due to climate change, may be necessary.47 Finally, to reduce the risk of burnout, it is important to practice self-care, including strategies to reduce feelings of being overwhelmed.

Patient

In clinical encounters, clinicians can be proactive in helping patients understand their climate-related anxieties around an uncertain future, including identifying barriers to climate action.48Emphasizing that climate action has health benefits for them and their communities now (eg, less polluted air leading to fewer health problems related to pollution) may engage patients unsure about their role in the fight against climate change. This simple message overcomes the human preference for immediate and concrete benefits over investment in long-term gains. Some patients may respond to the suggestion that adopting a plant-based diet is beneficial for their own health as well as for planetary health, given the substantial contribution of animal farming to global warming.49

Continue to: Clinics must prepare for disasters...

 

 

Clinics must prepare for disasters in their communities to prevent disruption of psychiatric care by having an action plan, including the provision of medications. Such action plans should be prioritized for the most likely scenarios in an individual’s setting (eg, heat waves, wildfires, hurricanes, or flooding).

It is important to educate clinic staff and include them in planning for emergencies, because an all-hands approach and buy-in from all team members is critical. Clinicians should review how patients would continue to receive services, particularly medications, in the event of a disaster. In some cases, providing a 90-day medication supply will suffice, while in others (eg, patients receiving long-acting antipsychotics or clozapine) more preparation is necessary. Some events are predictable and can be organized annually, such as clinicians becoming vaccine ambassadors and organizing vaccine campaigns every fall50; winter-related disaster preparation every fall; and heat wave education every spring (leaflets for patients, staff, and family members; review of safety of medications during heat waves). Plan for, monitor, and coordinate medical care and services for climate refugees and other populations that may otherwise delay medical care and impede illness prevention. Finally, support climate refugees, including connecting them to services or providing trauma-informed care.

Political

Some clinicians may feel compelled to become politically active to advocate for changes within the health care system. Two initiatives related to decarbonizing the health care sector are My Green Doctor51 and Health Care Without Harm,52 which offer help in shifting your office, clinic, or hospital towards carbon neutrality.

Climate change unevenly affects people and will continue to exacerbate inequalities in society, including individuals with mental illness.53 To work toward climate justice on behalf of their patients, clinicians could join (or form) climate committees of special interest groups in their professional organizations or setting. Joining like-minded groups working on climate change at the local or national level prevents an omission of a psychiatric voice and counteracts burnout. It is important to stay focused on the root causes of the problem during activism: doing something to reduce fossil fuel use is ultimately most important.54 The concrete goal of reaching the Paris 1.5-degree Celsius climate goal is a critical benchmark against which any other action can be measured.54

Planning for the future

Over the course of history, societies have always faced difficult periods in which they needed to rebuild after natural disasters or self-inflicted catastrophes such as terrorist attacks or wars. Since the advent of the nuclear age, people have lived under the existential threat of nuclear war. The Anthropocene is a proposed geological term that reflects the enormous and possibly disastrous impact human activity has had on our planet.55 While not yet formally adopted, this term has heuristic value, directing attention and reflection to our role and its now undisputed consequences. In the future, historians will debate if the scale of our current climate crisis has been different. It is, however, not controversial that humanity will be faced with the effects of climate change for the foreseeable future.10 Already, even “normal” weather events are fueled by energy in overcharged and altered weather systems due to global warming, leading to weather events ranging from droughts to floods and storms that are more severe, more frequent, and have longer-lasting effects on communities.56

Continue to: As physicians, we are tasked...

 

 

As physicians, we are tasked by society to create and maintain a health care system that addresses the needs of our patients and the communities in which they live. Increasingly, we are forced to contend with an addition to the traditional 5 phases of acute disaster management (prevention, mitigation, preparedness, response, and recovery) to manage prolonged or even parallel disasters, where a series of disasters occurs before the community has recovered and healed. We must grapple with a sense of an “extended period of insecurity and instability” (permacrisis) and must better prepare for and prevent the polycrisis (many simultaneous crises) or the metacrisis of our “age of turmoil”57 in which we must limit global warming, mitigate its damage, and increase community resilience to adapt.

Leading by personal example and providing hope may be what some patients need, as the reality of climate change contributes to the general uneasiness about the future and doomsday scenarios to which many fall victim. At the level of professional societies, many are calling for leadership, including from mental health organizations, to bolster the “social climate,” to help us strengthen our emotional resilience and social bonds to better withstand climate change together.58 It is becoming harder to justify standing on the sidelines,59 and it may be better for both our world and a clinician’s own sanity to be engaged in professional and private hopeful action1 to address climate change. Without ecological or planetary health, there can be no mental health.

Bottom Line

Clinicians can prepare their patients for climate-related disruptions and manage the impact climate change has on their mental health. Addressing climate change at clinical and political levels is consistent with the leadership roles and professional ethics clinicians face in daily practice.

Related Resources

Drug Brand Names

Clozapine • Clozaril

References

1. Kretz L. Hope in environmental philosophy. J Agricult Environ Ethics. 2013;26:925-944. doi:10.1007/s10806-012-9425-8

2. Ursano RJ, Morganstein JC, Cooper R. Position statement on mental health and climate change. American Psychiatric Association. March 2023. Accessed August 6, 2023. https://www.psychiatry.org/getattachment/0ce71f37-61a6-44d0-8fcd-c752b7e935fd/Position-Mental-Health-Climate-Change.pdf

3. Eckelman MJ, Huang K, Lagasse R, et al. Health care pollution and public health damage in the United States: an update. Health Aff (Millwood). 2020;39:2071-2079.

4. Dzau VJ, Levine R, Barrett G, et al. Decarbonizing the U.S. health sector - a call to action. N Engl J Med. 2021;385(23):2117-2119. doi:10.1056/NEJMp2115675

5. Haase E, Augustinavicius JH, K. Climate change and psychiatry. In: Tasman A, Riba MB, Alarcón RD, et al, eds. Tasman’s Psychiatry. 5th ed. Springer; 2023.

6. Belkin G. Mental health and the global race to resilience. Psychiatr Times. 2023;40(3):26.

7. Hu SR, Yang JQ. Harvard Medical School will integrate climate change into M.D. curriculum. The Harvard Crimson. February 3, 2023. Accessed August 6, 2023. https://www.thecrimson.com/article/2023/2/3/hms-climate-curriculum/#:~:text=The%20new%20climate%20change%20curriculum,in%20arriving%20at%20climate%20solutions

8. Funk C, Gramlich J. Amid coronavirus threat, Americans generally have a high level of trust in medical doctors. Pew Research Center. March 13, 2020. Accessed August 6, 2023. https://www.pewresearch.org/fact-tank/2020/03/13/amid-coronavirus-threat-americans-generally-have-a-high-level-of-trust-in-medical-doctors/

9. Coverdale J, Balon R, Beresin EV, et al. Climate change: a call to action for the psychiatric profession. Acad Psychiatry. 2018;42(3):317-323. doi:10.1007/s40596-018-0885-7

10. Intergovernmental Panel on Climate Change. AR6 synthesis report: climate change 2023. Accessed August 6, 2023. https://www.ipcc.ch/report/sixth-assessment-report-cycle/

11. Perera FP. Multiple threats to child health from fossil fuel combustion: impacts of air pollution and climate change. Environ Health Perspect. 2017;125(2):141-148. doi:10.1289/EHP299

12. Hahad O, Lelieveldz J, Birklein F, et al. Ambient air pollution increases the risk of cerebrovascular and neuropsychiatric disorders through induction of inflammation and oxidative stress. Int J Mol Sci. 2020;21(12):4306. doi:10.3390/ijms21124306

13. Brockmeyer S, D’Angiulli A. How air pollution alters brain development: the role of neuroinflammation. Translational Neurosci. 2016;7(1):24-30. doi:10.1515/tnsci-2016-0005

14. Yang T, Wang J, Huang J, et al. Long-term exposure to multiple ambient air pollutants and association with incident depression and anxiety. JAMA Psychiatry. 2023;80:305-313. doi:10.1001/jamapsychiatry.2022.4812

15. Worthington MA, Petkova E, Freudenreich O, et al. Air pollution and hippocampal atrophy in first episode schizophrenia. Schizophr Res. 2020;218:63-69. doi:10.1016/j.schres.2020.03.001

16. Dumont C, Haase E, Dolber T, et al. Climate change and risk of completed suicide. J Nerv Ment Dis. 2020;208(7):559-565. doi:10.1097/NMD.0000000000001162

17. Burke M, Gonzales F, Bayis P, et al. Higher temperatures increase suicide rates in the United States and Mexico. Nat Climate Change. 2018;8:723-729. doi:10.1038/s41558-018-0222-x

18. Frangione B, Villamizar LAR, Lang JJ, et al. Short-term changes in meteorological conditions and suicide: a systematic review and meta-analysis. Environ Res. 2022;207:112230. doi:10.1016/j.envres.2021.112230

19. Rocklov J, Dubrow R. Climate change: an enduring challenge for vector-borne disease prevention and control. Nat Immunol. 2020;21(5):479-483. doi:10.1038/s41590-020-0648-y

20. Carlson CJ, Albery GF, Merow C, et al. Climate change increases cross-species viral transmission risk. Nature. 2022;607(7919):555-562. doi:10.1038/s41586-022-04788-w

21. Roseboom TJ, Painter RC, van Abeelen AFM, et al. Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas. 2011;70(2):141-145. doi:10.1016/j.maturitas.2011.06.017

22. Liu Y, Diao L, Xu L. The impact of childhood experience of starvations on the health of older adults: evidence from China. Int J Health Plann Manage. 2021;36(2):515-531. doi:10.1002/hpm.3099

23. Rothschild J, Haase E. The mental health of women and climate change: direct neuropsychiatric impacts and associated psychological concerns. Int J Gynaecol Obstet. 2023;160(2):405-413. doi:10.1002/ijgo.14479

24. Cianconi P, Betro S, Janiri L. The impact of climate change on mental health: a systematic descriptive review. Frontiers Psychiatry. 2020;11:74. doi:10.3389/fpsyt.2020.00074

25. World Economic Forum. Climate refugees – the world’s forgotten victims. June 18, 2021. Accessed August 6, 2023. https://www.weforum.org/agenda/2021/06/climate-refugees-the-world-s-forgotten-victims

26. Climate Refugees. Accessed August 6, 2023. https://www.climate-refugees.org/why

27. Pihkala P. Anxiety and the ecological crisis: an analysis of eco-anxiety and climate anxiety. Sustainability. 2020;12(19):7836. doi:10.3390/su12197836

28. Galway LP, Beery T, Jones-Casey K, et al. Mapping the solastalgia literature: a scoping review study. Int J Environ Res Public Health. 2019;16(15):2662. doi:10.3390/ijerph16152662

29. Albrecht GA. Earth Emotions. New Words for a New World. Cornell University Press; 2019.

30. Sorensen C, Hess J. Treatment and prevention of heat-related illness. N Engl J Med. 2022;387(15):1404-1413. doi:10.1056/NEJMcp2210623

31. Chong TWH, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res. 2004;69(2-3):149-157. doi:10.1016/s0920-9964(03)00222-6

32. von Salis S, Ehlert U, Fischer S. Altered experienced thermoregulation in depression--no evidence for an effect of early life stress. Front Psychiatry. 2021;12:620656. doi:10.3389/fpsyt.2021.620656

33. Sarchiapone M, Gramaglia C, Iosue M, et al. The association between electrodermal activity (EDA), depression and suicidal behaviour: a systematic review and narrative synthesis. BMC Psychiatry. 2018;18(1):22. doi:10.1186/s12888-017-1551-4

34. Martin-Latry K, Goumy MP, Latry P, et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry. 2007;22(6):335-338. doi:10.1016/j.eurpsy.2007.03.007

35. Ebi KL, Capon A, Berry P, et al. Hot weather and heat extremes: health risks. Lancet. 2021;398(10301):698-708. doi:10.1016/S0140-6736(21)01208-3

36. Lee MJ, McLean KE, Kuo M, et al. Chronic diseases associated with mortality in British Columbia, Canada during the 2021 Western North America extreme heat event. Geohealth. 2023;7(3):e2022GH000729. doi:10.1029/2022GH000729

37. Busch AB, Huskamp HA, Raja P, et al. Disruptions in care for Medicare beneficiaries with severe mental illness during the COVID-19 pandemic. JAMA Netw Open. 2022;5(1):e2145677. doi:10.1001/jamanetworkopen.2021.45677

38. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45(3):222-223. doi:10.1503/jpn.200061

39. MacLaurin SA, Mulligan C, Van Alphen MU, et al. Optimal long-acting injectable antipsychotic management during COVID-19. J Clin Psychiatry. 2021;82(1): 20l13730. doi:10.4088/JCP.20l13730

40. Bartels SJ, Baggett TP, Freudenreich O, et al. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness. Psychiatr Serv. 2020;71(10):1078-1081. doi:10.1176/appi.ps.202000244

41. Van Alphen MU, Lim C, Freudenreich O. Mobile vaccine clinics for patients with serious mental illness and health care workers in outpatient mental health clinics. Psychiatr Serv. February 8, 2023. doi:10.1176/appi.ps.20220460

42. Lim C, Van Alphen MU, Maclaurin S, et al. Increasing COVID-19 vaccination rates among patients with serious mental illness: a pilot intervention study. Psychiatr Serv. 2022;73(11):1274-1277. doi:10.1176/appi.ps.202100702

43. Marlon JR, Bloodhart B, Ballew MT, et al. How hope and doubt affect climate change mobilization. Front Commun. May 21, 2019. doi:10.3389/fcomm.2019.00020

44. Dorison CA, Lerner JS, Heller BH, et al. In COVID-19 health messaging, loss framing increases anxiety with little-to-no concomitant benefits: experimental evidence from 84 countries. Affective Sci. 2022;3(3):577-602. doi:10.1007/s42761-022-00128-3

45. Maibach E. Increasing public awareness and facilitating behavior change: two guiding heuristics. George Mason University, Center for Climate Change Communication. September 2015. Accessed August 6, 2023. https://www.climatechangecommunication.org/wp-content/uploads/2018/06/Maibach-Two-hueristics-September-2015-revised.pdf

46. Koh KA, Raviola G, Stoddard FJ Jr. Psychiatry and crisis communication during COVID-19: a view from the trenches. Psychiatr Serv. 2021;72(5):615. doi:10.1176/appi.ps.202000912

47. Velez G, Adam B, Shadid O, et al. The clock is ticking: are we prepared for mass climate migration? Psychiatr News. March 24, 2023. Accessed August 6, 2023. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2023.04.4.3

48. Ingle HE, Mikulewicz M. Mental health and climate change: tackling invisible injustice. Lancet Planet Health. 2020;4:e128-e130. doi:10.1016/S2542-5196(20)30081-4

49. Shah UA, Merlo G. Personal and planetary health--the connection with dietary choices. JAMA. 2023;329(21):1823-1824. doi:10.1001/jama.2023.6118

50. Lim C, Van Alphen MU, Freudenreich O. Becoming vaccine ambassadors: a new role for psychiatrists. Current Psychiatry. 2021;20(8):10-11,17-21,26-28,38. doi:10.12788/cp.0155

51. My Green Doctor. Accessed August 6, 2023. https://mygreendoctor.org/

52. Healthcare Without Harm. Accessed August 6, 2023. https://noharm.org/

53. Levy BS, Patz JA. Climate change, human rights, and social justice. Ann Glob Health. 2015;81:310-322.

54. Intergovernmental Panel on Climate Change. Global warming of 1.5° C 2018. Accessed August 6, 2023. https://www.ipcc.ch/sr15/

55. Steffen W, Crutzen J, McNeill JR. The Anthropocene: are humans now overwhelming the great forces of nature? Ambio. 2007;36(8):614-621. doi:10.1579/0044-7447(2007)36[614:taahno]2.0.co;2

56. American Meteorological Society. Explaining extreme events from a climate perspective. Accessed August 6, 2023. https://www.ametsoc.org/ams/index.cfm/publications/bulletin-of-the-american-meteorological-society-bams/explaining-extreme-events-from-a-climate-perspective/

57. Nierenberg AA. Coping in the age of turmoil. Psychiatr Ann. 2022;52(7):263. July 1, 2022. doi:10.3928/23258160-20220701-01

58. Belkin G. Leadership for the social climate. N Engl J Med. 2020;382(21):1975-1977. doi:10.1056/NEJMp2001507

59. Skinner JR. Doctors and climate change: first do no harm. J Paediatr Child Health. 2021;57(11):1754-1758. doi:10.1111/jpc.15658

Article PDF
Author and Disclosure Information

Oliver Freudenreich, MD, FACLP
Co-Director, Massachusetts General Hospital Psychosis Clinical and Research Program
Director, Massachusetts General Hospital Fellowship in Public and Community Psychiatry
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Katherine A. Koh, MD, MSc
Co-Chair, Disaster Readiness Committee, Massachusetts Psychiatry Society
Assistant Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Elizabeth K. Haase, MD
Chair, Climate Committee, Group for the Advancement of Psychiatry
Physician Chief, Carson Tahoe Regional Medical Center Behavioral Health
Clinical Professor of Psychiatry
University of Nevada School of Medicine at Reno
Reno, Nevada

Disclosures
Dr. Freudenreich has served as a consultant for Alkermes, the American Psychiatric Association, Janssen, Karuna, Neurocrine, and Vida, received research grants from Alkermes, Janssen, Karuna, and Otsuka, received medical education honoraria from Elsevier and Medscape, and received royalties from Springer Publishing, UpToDate, and Wolters Kluwer. The other authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Issue
Current Psychiatry - 22(9)
Publications
Topics
Page Number
32-39
Sections
Author and Disclosure Information

Oliver Freudenreich, MD, FACLP
Co-Director, Massachusetts General Hospital Psychosis Clinical and Research Program
Director, Massachusetts General Hospital Fellowship in Public and Community Psychiatry
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Katherine A. Koh, MD, MSc
Co-Chair, Disaster Readiness Committee, Massachusetts Psychiatry Society
Assistant Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Elizabeth K. Haase, MD
Chair, Climate Committee, Group for the Advancement of Psychiatry
Physician Chief, Carson Tahoe Regional Medical Center Behavioral Health
Clinical Professor of Psychiatry
University of Nevada School of Medicine at Reno
Reno, Nevada

Disclosures
Dr. Freudenreich has served as a consultant for Alkermes, the American Psychiatric Association, Janssen, Karuna, Neurocrine, and Vida, received research grants from Alkermes, Janssen, Karuna, and Otsuka, received medical education honoraria from Elsevier and Medscape, and received royalties from Springer Publishing, UpToDate, and Wolters Kluwer. The other authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Author and Disclosure Information

Oliver Freudenreich, MD, FACLP
Co-Director, Massachusetts General Hospital Psychosis Clinical and Research Program
Director, Massachusetts General Hospital Fellowship in Public and Community Psychiatry
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Katherine A. Koh, MD, MSc
Co-Chair, Disaster Readiness Committee, Massachusetts Psychiatry Society
Assistant Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Elizabeth K. Haase, MD
Chair, Climate Committee, Group for the Advancement of Psychiatry
Physician Chief, Carson Tahoe Regional Medical Center Behavioral Health
Clinical Professor of Psychiatry
University of Nevada School of Medicine at Reno
Reno, Nevada

Disclosures
Dr. Freudenreich has served as a consultant for Alkermes, the American Psychiatric Association, Janssen, Karuna, Neurocrine, and Vida, received research grants from Alkermes, Janssen, Karuna, and Otsuka, received medical education honoraria from Elsevier and Medscape, and received royalties from Springer Publishing, UpToDate, and Wolters Kluwer. The other authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Article PDF
Article PDF

Hope is engagement with the act of mapping our destinies.” 1

—Valerie Braithwaite

Why should psychiatrists care about climate change and try to mitigate its effects? First, we are tasked by society with managing the psychological and neuropsychiatric sequelae from disasters, which include climate change. The American Psychiatric Association’s position statement on climate change includes it as a legitimate focus for our specialty.2 Second, as physicians, we are morally obligated to do no harm. Since the health care sector contributes significantly to climate change (8.5% of national carbon emissions stem from health care) and causes demonstrable health impacts,3 managing these impacts and decarbonizing the health care industry is morally imperative.4 And third, psychiatric clinicians have transferrable skills that can address fears of climate change, challenge climate change denialism,5 motivate people to adopt more pro-environmental behaviors, and help communities not only endure the emotional impact of climate change but become more psychologically resilient.6

Most psychiatrists, however, did not receive formal training on climate change and the related field of disaster preparedness. For example, Harvard Medical School did not include a course on climate change in their medical student curriculum until 2023.7 In this article, we provide a basic framework of climate change and its impact on mental health, with particular focus on patients with serious mental illness (SMI). We offer concrete steps clinicians can take to prevent or mitigate harm from climate change for their patients, prepare for disasters at the level of individual patient encounters, and strengthen their clinics and communities. We also encourage clinicians to take active leadership roles in their professional organizations to be part of climate solutions, building on the trust patients continue to have in their physicians.8 Even if clinicians do not view climate change concerns under their conceived clinical care mandate, having a working knowledge about it is important because patients, paraprofessional staff, or medical trainees are likely to bring it up.9

Climate change and mental health

Climate change is harmful to human health, including mental health.10 It can impact mental health directly via its impact on brain function and neuropsychiatric sequelae, and indirectly via climate-related disasters leading to acute or chronic stress, losses, and displacement with psychiatric and psychological sequelae (Table 111-29).

Impact of climate change on mental health

Direct impact

The effects of air pollution, heat, infections, and starvation are examples of how climate change directly impacts mental health. Air pollution and brain health are a concern for psychiatry, given the well-described effects of air deterioration on the developing brain.11 In animal models, airborne pollutants lead to widespread neuroinflam­mation and cell loss via a multitude of mechanisms.12 This is consistent with worse cognitive and behavioral functions across a wide range of cognitive domains seen in children exposed to pollution compared to those who grew up in environments with healthy air.13 Even low-level exposure to air pollution increases the risk for later onset of depression, suicide, and anxiety.14 Hippocampal atrophy observed in patients with first-episode psychosis may also be partially attributable to air pollution.15 An association between heat and suicide (and to a lesser extent, aggression) has also been reported.16

Worse physical health (eg, strokes) due to excessive heat can further compound mental health via elevated rates of depression. Data from the United States and Mexico show that for each degree Celsius increase in ambient temperature, suicide rates may increase by approximately 1%.17 A meta-analysis by Frangione et al18 similarly concluded that each degree Celsius increase results in an overall risk ratio of 1.016 (95% CI, 1.012 to 1.019) for deaths by suicide and suicide attempts. Additionally, global warming is shifting the endemic areas for many infectious agents, particularly vector-borne diseases,19 to regions in which they had hitherto been unknown, increasing the risk for future outbreaks and even pandemics.20 These infectious illnesses often carry neuropsychiatric morbidity, with seizures, encephalopathy with incomplete recovery, and psychiatric syndromes occurring in many cases. Crop failure can lead to starvation during pregnancy and childhood, which has wide-ranging consequences for brain development and later physical and psychological health in adults.21,22 Mothers affected by starvation also experience negative impacts on childbearing and childrearing.23

Indirect impact

Climate change’s indirect impact on mental health can stem from the stress of living through a disaster such as an extreme weather event; from losses, including the death of friends and family members; and from becoming temporarily displaced.24 Some climate change–driven disasters can be viewed as slow-moving, such as drought and the rising of sea levels, where displacement becomes permanent. Managing mass migration from internally or externally displaced people who must abandon their communities because of climate change will have significant repercussions for all societies.25 The term “climate refugee” is not (yet) included in the United Nations’ official definition of refugees; it defines refugees as individuals who have fled their countries because of war, violence, or persecution.26 These and other bureaucratic issues can come up when clinicians are trying to help migrants with immigration-related paperwork.

Continue to: As the inevitability of climate change...

 

 

As the inevitability of climate change sinks in, its long-term ramifications have introduced a new lexicon of psychological suffering related to the crisis.27 Common terms for such distress include ecoanxiety (fear of what is happening and will happen with climate change), ecogrief (sadness about the destruction of species and natural habitats), solastalgia28 (the nostalgia an individual feels for emotionally treasured landscapes that have changed), and terrafuria or ecorage (the reaction to betrayal and inaction by governments and leaders).29 Climate-related emotions can lead to pessimism about the future and a nihilistic outlook on an individual’s ability to effect change and have agency over their life’s outcomes.

The categories of direct and indirect impacts are not mutually exclusive. A child may be starving due to weather-related crop failure as the family is forced to move to another country, then have to contend with prejudice and bullying as an immigrant, and later become anxiously preoccupied with climate change and its ability to cause further distress.

Effect on individuals with serious mental illness

Patients with SMI are particularly vulnerable to the impact of climate change. They are less resilient to climate change–related events, such as heat waves or temporary displacement from flooding, both at the personal level due to illness factors (eg, negative symptoms or cognitive impairment) and at the community level due to social factors (eg, weaker social support or poverty).

Recognizing the increased vulnerability to heat waves and preparing for them is particularly important for patients with SMI because they are at an increased risk for heat-related illnesses.30 For example, patients may not appreciate the danger from heat and live in conditions that put them at risk (ie, not having air conditioning in their home or living alone). Their illness alone impairs heat regulation31; patients with depression and anxiety also dissipate heat less effectively.32,33 Additionally, many psychiatric medications, particularly antipsychotics, impair key mechanisms of heat dissipation.34,35 Antipsychotics render organisms more poikilothermic (susceptible to environmental temperature, like cold-blooded animals) and can be anticholinergic, which impedes sweating. A recent analysis of heat-related deaths during a period of extreme and prolonged heat in British Columbia in 2021 affirmed these concerns, reporting that patients with schizophrenia had the highest odds of death during this heat-related event.36

COVID-19 has shown that flexible models of care are needed to prevent disengagement from medical and psychiatric care37 and assure continued treatment with essential medications such as clozapine38 and long-acting injectable antipsychotics39 during periods of social change, as with climate change. While telehealth was critical during the COVID-19 pandemic40 and is here to stay, it alone may be insufficient given the digital divide (patients with SMI may be less likely to have access to or be proficient in the use of digital technologies). The pandemic has shown the importance of public health efforts, including benefits from targeted outreach, with regards to vaccinations for this patient group.41,42Table 2 summarizes things clinicians should consider when preparing patients with SMI for the effects of climate change.

Preparing vulnerable patients with serious mental illness for climate change

Continue to: The psychiatrist's role

 

 

The psychiatrist’s role

There are many ways a psychiatrist can professionally get involved in addressing climate change. Table 343-53 outlines the 3 Ps of climate action (taking actions to mitigate the effects of climate change): personal, patient (and clinic), and political (advocacy).

The 3 Ps of climate action

Personal

Even if clinicians believe climate change is important for their clinical work, they may still feel overwhelmed and unsure what to do in the context of competing responsibilities. A necessary first step is overcoming paralysis from the enormity of the problem, including the need to shift away from an expanding consumption model to environmental sustainability in a short period of time.

A good starting point is to get educated on the facts of climate change and how to discuss it in an office setting as well as in your personal life. A basic principle of climate change communication is that constructive hope (progress achieved despite everything) coupled with constructive doubt (the reality of the threat) can mobilize people towards action, whereas false hope or fatalistic doubt impedes action.43 The importance of optimal public health messaging cannot be overstated; well-meaning campaigns to change behavior can fail if they emphasize the wrong message. For example, in a study examining COVID-19 messaging in >80 countries, Dorison et al44 found that negatively framed messages mostly increased anxiety but had no benefit with regard to shifting people toward desired behaviors. The best public health messages are brief, repeated, and delivered by a trusted person.45 Good messages are targeted to a concrete concern and where action would pay off now and not in some distant future.

In addition, clinicians can learn how to confront climate disavowal and difficult emotions in themselves and even plan to shift to carbon neutrality, such as purchasing carbon offsets or green sources of energy and transportation. They may not be familiar with principles of disaster preparedness or crisis communication.46 Acquiring those professional skills may suggest next steps for action. Being familiar with the challenges and resources for immigrants, including individuals displaced due to climate change, may be necessary.47 Finally, to reduce the risk of burnout, it is important to practice self-care, including strategies to reduce feelings of being overwhelmed.

Patient

In clinical encounters, clinicians can be proactive in helping patients understand their climate-related anxieties around an uncertain future, including identifying barriers to climate action.48Emphasizing that climate action has health benefits for them and their communities now (eg, less polluted air leading to fewer health problems related to pollution) may engage patients unsure about their role in the fight against climate change. This simple message overcomes the human preference for immediate and concrete benefits over investment in long-term gains. Some patients may respond to the suggestion that adopting a plant-based diet is beneficial for their own health as well as for planetary health, given the substantial contribution of animal farming to global warming.49

Continue to: Clinics must prepare for disasters...

 

 

Clinics must prepare for disasters in their communities to prevent disruption of psychiatric care by having an action plan, including the provision of medications. Such action plans should be prioritized for the most likely scenarios in an individual’s setting (eg, heat waves, wildfires, hurricanes, or flooding).

It is important to educate clinic staff and include them in planning for emergencies, because an all-hands approach and buy-in from all team members is critical. Clinicians should review how patients would continue to receive services, particularly medications, in the event of a disaster. In some cases, providing a 90-day medication supply will suffice, while in others (eg, patients receiving long-acting antipsychotics or clozapine) more preparation is necessary. Some events are predictable and can be organized annually, such as clinicians becoming vaccine ambassadors and organizing vaccine campaigns every fall50; winter-related disaster preparation every fall; and heat wave education every spring (leaflets for patients, staff, and family members; review of safety of medications during heat waves). Plan for, monitor, and coordinate medical care and services for climate refugees and other populations that may otherwise delay medical care and impede illness prevention. Finally, support climate refugees, including connecting them to services or providing trauma-informed care.

Political

Some clinicians may feel compelled to become politically active to advocate for changes within the health care system. Two initiatives related to decarbonizing the health care sector are My Green Doctor51 and Health Care Without Harm,52 which offer help in shifting your office, clinic, or hospital towards carbon neutrality.

Climate change unevenly affects people and will continue to exacerbate inequalities in society, including individuals with mental illness.53 To work toward climate justice on behalf of their patients, clinicians could join (or form) climate committees of special interest groups in their professional organizations or setting. Joining like-minded groups working on climate change at the local or national level prevents an omission of a psychiatric voice and counteracts burnout. It is important to stay focused on the root causes of the problem during activism: doing something to reduce fossil fuel use is ultimately most important.54 The concrete goal of reaching the Paris 1.5-degree Celsius climate goal is a critical benchmark against which any other action can be measured.54

Planning for the future

Over the course of history, societies have always faced difficult periods in which they needed to rebuild after natural disasters or self-inflicted catastrophes such as terrorist attacks or wars. Since the advent of the nuclear age, people have lived under the existential threat of nuclear war. The Anthropocene is a proposed geological term that reflects the enormous and possibly disastrous impact human activity has had on our planet.55 While not yet formally adopted, this term has heuristic value, directing attention and reflection to our role and its now undisputed consequences. In the future, historians will debate if the scale of our current climate crisis has been different. It is, however, not controversial that humanity will be faced with the effects of climate change for the foreseeable future.10 Already, even “normal” weather events are fueled by energy in overcharged and altered weather systems due to global warming, leading to weather events ranging from droughts to floods and storms that are more severe, more frequent, and have longer-lasting effects on communities.56

Continue to: As physicians, we are tasked...

 

 

As physicians, we are tasked by society to create and maintain a health care system that addresses the needs of our patients and the communities in which they live. Increasingly, we are forced to contend with an addition to the traditional 5 phases of acute disaster management (prevention, mitigation, preparedness, response, and recovery) to manage prolonged or even parallel disasters, where a series of disasters occurs before the community has recovered and healed. We must grapple with a sense of an “extended period of insecurity and instability” (permacrisis) and must better prepare for and prevent the polycrisis (many simultaneous crises) or the metacrisis of our “age of turmoil”57 in which we must limit global warming, mitigate its damage, and increase community resilience to adapt.

Leading by personal example and providing hope may be what some patients need, as the reality of climate change contributes to the general uneasiness about the future and doomsday scenarios to which many fall victim. At the level of professional societies, many are calling for leadership, including from mental health organizations, to bolster the “social climate,” to help us strengthen our emotional resilience and social bonds to better withstand climate change together.58 It is becoming harder to justify standing on the sidelines,59 and it may be better for both our world and a clinician’s own sanity to be engaged in professional and private hopeful action1 to address climate change. Without ecological or planetary health, there can be no mental health.

Bottom Line

Clinicians can prepare their patients for climate-related disruptions and manage the impact climate change has on their mental health. Addressing climate change at clinical and political levels is consistent with the leadership roles and professional ethics clinicians face in daily practice.

Related Resources

Drug Brand Names

Clozapine • Clozaril

Hope is engagement with the act of mapping our destinies.” 1

—Valerie Braithwaite

Why should psychiatrists care about climate change and try to mitigate its effects? First, we are tasked by society with managing the psychological and neuropsychiatric sequelae from disasters, which include climate change. The American Psychiatric Association’s position statement on climate change includes it as a legitimate focus for our specialty.2 Second, as physicians, we are morally obligated to do no harm. Since the health care sector contributes significantly to climate change (8.5% of national carbon emissions stem from health care) and causes demonstrable health impacts,3 managing these impacts and decarbonizing the health care industry is morally imperative.4 And third, psychiatric clinicians have transferrable skills that can address fears of climate change, challenge climate change denialism,5 motivate people to adopt more pro-environmental behaviors, and help communities not only endure the emotional impact of climate change but become more psychologically resilient.6

Most psychiatrists, however, did not receive formal training on climate change and the related field of disaster preparedness. For example, Harvard Medical School did not include a course on climate change in their medical student curriculum until 2023.7 In this article, we provide a basic framework of climate change and its impact on mental health, with particular focus on patients with serious mental illness (SMI). We offer concrete steps clinicians can take to prevent or mitigate harm from climate change for their patients, prepare for disasters at the level of individual patient encounters, and strengthen their clinics and communities. We also encourage clinicians to take active leadership roles in their professional organizations to be part of climate solutions, building on the trust patients continue to have in their physicians.8 Even if clinicians do not view climate change concerns under their conceived clinical care mandate, having a working knowledge about it is important because patients, paraprofessional staff, or medical trainees are likely to bring it up.9

Climate change and mental health

Climate change is harmful to human health, including mental health.10 It can impact mental health directly via its impact on brain function and neuropsychiatric sequelae, and indirectly via climate-related disasters leading to acute or chronic stress, losses, and displacement with psychiatric and psychological sequelae (Table 111-29).

Impact of climate change on mental health

Direct impact

The effects of air pollution, heat, infections, and starvation are examples of how climate change directly impacts mental health. Air pollution and brain health are a concern for psychiatry, given the well-described effects of air deterioration on the developing brain.11 In animal models, airborne pollutants lead to widespread neuroinflam­mation and cell loss via a multitude of mechanisms.12 This is consistent with worse cognitive and behavioral functions across a wide range of cognitive domains seen in children exposed to pollution compared to those who grew up in environments with healthy air.13 Even low-level exposure to air pollution increases the risk for later onset of depression, suicide, and anxiety.14 Hippocampal atrophy observed in patients with first-episode psychosis may also be partially attributable to air pollution.15 An association between heat and suicide (and to a lesser extent, aggression) has also been reported.16

Worse physical health (eg, strokes) due to excessive heat can further compound mental health via elevated rates of depression. Data from the United States and Mexico show that for each degree Celsius increase in ambient temperature, suicide rates may increase by approximately 1%.17 A meta-analysis by Frangione et al18 similarly concluded that each degree Celsius increase results in an overall risk ratio of 1.016 (95% CI, 1.012 to 1.019) for deaths by suicide and suicide attempts. Additionally, global warming is shifting the endemic areas for many infectious agents, particularly vector-borne diseases,19 to regions in which they had hitherto been unknown, increasing the risk for future outbreaks and even pandemics.20 These infectious illnesses often carry neuropsychiatric morbidity, with seizures, encephalopathy with incomplete recovery, and psychiatric syndromes occurring in many cases. Crop failure can lead to starvation during pregnancy and childhood, which has wide-ranging consequences for brain development and later physical and psychological health in adults.21,22 Mothers affected by starvation also experience negative impacts on childbearing and childrearing.23

Indirect impact

Climate change’s indirect impact on mental health can stem from the stress of living through a disaster such as an extreme weather event; from losses, including the death of friends and family members; and from becoming temporarily displaced.24 Some climate change–driven disasters can be viewed as slow-moving, such as drought and the rising of sea levels, where displacement becomes permanent. Managing mass migration from internally or externally displaced people who must abandon their communities because of climate change will have significant repercussions for all societies.25 The term “climate refugee” is not (yet) included in the United Nations’ official definition of refugees; it defines refugees as individuals who have fled their countries because of war, violence, or persecution.26 These and other bureaucratic issues can come up when clinicians are trying to help migrants with immigration-related paperwork.

Continue to: As the inevitability of climate change...

 

 

As the inevitability of climate change sinks in, its long-term ramifications have introduced a new lexicon of psychological suffering related to the crisis.27 Common terms for such distress include ecoanxiety (fear of what is happening and will happen with climate change), ecogrief (sadness about the destruction of species and natural habitats), solastalgia28 (the nostalgia an individual feels for emotionally treasured landscapes that have changed), and terrafuria or ecorage (the reaction to betrayal and inaction by governments and leaders).29 Climate-related emotions can lead to pessimism about the future and a nihilistic outlook on an individual’s ability to effect change and have agency over their life’s outcomes.

The categories of direct and indirect impacts are not mutually exclusive. A child may be starving due to weather-related crop failure as the family is forced to move to another country, then have to contend with prejudice and bullying as an immigrant, and later become anxiously preoccupied with climate change and its ability to cause further distress.

Effect on individuals with serious mental illness

Patients with SMI are particularly vulnerable to the impact of climate change. They are less resilient to climate change–related events, such as heat waves or temporary displacement from flooding, both at the personal level due to illness factors (eg, negative symptoms or cognitive impairment) and at the community level due to social factors (eg, weaker social support or poverty).

Recognizing the increased vulnerability to heat waves and preparing for them is particularly important for patients with SMI because they are at an increased risk for heat-related illnesses.30 For example, patients may not appreciate the danger from heat and live in conditions that put them at risk (ie, not having air conditioning in their home or living alone). Their illness alone impairs heat regulation31; patients with depression and anxiety also dissipate heat less effectively.32,33 Additionally, many psychiatric medications, particularly antipsychotics, impair key mechanisms of heat dissipation.34,35 Antipsychotics render organisms more poikilothermic (susceptible to environmental temperature, like cold-blooded animals) and can be anticholinergic, which impedes sweating. A recent analysis of heat-related deaths during a period of extreme and prolonged heat in British Columbia in 2021 affirmed these concerns, reporting that patients with schizophrenia had the highest odds of death during this heat-related event.36

COVID-19 has shown that flexible models of care are needed to prevent disengagement from medical and psychiatric care37 and assure continued treatment with essential medications such as clozapine38 and long-acting injectable antipsychotics39 during periods of social change, as with climate change. While telehealth was critical during the COVID-19 pandemic40 and is here to stay, it alone may be insufficient given the digital divide (patients with SMI may be less likely to have access to or be proficient in the use of digital technologies). The pandemic has shown the importance of public health efforts, including benefits from targeted outreach, with regards to vaccinations for this patient group.41,42Table 2 summarizes things clinicians should consider when preparing patients with SMI for the effects of climate change.

Preparing vulnerable patients with serious mental illness for climate change

Continue to: The psychiatrist's role

 

 

The psychiatrist’s role

There are many ways a psychiatrist can professionally get involved in addressing climate change. Table 343-53 outlines the 3 Ps of climate action (taking actions to mitigate the effects of climate change): personal, patient (and clinic), and political (advocacy).

The 3 Ps of climate action

Personal

Even if clinicians believe climate change is important for their clinical work, they may still feel overwhelmed and unsure what to do in the context of competing responsibilities. A necessary first step is overcoming paralysis from the enormity of the problem, including the need to shift away from an expanding consumption model to environmental sustainability in a short period of time.

A good starting point is to get educated on the facts of climate change and how to discuss it in an office setting as well as in your personal life. A basic principle of climate change communication is that constructive hope (progress achieved despite everything) coupled with constructive doubt (the reality of the threat) can mobilize people towards action, whereas false hope or fatalistic doubt impedes action.43 The importance of optimal public health messaging cannot be overstated; well-meaning campaigns to change behavior can fail if they emphasize the wrong message. For example, in a study examining COVID-19 messaging in >80 countries, Dorison et al44 found that negatively framed messages mostly increased anxiety but had no benefit with regard to shifting people toward desired behaviors. The best public health messages are brief, repeated, and delivered by a trusted person.45 Good messages are targeted to a concrete concern and where action would pay off now and not in some distant future.

In addition, clinicians can learn how to confront climate disavowal and difficult emotions in themselves and even plan to shift to carbon neutrality, such as purchasing carbon offsets or green sources of energy and transportation. They may not be familiar with principles of disaster preparedness or crisis communication.46 Acquiring those professional skills may suggest next steps for action. Being familiar with the challenges and resources for immigrants, including individuals displaced due to climate change, may be necessary.47 Finally, to reduce the risk of burnout, it is important to practice self-care, including strategies to reduce feelings of being overwhelmed.

Patient

In clinical encounters, clinicians can be proactive in helping patients understand their climate-related anxieties around an uncertain future, including identifying barriers to climate action.48Emphasizing that climate action has health benefits for them and their communities now (eg, less polluted air leading to fewer health problems related to pollution) may engage patients unsure about their role in the fight against climate change. This simple message overcomes the human preference for immediate and concrete benefits over investment in long-term gains. Some patients may respond to the suggestion that adopting a plant-based diet is beneficial for their own health as well as for planetary health, given the substantial contribution of animal farming to global warming.49

Continue to: Clinics must prepare for disasters...

 

 

Clinics must prepare for disasters in their communities to prevent disruption of psychiatric care by having an action plan, including the provision of medications. Such action plans should be prioritized for the most likely scenarios in an individual’s setting (eg, heat waves, wildfires, hurricanes, or flooding).

It is important to educate clinic staff and include them in planning for emergencies, because an all-hands approach and buy-in from all team members is critical. Clinicians should review how patients would continue to receive services, particularly medications, in the event of a disaster. In some cases, providing a 90-day medication supply will suffice, while in others (eg, patients receiving long-acting antipsychotics or clozapine) more preparation is necessary. Some events are predictable and can be organized annually, such as clinicians becoming vaccine ambassadors and organizing vaccine campaigns every fall50; winter-related disaster preparation every fall; and heat wave education every spring (leaflets for patients, staff, and family members; review of safety of medications during heat waves). Plan for, monitor, and coordinate medical care and services for climate refugees and other populations that may otherwise delay medical care and impede illness prevention. Finally, support climate refugees, including connecting them to services or providing trauma-informed care.

Political

Some clinicians may feel compelled to become politically active to advocate for changes within the health care system. Two initiatives related to decarbonizing the health care sector are My Green Doctor51 and Health Care Without Harm,52 which offer help in shifting your office, clinic, or hospital towards carbon neutrality.

Climate change unevenly affects people and will continue to exacerbate inequalities in society, including individuals with mental illness.53 To work toward climate justice on behalf of their patients, clinicians could join (or form) climate committees of special interest groups in their professional organizations or setting. Joining like-minded groups working on climate change at the local or national level prevents an omission of a psychiatric voice and counteracts burnout. It is important to stay focused on the root causes of the problem during activism: doing something to reduce fossil fuel use is ultimately most important.54 The concrete goal of reaching the Paris 1.5-degree Celsius climate goal is a critical benchmark against which any other action can be measured.54

Planning for the future

Over the course of history, societies have always faced difficult periods in which they needed to rebuild after natural disasters or self-inflicted catastrophes such as terrorist attacks or wars. Since the advent of the nuclear age, people have lived under the existential threat of nuclear war. The Anthropocene is a proposed geological term that reflects the enormous and possibly disastrous impact human activity has had on our planet.55 While not yet formally adopted, this term has heuristic value, directing attention and reflection to our role and its now undisputed consequences. In the future, historians will debate if the scale of our current climate crisis has been different. It is, however, not controversial that humanity will be faced with the effects of climate change for the foreseeable future.10 Already, even “normal” weather events are fueled by energy in overcharged and altered weather systems due to global warming, leading to weather events ranging from droughts to floods and storms that are more severe, more frequent, and have longer-lasting effects on communities.56

Continue to: As physicians, we are tasked...

 

 

As physicians, we are tasked by society to create and maintain a health care system that addresses the needs of our patients and the communities in which they live. Increasingly, we are forced to contend with an addition to the traditional 5 phases of acute disaster management (prevention, mitigation, preparedness, response, and recovery) to manage prolonged or even parallel disasters, where a series of disasters occurs before the community has recovered and healed. We must grapple with a sense of an “extended period of insecurity and instability” (permacrisis) and must better prepare for and prevent the polycrisis (many simultaneous crises) or the metacrisis of our “age of turmoil”57 in which we must limit global warming, mitigate its damage, and increase community resilience to adapt.

Leading by personal example and providing hope may be what some patients need, as the reality of climate change contributes to the general uneasiness about the future and doomsday scenarios to which many fall victim. At the level of professional societies, many are calling for leadership, including from mental health organizations, to bolster the “social climate,” to help us strengthen our emotional resilience and social bonds to better withstand climate change together.58 It is becoming harder to justify standing on the sidelines,59 and it may be better for both our world and a clinician’s own sanity to be engaged in professional and private hopeful action1 to address climate change. Without ecological or planetary health, there can be no mental health.

Bottom Line

Clinicians can prepare their patients for climate-related disruptions and manage the impact climate change has on their mental health. Addressing climate change at clinical and political levels is consistent with the leadership roles and professional ethics clinicians face in daily practice.

Related Resources

Drug Brand Names

Clozapine • Clozaril

References

1. Kretz L. Hope in environmental philosophy. J Agricult Environ Ethics. 2013;26:925-944. doi:10.1007/s10806-012-9425-8

2. Ursano RJ, Morganstein JC, Cooper R. Position statement on mental health and climate change. American Psychiatric Association. March 2023. Accessed August 6, 2023. https://www.psychiatry.org/getattachment/0ce71f37-61a6-44d0-8fcd-c752b7e935fd/Position-Mental-Health-Climate-Change.pdf

3. Eckelman MJ, Huang K, Lagasse R, et al. Health care pollution and public health damage in the United States: an update. Health Aff (Millwood). 2020;39:2071-2079.

4. Dzau VJ, Levine R, Barrett G, et al. Decarbonizing the U.S. health sector - a call to action. N Engl J Med. 2021;385(23):2117-2119. doi:10.1056/NEJMp2115675

5. Haase E, Augustinavicius JH, K. Climate change and psychiatry. In: Tasman A, Riba MB, Alarcón RD, et al, eds. Tasman’s Psychiatry. 5th ed. Springer; 2023.

6. Belkin G. Mental health and the global race to resilience. Psychiatr Times. 2023;40(3):26.

7. Hu SR, Yang JQ. Harvard Medical School will integrate climate change into M.D. curriculum. The Harvard Crimson. February 3, 2023. Accessed August 6, 2023. https://www.thecrimson.com/article/2023/2/3/hms-climate-curriculum/#:~:text=The%20new%20climate%20change%20curriculum,in%20arriving%20at%20climate%20solutions

8. Funk C, Gramlich J. Amid coronavirus threat, Americans generally have a high level of trust in medical doctors. Pew Research Center. March 13, 2020. Accessed August 6, 2023. https://www.pewresearch.org/fact-tank/2020/03/13/amid-coronavirus-threat-americans-generally-have-a-high-level-of-trust-in-medical-doctors/

9. Coverdale J, Balon R, Beresin EV, et al. Climate change: a call to action for the psychiatric profession. Acad Psychiatry. 2018;42(3):317-323. doi:10.1007/s40596-018-0885-7

10. Intergovernmental Panel on Climate Change. AR6 synthesis report: climate change 2023. Accessed August 6, 2023. https://www.ipcc.ch/report/sixth-assessment-report-cycle/

11. Perera FP. Multiple threats to child health from fossil fuel combustion: impacts of air pollution and climate change. Environ Health Perspect. 2017;125(2):141-148. doi:10.1289/EHP299

12. Hahad O, Lelieveldz J, Birklein F, et al. Ambient air pollution increases the risk of cerebrovascular and neuropsychiatric disorders through induction of inflammation and oxidative stress. Int J Mol Sci. 2020;21(12):4306. doi:10.3390/ijms21124306

13. Brockmeyer S, D’Angiulli A. How air pollution alters brain development: the role of neuroinflammation. Translational Neurosci. 2016;7(1):24-30. doi:10.1515/tnsci-2016-0005

14. Yang T, Wang J, Huang J, et al. Long-term exposure to multiple ambient air pollutants and association with incident depression and anxiety. JAMA Psychiatry. 2023;80:305-313. doi:10.1001/jamapsychiatry.2022.4812

15. Worthington MA, Petkova E, Freudenreich O, et al. Air pollution and hippocampal atrophy in first episode schizophrenia. Schizophr Res. 2020;218:63-69. doi:10.1016/j.schres.2020.03.001

16. Dumont C, Haase E, Dolber T, et al. Climate change and risk of completed suicide. J Nerv Ment Dis. 2020;208(7):559-565. doi:10.1097/NMD.0000000000001162

17. Burke M, Gonzales F, Bayis P, et al. Higher temperatures increase suicide rates in the United States and Mexico. Nat Climate Change. 2018;8:723-729. doi:10.1038/s41558-018-0222-x

18. Frangione B, Villamizar LAR, Lang JJ, et al. Short-term changes in meteorological conditions and suicide: a systematic review and meta-analysis. Environ Res. 2022;207:112230. doi:10.1016/j.envres.2021.112230

19. Rocklov J, Dubrow R. Climate change: an enduring challenge for vector-borne disease prevention and control. Nat Immunol. 2020;21(5):479-483. doi:10.1038/s41590-020-0648-y

20. Carlson CJ, Albery GF, Merow C, et al. Climate change increases cross-species viral transmission risk. Nature. 2022;607(7919):555-562. doi:10.1038/s41586-022-04788-w

21. Roseboom TJ, Painter RC, van Abeelen AFM, et al. Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas. 2011;70(2):141-145. doi:10.1016/j.maturitas.2011.06.017

22. Liu Y, Diao L, Xu L. The impact of childhood experience of starvations on the health of older adults: evidence from China. Int J Health Plann Manage. 2021;36(2):515-531. doi:10.1002/hpm.3099

23. Rothschild J, Haase E. The mental health of women and climate change: direct neuropsychiatric impacts and associated psychological concerns. Int J Gynaecol Obstet. 2023;160(2):405-413. doi:10.1002/ijgo.14479

24. Cianconi P, Betro S, Janiri L. The impact of climate change on mental health: a systematic descriptive review. Frontiers Psychiatry. 2020;11:74. doi:10.3389/fpsyt.2020.00074

25. World Economic Forum. Climate refugees – the world’s forgotten victims. June 18, 2021. Accessed August 6, 2023. https://www.weforum.org/agenda/2021/06/climate-refugees-the-world-s-forgotten-victims

26. Climate Refugees. Accessed August 6, 2023. https://www.climate-refugees.org/why

27. Pihkala P. Anxiety and the ecological crisis: an analysis of eco-anxiety and climate anxiety. Sustainability. 2020;12(19):7836. doi:10.3390/su12197836

28. Galway LP, Beery T, Jones-Casey K, et al. Mapping the solastalgia literature: a scoping review study. Int J Environ Res Public Health. 2019;16(15):2662. doi:10.3390/ijerph16152662

29. Albrecht GA. Earth Emotions. New Words for a New World. Cornell University Press; 2019.

30. Sorensen C, Hess J. Treatment and prevention of heat-related illness. N Engl J Med. 2022;387(15):1404-1413. doi:10.1056/NEJMcp2210623

31. Chong TWH, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res. 2004;69(2-3):149-157. doi:10.1016/s0920-9964(03)00222-6

32. von Salis S, Ehlert U, Fischer S. Altered experienced thermoregulation in depression--no evidence for an effect of early life stress. Front Psychiatry. 2021;12:620656. doi:10.3389/fpsyt.2021.620656

33. Sarchiapone M, Gramaglia C, Iosue M, et al. The association between electrodermal activity (EDA), depression and suicidal behaviour: a systematic review and narrative synthesis. BMC Psychiatry. 2018;18(1):22. doi:10.1186/s12888-017-1551-4

34. Martin-Latry K, Goumy MP, Latry P, et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry. 2007;22(6):335-338. doi:10.1016/j.eurpsy.2007.03.007

35. Ebi KL, Capon A, Berry P, et al. Hot weather and heat extremes: health risks. Lancet. 2021;398(10301):698-708. doi:10.1016/S0140-6736(21)01208-3

36. Lee MJ, McLean KE, Kuo M, et al. Chronic diseases associated with mortality in British Columbia, Canada during the 2021 Western North America extreme heat event. Geohealth. 2023;7(3):e2022GH000729. doi:10.1029/2022GH000729

37. Busch AB, Huskamp HA, Raja P, et al. Disruptions in care for Medicare beneficiaries with severe mental illness during the COVID-19 pandemic. JAMA Netw Open. 2022;5(1):e2145677. doi:10.1001/jamanetworkopen.2021.45677

38. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45(3):222-223. doi:10.1503/jpn.200061

39. MacLaurin SA, Mulligan C, Van Alphen MU, et al. Optimal long-acting injectable antipsychotic management during COVID-19. J Clin Psychiatry. 2021;82(1): 20l13730. doi:10.4088/JCP.20l13730

40. Bartels SJ, Baggett TP, Freudenreich O, et al. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness. Psychiatr Serv. 2020;71(10):1078-1081. doi:10.1176/appi.ps.202000244

41. Van Alphen MU, Lim C, Freudenreich O. Mobile vaccine clinics for patients with serious mental illness and health care workers in outpatient mental health clinics. Psychiatr Serv. February 8, 2023. doi:10.1176/appi.ps.20220460

42. Lim C, Van Alphen MU, Maclaurin S, et al. Increasing COVID-19 vaccination rates among patients with serious mental illness: a pilot intervention study. Psychiatr Serv. 2022;73(11):1274-1277. doi:10.1176/appi.ps.202100702

43. Marlon JR, Bloodhart B, Ballew MT, et al. How hope and doubt affect climate change mobilization. Front Commun. May 21, 2019. doi:10.3389/fcomm.2019.00020

44. Dorison CA, Lerner JS, Heller BH, et al. In COVID-19 health messaging, loss framing increases anxiety with little-to-no concomitant benefits: experimental evidence from 84 countries. Affective Sci. 2022;3(3):577-602. doi:10.1007/s42761-022-00128-3

45. Maibach E. Increasing public awareness and facilitating behavior change: two guiding heuristics. George Mason University, Center for Climate Change Communication. September 2015. Accessed August 6, 2023. https://www.climatechangecommunication.org/wp-content/uploads/2018/06/Maibach-Two-hueristics-September-2015-revised.pdf

46. Koh KA, Raviola G, Stoddard FJ Jr. Psychiatry and crisis communication during COVID-19: a view from the trenches. Psychiatr Serv. 2021;72(5):615. doi:10.1176/appi.ps.202000912

47. Velez G, Adam B, Shadid O, et al. The clock is ticking: are we prepared for mass climate migration? Psychiatr News. March 24, 2023. Accessed August 6, 2023. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2023.04.4.3

48. Ingle HE, Mikulewicz M. Mental health and climate change: tackling invisible injustice. Lancet Planet Health. 2020;4:e128-e130. doi:10.1016/S2542-5196(20)30081-4

49. Shah UA, Merlo G. Personal and planetary health--the connection with dietary choices. JAMA. 2023;329(21):1823-1824. doi:10.1001/jama.2023.6118

50. Lim C, Van Alphen MU, Freudenreich O. Becoming vaccine ambassadors: a new role for psychiatrists. Current Psychiatry. 2021;20(8):10-11,17-21,26-28,38. doi:10.12788/cp.0155

51. My Green Doctor. Accessed August 6, 2023. https://mygreendoctor.org/

52. Healthcare Without Harm. Accessed August 6, 2023. https://noharm.org/

53. Levy BS, Patz JA. Climate change, human rights, and social justice. Ann Glob Health. 2015;81:310-322.

54. Intergovernmental Panel on Climate Change. Global warming of 1.5° C 2018. Accessed August 6, 2023. https://www.ipcc.ch/sr15/

55. Steffen W, Crutzen J, McNeill JR. The Anthropocene: are humans now overwhelming the great forces of nature? Ambio. 2007;36(8):614-621. doi:10.1579/0044-7447(2007)36[614:taahno]2.0.co;2

56. American Meteorological Society. Explaining extreme events from a climate perspective. Accessed August 6, 2023. https://www.ametsoc.org/ams/index.cfm/publications/bulletin-of-the-american-meteorological-society-bams/explaining-extreme-events-from-a-climate-perspective/

57. Nierenberg AA. Coping in the age of turmoil. Psychiatr Ann. 2022;52(7):263. July 1, 2022. doi:10.3928/23258160-20220701-01

58. Belkin G. Leadership for the social climate. N Engl J Med. 2020;382(21):1975-1977. doi:10.1056/NEJMp2001507

59. Skinner JR. Doctors and climate change: first do no harm. J Paediatr Child Health. 2021;57(11):1754-1758. doi:10.1111/jpc.15658

References

1. Kretz L. Hope in environmental philosophy. J Agricult Environ Ethics. 2013;26:925-944. doi:10.1007/s10806-012-9425-8

2. Ursano RJ, Morganstein JC, Cooper R. Position statement on mental health and climate change. American Psychiatric Association. March 2023. Accessed August 6, 2023. https://www.psychiatry.org/getattachment/0ce71f37-61a6-44d0-8fcd-c752b7e935fd/Position-Mental-Health-Climate-Change.pdf

3. Eckelman MJ, Huang K, Lagasse R, et al. Health care pollution and public health damage in the United States: an update. Health Aff (Millwood). 2020;39:2071-2079.

4. Dzau VJ, Levine R, Barrett G, et al. Decarbonizing the U.S. health sector - a call to action. N Engl J Med. 2021;385(23):2117-2119. doi:10.1056/NEJMp2115675

5. Haase E, Augustinavicius JH, K. Climate change and psychiatry. In: Tasman A, Riba MB, Alarcón RD, et al, eds. Tasman’s Psychiatry. 5th ed. Springer; 2023.

6. Belkin G. Mental health and the global race to resilience. Psychiatr Times. 2023;40(3):26.

7. Hu SR, Yang JQ. Harvard Medical School will integrate climate change into M.D. curriculum. The Harvard Crimson. February 3, 2023. Accessed August 6, 2023. https://www.thecrimson.com/article/2023/2/3/hms-climate-curriculum/#:~:text=The%20new%20climate%20change%20curriculum,in%20arriving%20at%20climate%20solutions

8. Funk C, Gramlich J. Amid coronavirus threat, Americans generally have a high level of trust in medical doctors. Pew Research Center. March 13, 2020. Accessed August 6, 2023. https://www.pewresearch.org/fact-tank/2020/03/13/amid-coronavirus-threat-americans-generally-have-a-high-level-of-trust-in-medical-doctors/

9. Coverdale J, Balon R, Beresin EV, et al. Climate change: a call to action for the psychiatric profession. Acad Psychiatry. 2018;42(3):317-323. doi:10.1007/s40596-018-0885-7

10. Intergovernmental Panel on Climate Change. AR6 synthesis report: climate change 2023. Accessed August 6, 2023. https://www.ipcc.ch/report/sixth-assessment-report-cycle/

11. Perera FP. Multiple threats to child health from fossil fuel combustion: impacts of air pollution and climate change. Environ Health Perspect. 2017;125(2):141-148. doi:10.1289/EHP299

12. Hahad O, Lelieveldz J, Birklein F, et al. Ambient air pollution increases the risk of cerebrovascular and neuropsychiatric disorders through induction of inflammation and oxidative stress. Int J Mol Sci. 2020;21(12):4306. doi:10.3390/ijms21124306

13. Brockmeyer S, D’Angiulli A. How air pollution alters brain development: the role of neuroinflammation. Translational Neurosci. 2016;7(1):24-30. doi:10.1515/tnsci-2016-0005

14. Yang T, Wang J, Huang J, et al. Long-term exposure to multiple ambient air pollutants and association with incident depression and anxiety. JAMA Psychiatry. 2023;80:305-313. doi:10.1001/jamapsychiatry.2022.4812

15. Worthington MA, Petkova E, Freudenreich O, et al. Air pollution and hippocampal atrophy in first episode schizophrenia. Schizophr Res. 2020;218:63-69. doi:10.1016/j.schres.2020.03.001

16. Dumont C, Haase E, Dolber T, et al. Climate change and risk of completed suicide. J Nerv Ment Dis. 2020;208(7):559-565. doi:10.1097/NMD.0000000000001162

17. Burke M, Gonzales F, Bayis P, et al. Higher temperatures increase suicide rates in the United States and Mexico. Nat Climate Change. 2018;8:723-729. doi:10.1038/s41558-018-0222-x

18. Frangione B, Villamizar LAR, Lang JJ, et al. Short-term changes in meteorological conditions and suicide: a systematic review and meta-analysis. Environ Res. 2022;207:112230. doi:10.1016/j.envres.2021.112230

19. Rocklov J, Dubrow R. Climate change: an enduring challenge for vector-borne disease prevention and control. Nat Immunol. 2020;21(5):479-483. doi:10.1038/s41590-020-0648-y

20. Carlson CJ, Albery GF, Merow C, et al. Climate change increases cross-species viral transmission risk. Nature. 2022;607(7919):555-562. doi:10.1038/s41586-022-04788-w

21. Roseboom TJ, Painter RC, van Abeelen AFM, et al. Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas. 2011;70(2):141-145. doi:10.1016/j.maturitas.2011.06.017

22. Liu Y, Diao L, Xu L. The impact of childhood experience of starvations on the health of older adults: evidence from China. Int J Health Plann Manage. 2021;36(2):515-531. doi:10.1002/hpm.3099

23. Rothschild J, Haase E. The mental health of women and climate change: direct neuropsychiatric impacts and associated psychological concerns. Int J Gynaecol Obstet. 2023;160(2):405-413. doi:10.1002/ijgo.14479

24. Cianconi P, Betro S, Janiri L. The impact of climate change on mental health: a systematic descriptive review. Frontiers Psychiatry. 2020;11:74. doi:10.3389/fpsyt.2020.00074

25. World Economic Forum. Climate refugees – the world’s forgotten victims. June 18, 2021. Accessed August 6, 2023. https://www.weforum.org/agenda/2021/06/climate-refugees-the-world-s-forgotten-victims

26. Climate Refugees. Accessed August 6, 2023. https://www.climate-refugees.org/why

27. Pihkala P. Anxiety and the ecological crisis: an analysis of eco-anxiety and climate anxiety. Sustainability. 2020;12(19):7836. doi:10.3390/su12197836

28. Galway LP, Beery T, Jones-Casey K, et al. Mapping the solastalgia literature: a scoping review study. Int J Environ Res Public Health. 2019;16(15):2662. doi:10.3390/ijerph16152662

29. Albrecht GA. Earth Emotions. New Words for a New World. Cornell University Press; 2019.

30. Sorensen C, Hess J. Treatment and prevention of heat-related illness. N Engl J Med. 2022;387(15):1404-1413. doi:10.1056/NEJMcp2210623

31. Chong TWH, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res. 2004;69(2-3):149-157. doi:10.1016/s0920-9964(03)00222-6

32. von Salis S, Ehlert U, Fischer S. Altered experienced thermoregulation in depression--no evidence for an effect of early life stress. Front Psychiatry. 2021;12:620656. doi:10.3389/fpsyt.2021.620656

33. Sarchiapone M, Gramaglia C, Iosue M, et al. The association between electrodermal activity (EDA), depression and suicidal behaviour: a systematic review and narrative synthesis. BMC Psychiatry. 2018;18(1):22. doi:10.1186/s12888-017-1551-4

34. Martin-Latry K, Goumy MP, Latry P, et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry. 2007;22(6):335-338. doi:10.1016/j.eurpsy.2007.03.007

35. Ebi KL, Capon A, Berry P, et al. Hot weather and heat extremes: health risks. Lancet. 2021;398(10301):698-708. doi:10.1016/S0140-6736(21)01208-3

36. Lee MJ, McLean KE, Kuo M, et al. Chronic diseases associated with mortality in British Columbia, Canada during the 2021 Western North America extreme heat event. Geohealth. 2023;7(3):e2022GH000729. doi:10.1029/2022GH000729

37. Busch AB, Huskamp HA, Raja P, et al. Disruptions in care for Medicare beneficiaries with severe mental illness during the COVID-19 pandemic. JAMA Netw Open. 2022;5(1):e2145677. doi:10.1001/jamanetworkopen.2021.45677

38. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45(3):222-223. doi:10.1503/jpn.200061

39. MacLaurin SA, Mulligan C, Van Alphen MU, et al. Optimal long-acting injectable antipsychotic management during COVID-19. J Clin Psychiatry. 2021;82(1): 20l13730. doi:10.4088/JCP.20l13730

40. Bartels SJ, Baggett TP, Freudenreich O, et al. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness. Psychiatr Serv. 2020;71(10):1078-1081. doi:10.1176/appi.ps.202000244

41. Van Alphen MU, Lim C, Freudenreich O. Mobile vaccine clinics for patients with serious mental illness and health care workers in outpatient mental health clinics. Psychiatr Serv. February 8, 2023. doi:10.1176/appi.ps.20220460

42. Lim C, Van Alphen MU, Maclaurin S, et al. Increasing COVID-19 vaccination rates among patients with serious mental illness: a pilot intervention study. Psychiatr Serv. 2022;73(11):1274-1277. doi:10.1176/appi.ps.202100702

43. Marlon JR, Bloodhart B, Ballew MT, et al. How hope and doubt affect climate change mobilization. Front Commun. May 21, 2019. doi:10.3389/fcomm.2019.00020

44. Dorison CA, Lerner JS, Heller BH, et al. In COVID-19 health messaging, loss framing increases anxiety with little-to-no concomitant benefits: experimental evidence from 84 countries. Affective Sci. 2022;3(3):577-602. doi:10.1007/s42761-022-00128-3

45. Maibach E. Increasing public awareness and facilitating behavior change: two guiding heuristics. George Mason University, Center for Climate Change Communication. September 2015. Accessed August 6, 2023. https://www.climatechangecommunication.org/wp-content/uploads/2018/06/Maibach-Two-hueristics-September-2015-revised.pdf

46. Koh KA, Raviola G, Stoddard FJ Jr. Psychiatry and crisis communication during COVID-19: a view from the trenches. Psychiatr Serv. 2021;72(5):615. doi:10.1176/appi.ps.202000912

47. Velez G, Adam B, Shadid O, et al. The clock is ticking: are we prepared for mass climate migration? Psychiatr News. March 24, 2023. Accessed August 6, 2023. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2023.04.4.3

48. Ingle HE, Mikulewicz M. Mental health and climate change: tackling invisible injustice. Lancet Planet Health. 2020;4:e128-e130. doi:10.1016/S2542-5196(20)30081-4

49. Shah UA, Merlo G. Personal and planetary health--the connection with dietary choices. JAMA. 2023;329(21):1823-1824. doi:10.1001/jama.2023.6118

50. Lim C, Van Alphen MU, Freudenreich O. Becoming vaccine ambassadors: a new role for psychiatrists. Current Psychiatry. 2021;20(8):10-11,17-21,26-28,38. doi:10.12788/cp.0155

51. My Green Doctor. Accessed August 6, 2023. https://mygreendoctor.org/

52. Healthcare Without Harm. Accessed August 6, 2023. https://noharm.org/

53. Levy BS, Patz JA. Climate change, human rights, and social justice. Ann Glob Health. 2015;81:310-322.

54. Intergovernmental Panel on Climate Change. Global warming of 1.5° C 2018. Accessed August 6, 2023. https://www.ipcc.ch/sr15/

55. Steffen W, Crutzen J, McNeill JR. The Anthropocene: are humans now overwhelming the great forces of nature? Ambio. 2007;36(8):614-621. doi:10.1579/0044-7447(2007)36[614:taahno]2.0.co;2

56. American Meteorological Society. Explaining extreme events from a climate perspective. Accessed August 6, 2023. https://www.ametsoc.org/ams/index.cfm/publications/bulletin-of-the-american-meteorological-society-bams/explaining-extreme-events-from-a-climate-perspective/

57. Nierenberg AA. Coping in the age of turmoil. Psychiatr Ann. 2022;52(7):263. July 1, 2022. doi:10.3928/23258160-20220701-01

58. Belkin G. Leadership for the social climate. N Engl J Med. 2020;382(21):1975-1977. doi:10.1056/NEJMp2001507

59. Skinner JR. Doctors and climate change: first do no harm. J Paediatr Child Health. 2021;57(11):1754-1758. doi:10.1111/jpc.15658

Issue
Current Psychiatry - 22(9)
Issue
Current Psychiatry - 22(9)
Page Number
32-39
Page Number
32-39
Publications
Publications
Topics
Article Type
Display Headline
Climate change and mental illness: What psychiatrists can do
Display Headline
Climate change and mental illness: What psychiatrists can do
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Preparing patients with serious mental illness for extreme HEAT

Article Type
Changed
Thu, 09/01/2022 - 09:24
Display Headline
Preparing patients with serious mental illness for extreme HEAT

Climate change is causing intense heat waves that threaten human health across the globe.1 Given their unique biological, behavioral, and social factors, patients with serious mental illness (SMI)—which includes schizophrenia spectrum disorders, bipolar disorder, and severe depression—are at higher risk of developing and dying from heat-related illnesses such as heat exhaustion and heat stroke.1 In this article, we discuss factors that increase the risk of heat-related illnesses in patients with SMI and outline steps you can take to educate and prepare patients for heat waves.

A confluence of factors increases risk

Thermoregulatory dysfunction is thought to be intrinsic to patients with schizophrenia partly due to dysregulated dopaminergic neurotransmission.2 This is compounded by these patients’ higher burden of chronic medical comorbidities such as cardiovascular and respiratory illnesses, which together with psychotropic (ie, antipsychotics, antidepressants, lithium, benzodiazepines) and medical medications (ie, certain antihypertensives, diuretics, treatment for urinary incontinence) further disrupt the body’s cooling strategies and increase vulnerability to heat-related illnesses.1,3 Antipsychotics commonly prescribed to patients with SMI increase hyperthermia risk largely by 2 mechanisms: central and peripheral thermal dysregulation, and anticholinergic properties (ie, olanzapine, clozapine, chlorpromazine).2,3 Other anticholinergic medications prescribed to treat extrapyramidal symptoms (ie, diphenhydramine, benztropine, trihexyphenidyl), anxiety, depression, and insomnia (ie, paroxetine, trazodone, doxepin) further add insult to injury because they impair sweating, which decreases the body’s ability to eliminate heat through evaporation.2,3 Additionally, high temperature exacerbates psychiatric symptoms in patients with SMI, resulting in increased hospitalizations and emergency department visits.1 Patients with SMI also commonly have cognitive deficits, which may interfere with their ability to prepare for extreme heat and make it difficult for them to protect themselves. Finally, patients with SMI often have lower socioeconomic status with reduced access to air conditioning.1,2

How to keep patients safe

The acronym HEAT provides a framework that psychiatrists can use to highlight the importance of planning for heat waves in their institution and guiding discussions with individual patients about heat-related illnesses (Table 1).

HEAT: Protecting patients against dangerous heat waves

Help the health care system where you work plan and prepare for heat waves. In-service training in mental health settings such as outpatient clinics, shelters, group homes, and residential programs can help staff identify patients at particular risk and reinforce key prevention messages.

Educate patients and their caregivers on strategies for preventing heat-related illness. Informational materials can be distributed in clinics, residential settings, and day programs. A 1-page downloadable pamphlet available at https://smiadviser.org/wp-content/uploads/2022/08/SMI-Heat-Stroke-ver1.0-FINAL.pdf summarizes key prevention messages of staying hydrated, staying cool, and staying safe.

Assess personalized heat-related risks. Inquire about patients’ daily activities, access to air conditioning, and water intake. Minimize the use of anticholinergic medications. Identify who patients can turn to for assistance, especially for those who struggle with cognitive impairment and social isolation.

Teach patients, caregivers, and staff the signs and symptoms of heat exhaustion and heat stroke and how to respond in such situations.

HEAT focuses psychiatric clinicians on preparing and protecting patients with SMI against dangerous heat waves. Clinicians can take a proactive leadership role in disseminating basic principles of heat-related illness prevention and heat-wave toolkits by using resources available from organizations such as the Climate Psychiatry Alliance (Table 2). They can also initiate advocacy efforts to raise awareness about the elevated risks of heat-related illnesses in this vulnerable population.

Heat-related illnesses: Additional resources

References

1. Schmeltz MT, Gamble JL. Risk characterization of hospitalizations for mental illness and/or behavioral disorders with concurrent heat-related illness. PLoS One. 2017;12(10):e0186509. doi:10.1371/journal.pone.0186509

2. Lee CP, Chen PJ, Chang CM. Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. Acta Neuropsychiatrica. 2015;27(6):380-385.

3. Bongers KS, Salahudeen MS, Peterson GM. Drug-associated non-pyrogenic hyperthermia: a narrative review. Eur J Clin Pharmacol. 2020;76(1):9-16.

Article PDF
Author and Disclosure Information

Dr. Lim is a psychiatrist, Massachusetts General Hospital, Boston, Massachusetts. Ms. MacLaurin is a psychiatric nurse practitioner, Massachusetts General Hospital, Boston, Massachusetts. Dr. Freudenreich is Co-Director, Psychosis Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts.

Disclosures
Dr. Lim reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products. Ms. MacLaurin has served as an advisor to Alkermes and Janssen. Dr. Freudenreich has served as an advisor to Alkermes, Janssen, and Neurocrine, and has received research funding from Alkermes, Janssen, and Otsuka.

Issue
Current Psychiatry - 21(9)
Publications
Topics
Page Number
27-28
Sections
Author and Disclosure Information

Dr. Lim is a psychiatrist, Massachusetts General Hospital, Boston, Massachusetts. Ms. MacLaurin is a psychiatric nurse practitioner, Massachusetts General Hospital, Boston, Massachusetts. Dr. Freudenreich is Co-Director, Psychosis Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts.

Disclosures
Dr. Lim reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products. Ms. MacLaurin has served as an advisor to Alkermes and Janssen. Dr. Freudenreich has served as an advisor to Alkermes, Janssen, and Neurocrine, and has received research funding from Alkermes, Janssen, and Otsuka.

Author and Disclosure Information

Dr. Lim is a psychiatrist, Massachusetts General Hospital, Boston, Massachusetts. Ms. MacLaurin is a psychiatric nurse practitioner, Massachusetts General Hospital, Boston, Massachusetts. Dr. Freudenreich is Co-Director, Psychosis Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts.

Disclosures
Dr. Lim reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products. Ms. MacLaurin has served as an advisor to Alkermes and Janssen. Dr. Freudenreich has served as an advisor to Alkermes, Janssen, and Neurocrine, and has received research funding from Alkermes, Janssen, and Otsuka.

Article PDF
Article PDF

Climate change is causing intense heat waves that threaten human health across the globe.1 Given their unique biological, behavioral, and social factors, patients with serious mental illness (SMI)—which includes schizophrenia spectrum disorders, bipolar disorder, and severe depression—are at higher risk of developing and dying from heat-related illnesses such as heat exhaustion and heat stroke.1 In this article, we discuss factors that increase the risk of heat-related illnesses in patients with SMI and outline steps you can take to educate and prepare patients for heat waves.

A confluence of factors increases risk

Thermoregulatory dysfunction is thought to be intrinsic to patients with schizophrenia partly due to dysregulated dopaminergic neurotransmission.2 This is compounded by these patients’ higher burden of chronic medical comorbidities such as cardiovascular and respiratory illnesses, which together with psychotropic (ie, antipsychotics, antidepressants, lithium, benzodiazepines) and medical medications (ie, certain antihypertensives, diuretics, treatment for urinary incontinence) further disrupt the body’s cooling strategies and increase vulnerability to heat-related illnesses.1,3 Antipsychotics commonly prescribed to patients with SMI increase hyperthermia risk largely by 2 mechanisms: central and peripheral thermal dysregulation, and anticholinergic properties (ie, olanzapine, clozapine, chlorpromazine).2,3 Other anticholinergic medications prescribed to treat extrapyramidal symptoms (ie, diphenhydramine, benztropine, trihexyphenidyl), anxiety, depression, and insomnia (ie, paroxetine, trazodone, doxepin) further add insult to injury because they impair sweating, which decreases the body’s ability to eliminate heat through evaporation.2,3 Additionally, high temperature exacerbates psychiatric symptoms in patients with SMI, resulting in increased hospitalizations and emergency department visits.1 Patients with SMI also commonly have cognitive deficits, which may interfere with their ability to prepare for extreme heat and make it difficult for them to protect themselves. Finally, patients with SMI often have lower socioeconomic status with reduced access to air conditioning.1,2

How to keep patients safe

The acronym HEAT provides a framework that psychiatrists can use to highlight the importance of planning for heat waves in their institution and guiding discussions with individual patients about heat-related illnesses (Table 1).

HEAT: Protecting patients against dangerous heat waves

Help the health care system where you work plan and prepare for heat waves. In-service training in mental health settings such as outpatient clinics, shelters, group homes, and residential programs can help staff identify patients at particular risk and reinforce key prevention messages.

Educate patients and their caregivers on strategies for preventing heat-related illness. Informational materials can be distributed in clinics, residential settings, and day programs. A 1-page downloadable pamphlet available at https://smiadviser.org/wp-content/uploads/2022/08/SMI-Heat-Stroke-ver1.0-FINAL.pdf summarizes key prevention messages of staying hydrated, staying cool, and staying safe.

Assess personalized heat-related risks. Inquire about patients’ daily activities, access to air conditioning, and water intake. Minimize the use of anticholinergic medications. Identify who patients can turn to for assistance, especially for those who struggle with cognitive impairment and social isolation.

Teach patients, caregivers, and staff the signs and symptoms of heat exhaustion and heat stroke and how to respond in such situations.

HEAT focuses psychiatric clinicians on preparing and protecting patients with SMI against dangerous heat waves. Clinicians can take a proactive leadership role in disseminating basic principles of heat-related illness prevention and heat-wave toolkits by using resources available from organizations such as the Climate Psychiatry Alliance (Table 2). They can also initiate advocacy efforts to raise awareness about the elevated risks of heat-related illnesses in this vulnerable population.

Heat-related illnesses: Additional resources

Climate change is causing intense heat waves that threaten human health across the globe.1 Given their unique biological, behavioral, and social factors, patients with serious mental illness (SMI)—which includes schizophrenia spectrum disorders, bipolar disorder, and severe depression—are at higher risk of developing and dying from heat-related illnesses such as heat exhaustion and heat stroke.1 In this article, we discuss factors that increase the risk of heat-related illnesses in patients with SMI and outline steps you can take to educate and prepare patients for heat waves.

A confluence of factors increases risk

Thermoregulatory dysfunction is thought to be intrinsic to patients with schizophrenia partly due to dysregulated dopaminergic neurotransmission.2 This is compounded by these patients’ higher burden of chronic medical comorbidities such as cardiovascular and respiratory illnesses, which together with psychotropic (ie, antipsychotics, antidepressants, lithium, benzodiazepines) and medical medications (ie, certain antihypertensives, diuretics, treatment for urinary incontinence) further disrupt the body’s cooling strategies and increase vulnerability to heat-related illnesses.1,3 Antipsychotics commonly prescribed to patients with SMI increase hyperthermia risk largely by 2 mechanisms: central and peripheral thermal dysregulation, and anticholinergic properties (ie, olanzapine, clozapine, chlorpromazine).2,3 Other anticholinergic medications prescribed to treat extrapyramidal symptoms (ie, diphenhydramine, benztropine, trihexyphenidyl), anxiety, depression, and insomnia (ie, paroxetine, trazodone, doxepin) further add insult to injury because they impair sweating, which decreases the body’s ability to eliminate heat through evaporation.2,3 Additionally, high temperature exacerbates psychiatric symptoms in patients with SMI, resulting in increased hospitalizations and emergency department visits.1 Patients with SMI also commonly have cognitive deficits, which may interfere with their ability to prepare for extreme heat and make it difficult for them to protect themselves. Finally, patients with SMI often have lower socioeconomic status with reduced access to air conditioning.1,2

How to keep patients safe

The acronym HEAT provides a framework that psychiatrists can use to highlight the importance of planning for heat waves in their institution and guiding discussions with individual patients about heat-related illnesses (Table 1).

HEAT: Protecting patients against dangerous heat waves

Help the health care system where you work plan and prepare for heat waves. In-service training in mental health settings such as outpatient clinics, shelters, group homes, and residential programs can help staff identify patients at particular risk and reinforce key prevention messages.

Educate patients and their caregivers on strategies for preventing heat-related illness. Informational materials can be distributed in clinics, residential settings, and day programs. A 1-page downloadable pamphlet available at https://smiadviser.org/wp-content/uploads/2022/08/SMI-Heat-Stroke-ver1.0-FINAL.pdf summarizes key prevention messages of staying hydrated, staying cool, and staying safe.

Assess personalized heat-related risks. Inquire about patients’ daily activities, access to air conditioning, and water intake. Minimize the use of anticholinergic medications. Identify who patients can turn to for assistance, especially for those who struggle with cognitive impairment and social isolation.

Teach patients, caregivers, and staff the signs and symptoms of heat exhaustion and heat stroke and how to respond in such situations.

HEAT focuses psychiatric clinicians on preparing and protecting patients with SMI against dangerous heat waves. Clinicians can take a proactive leadership role in disseminating basic principles of heat-related illness prevention and heat-wave toolkits by using resources available from organizations such as the Climate Psychiatry Alliance (Table 2). They can also initiate advocacy efforts to raise awareness about the elevated risks of heat-related illnesses in this vulnerable population.

Heat-related illnesses: Additional resources

References

1. Schmeltz MT, Gamble JL. Risk characterization of hospitalizations for mental illness and/or behavioral disorders with concurrent heat-related illness. PLoS One. 2017;12(10):e0186509. doi:10.1371/journal.pone.0186509

2. Lee CP, Chen PJ, Chang CM. Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. Acta Neuropsychiatrica. 2015;27(6):380-385.

3. Bongers KS, Salahudeen MS, Peterson GM. Drug-associated non-pyrogenic hyperthermia: a narrative review. Eur J Clin Pharmacol. 2020;76(1):9-16.

References

1. Schmeltz MT, Gamble JL. Risk characterization of hospitalizations for mental illness and/or behavioral disorders with concurrent heat-related illness. PLoS One. 2017;12(10):e0186509. doi:10.1371/journal.pone.0186509

2. Lee CP, Chen PJ, Chang CM. Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. Acta Neuropsychiatrica. 2015;27(6):380-385.

3. Bongers KS, Salahudeen MS, Peterson GM. Drug-associated non-pyrogenic hyperthermia: a narrative review. Eur J Clin Pharmacol. 2020;76(1):9-16.

Issue
Current Psychiatry - 21(9)
Issue
Current Psychiatry - 21(9)
Page Number
27-28
Page Number
27-28
Publications
Publications
Topics
Article Type
Display Headline
Preparing patients with serious mental illness for extreme HEAT
Display Headline
Preparing patients with serious mental illness for extreme HEAT
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Becoming vaccine ambassadors: A new role for psychiatrists

Article Type
Changed
Thu, 12/15/2022 - 14:37
Display Headline
Becoming vaccine ambassadors: A new role for psychiatrists

After more than 600,000 deaths in the United States from the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), several safe and effective vaccines against the virus have become available. Vaccines are the most effective preventive measure against COVID-19 and the most promising way to achieve herd immunity to end the current pandemic. However, obstacles to reaching this goal include vaccine skepticism, structural barriers, or simple inertia to get vaccinated. These challenges provide opportunities for psychiatrists to use their medical knowledge and expertise, applying behavior management techniques such as motivational interviewing and nudging to encourage their patients to get vaccinated. In particular, marginalized patients with serious mental illness (SMI), who are subject to disproportionately high rates of COVID-19 infection and more severe outcomes,1 have much to gain if psychiatrists become involved in the COVID-19 vaccination campaign.

In this article, we define vaccine hesitancy and highlight what makes psychiatrists ideal vaccine ambassadors, given their unique skill set and longitudinal, trust-based connection with their patients. We expand on the particular vulnerabilities of patients with SMI, including structural barriers to vaccination that lead to health disparities and inequity. Finally, building on “The ABCs of successful vaccinations” framework published in Current Psychiatry March 2021,2 we outline how psychiatrists can address vaccine misconceptions, employ effective communication strategies to build vaccine confidence, and help patients overcome structural barriers and get the COVID-19 vaccination. While we are currently focused on ending the COVID-19 pandemic, our broader mission as psychiatrists should be to become ambassadors for other vaccinations as well, such as the annual influenza vaccine.

What is vaccine hesitancy?

The World Health Organization (WHO) defines vaccine hesitancy as a “delay in acceptance or refusal of vaccines despite availability of vaccine services.”3,4 Vaccine hesitancy occurs on a continuum ranging from uncertainty about accepting a vaccine to absolute refusal.4,5 It involves a complex decision-making process driven by contextual, individual, and social influences, and vaccine-specific issues.4 In the “3C” model developed by the WHO Strategic Advisory Group of Experts (SAGE) Working Group, vaccine hesitancy is influenced by confidence (trust in vaccines, in the health care system, and in policy makers), complacency (lower perceived risk), and convenience (availability, affordability, accessibility, language and health literacy, appeal of vaccination program).4

In 2019, the WHO named vaccine hesitancy as one of the top 10 global health threats.3 Hesitancy to receive COVID-19 vaccines may be particularly high because of their rapid development. In addition, the tumultuous political environment that often featured inconsistent messaging about the virus, its dangers, and its transmission since the early days of the pandemic created widespread public confusion and doubt as scientific understandings evolved. “Anti-vaxxer” movements that completely rejected vaccine efficacy disseminated misinformation online. Followers of these movements may have such extreme overvalued ideas that any effort to persuade them otherwise with scientific evidence will accomplish very little.6,7 Therefore, focusing on individuals who are “sitting on the fence” about getting vaccinated can be more productive because they represent a much larger group than those who adamantly refuse vaccines, and they may be more amenable to changing beliefs and behaviors.8

The US Census Bureau’s Household Pulse Survey asked, “How likely are you to accept the vaccine?”9 As of late June 2021, 11.4% of US adults reported they would “definitely not get a vaccine” or “probably not get a vaccine,” and that number increases to 16.9% when including those who are “unsure,” although there is wide geographical variability.10

A recent study in Denmark showed that willingness to receive the COVID-19 vaccine was slightly lower among patients with mental illness (84.8%) compared with the general population (89.5%).11 Given the small difference, vaccine hesitancy was not considered to be a major barrier for vaccination among patients with mental illness in Denmark. This is similar to the findings of a pre-pandemic study at a community mental health clinic in the United States involving other vaccinations, which suggested that 84% of patients with SMI perceived vaccinations as safe, effective, and important.12 In this clinic, identified barriers to vaccinations in general among patients with SMI included lack of awareness and knowledge (42.2%), accessibility (16.3%), personal cost (13.3%), fears about immunization (10.4%), and lack of recommendations by primary care providers (PCPs) (1.5%).12

It is critical to distinguish attitude-driven vaccine hesitancy from a lack of education and opportunity to receive a vaccine. Particularly disadvantaged communities may be mislabeled as “vaccine hesitant” when in fact they may not have the ability to be as proactive as other population groups (eg, difficulty scheduling appointments over the Internet).

Continue to: What makes psychiatrists ideal vaccine ambassadors?

 

 

What makes psychiatrists ideal vaccine ambassadors?

There are several reasons psychiatrists can be well-positioned to contribute to the success of vaccination campaigns (Table 1). These include their frequent contact with patients and their care teams, the high trust those patients have in them, and their medical expertise and skills in applied behavioral and social science techniques, including motivational interviewing and nudging. Vaccination efforts and outreach are more effective when led by the clinician with whom the patient has the most contact because resolving vaccine hesitancy is not a one-time discussion but requires ongoing communication, persistence, and consistency.13 Patients may contact their psychiatrists more frequently than their other clinicians, including PCPs. For this reason, psychiatrists can serve as the gateway to health care, particularly for patients with SMI.14 In addition, interruptions in nonemergency services caused by the COVID-19 pandemic may affect vaccine delivery because patients may have been unable to see their PCPs regularly during the pandemic.15

What makes psychiatrists ideal vaccine ambassadors?

Psychiatrists’ medical expertise and their ability to develop rapport with their patients promote trust-building. Receiving credible information from a trusted source such as a patient’s psychiatrist can be impactful. A recent poll suggested that individual health care clinicians have been consistently identified as the most trusted sources for vaccine information, including for the COVID-19 vaccines.16 There is also higher trust when there is greater continuity of care both in terms of length of time the patient has known the clinician and the number of consultations,17 an inherent part of psychiatric practice. In addition, research has shown that patients trust their psychiatrists as much as they trust their general practitioners.18

Psychiatrists are experts in behavior change, promoting healthy behaviors through motivational interviewing and nudging. They also have experience with managing patients who hold overvalued ideas as well as dealing with uncertainty, given their scientific and medical training.

Motivational interviewing is a patient-centered, collaborative approach widely used by psychiatrists to treat unhealthy behaviors such as substance use. Clinicians elicit and strengthen the patient’s desire and motivation for change while respecting their autonomy. Instead of presenting persuasive facts, the clinician creates a welcoming, nonthreatening, safe environment by engaging patients in open dialogue, reflecting back the patients’ concerns with empathy, helping them realize contradictions in behavior, and supporting self-sufficiency.19 In a nonpsychiatric setting, studies have shown the effectiveness of motivational interviewing in increasing uptake of human papillomavirus vaccines and of pediatric vaccines.20

Nudging, which comes from behavioral economics and psychology, underscores the importance of structuring a choice architecture in changing the way people make their everyday decisions.21 Nudging still gives people a choice and respects autonomy, but it leads patients to more efficient and productive decision-making. Many nudges are based around giving good “default options” because people often do not make efforts to deviate from default options. In addition, social nudges are powerful, giving people a social reference point and normalizing certain behaviors.21 Psychiatrists have become skilled in nudging from working with patients with varying levels of insight and cognitive capabilities. That is, they give simple choices, prompts, and frequent feedback to reinforce “good” decisions and to discourage “bad” decisions.

Continue to: Managing overvalued ideas

 

 

Managing overvalued ideas. Psychiatrists are also well-versed in having discussions with patients who hold irrational beliefs (psychosis) or overvalued ideas. For example, psychiatrists frequently manage anorexia nervosa and hypochondria, which are rooted in overvalued ideas.7 While psychiatrists may not be able to directly confront the overvalued ideas, they can work around such ideas while waiting for more flexible moments. Similarly, managing patients with intense emotional commitment7 to commonly held anti-vaccination ideas may not be much different. Psychiatrists can work around resistance until patients may be less strongly attached to those overvalued ideas in instances when other techniques, such as motivational interviewing and nudging, may be more effective.

Managing uncertainty. Psychiatrists are experts in managing “not knowing” and uncertainty. Due to their medical scientific training, they are familiar with the process of science, and how understanding changes through trial and error. In contrast, most patients usually only see the end product (ie, a drug comes to market). Discussions with patients that acknowledge uncertainty and emphasize that changes in what is known are expected and appropriate as scientific knowledge evolves could help preempt skepticism when messages are updated.
 

Why do patients with SMI need more help?

SMI as a high-risk group. Patients with SMI are part of a “tragic” epidemiologic triad of agent-host-environment15 that places them at remarkably elevated risk for COVID-19 infection and more serious complications and death when infected.1 After age, a diagnosis of a schizophrenia spectrum disorder is the second largest predictor of mortality from COVID-19, with a 2.7-fold increase in mortality.22 This is how the elements of the triad come together: SARS-Cov-2 is a highly infectious agent affecting individuals who are vulnerable hosts because of their high frequency of medical comorbidities, including cardio­vascular disease, type 2 diabetes, and respiratory tract diseases, which are all risk factors for worse outcomes due to COVID-19.23 In addition, SMI is associated with socioeconomic risk factors for SARS-Cov-2 infection, including poverty, homelessness, and crowded settings such as jails, group homes, hospitals, and shelters, which constitute ideal environments for high transmission of the virus.

Structural barriers to vaccination. Studies have suggested lower rates of vaccination among people with SMI for various other infectious diseases compared with the general population.12 For example, in 1 outpatient mental health setting, influenza vaccination rates were 24% to 28%, which was lower than the national vaccination rate of 40.9% for the same influenza season (2010 to 2011).24 More recently, a study in Israel examining the COVID-19 vaccination rate among >25,000 patients with schizophrenia suggested under-vaccination of this cohort. The results showed that the odds of getting the COVID-19 vaccination were significantly lower in the schizophrenia group compared with the general population (odds ratio = 0.80, 95% CI: 0.77 to 0.83).25

Patients with SMI encounter considerable system-level barriers to vaccinations in general, such as reduced access to health care due to cost and a lack of transportation,12 the digital divide given their reduced access to the internet and computers for information and scheduling,26 and lack of vaccination recommendations from their PCPs.12 Studies have also shown that patients with SMI often receive suboptimal medical care because of stigmatization and discrimination.27 They also have lower rates of preventive care utilization, seeking medical services only in times of crisis and seeking mental health services more often than physical health care.28-30

Continue to: Patients with SMI face...

 

 

Patients with SMI face additional individual challenges that impede vaccine uptake, such as lack of knowledge and awareness about the virus and vaccinations, general cognitive impairment, low digital literacy skills,31 low language literacy and educational attainment, baseline delusions, and negative symptoms such as apathy, avolition, and anhedonia.1 Thus, even if they overcome the external barriers and obtain vaccine-related information, these patients may experience difficulty in understanding the content and applying this information to their personal circumstances as a result of low health literacy.

How psychiatrists can help

The concept of using mental health care sites and trained clinicians to increase medical disease prevention is not new. The rigorously tested intervention model STIRR (Screen, Test, Immunize, Reduce risk, and Refer) uses co-located nurse practitioners in community mental health centers to provide risk assessment, counseling, and blood testing for hepatitis and HIV, as well as on-site vaccinations for hepatitis to patients dually diagnosed with SMI and substance use disorders.32 Similarly, when a vaccination program was integrated into an outpatient mental health clinic offering various on-site vaccinations, vaccination rates increased by up to 25% over baseline.12 Such public health approaches of integrating medical care at the site of mental health care, where patients with SMI are most reliably engaged, can be highly cost-effective33 in terms of reducing disease burden among patients with SMI.

While the psychiatrist may not have the time and resources to directly follow through on all aspects of vaccinations, they can assume leadership and work with the larger team—including therapists and counselors, nurse practitioners, social workers, case managers, care coordinators, or PCPs with whom they regularly collaborate in caring for patients with SMI—to communicate what they have learned about patient hesitancies, share suggestions for future conversations to address these hesitancies, and relay what structural barriers the patient may need assistance to address.

Prioritization of patients with SMI for vaccine eligibility does not directly lead to vaccine uptake. Patients with SMI need extra support from their primary point of health care contact, namely their psychiatrists. Psychiatrists may bring a set of specialized skills uniquely suited to this moment to address vaccine hesitancy and overall lack of vaccine resources and awareness. Freudenreich et al2 recently proposed “The ABCs of Successful Vaccinations” framework that psychiatrists can use in their interactions with patients to encourage vaccination by focusing on:

  • attitudes towards vaccination
  • barriers to vaccination
  • completed vaccination series.

Understand attitudes toward vaccination. Decision-making may be an emotional and psychological experience that is informed by thoughts and feelings,34 and psychiatrists are uniquely positioned to tailor messages to individual patients by using motivational interviewing and applying nudging techniques.8 Given the large role of the pandemic in everyday life, it would be natural to address vaccine-related concerns in the course of routine rapport-building. Table 219,34-38 shows example phrases of COVID-19 vaccine messages that are based on communication strategies that have demonstrated success in health behavior domains (including vaccinations).39

Evidence-based communication strategies to increase vaccine uptake

Continue to: First, a strong recommendation...

 

 

First, a strong recommendation should be made using the presumptive approach.40 If vaccine hesitancy is detected, psychiatrists should next attempt to understand patients’ reasoning with open-ended questions to probe vaccine-related concerns. Motivational interviewing can then be used to target the fence sitters (rather than anti-vaxxers).6 Psychiatrists can also communicate with therapists about the need for further follow up on patients’ hesitancies.

When assuring patients of vaccine safety and efficacy, it is helpful to explain the vaccine development process, including FDA approval, extensive clinical trials, monitoring, and the distribution process. Providing clear, transparent, accurate information about the risks and benefits of the vaccines is important, as well as monitoring misinformation and developing convincing counter messages that elicit positive emotions toward the vaccines.41 Examples of messages to counter common vaccine-related concerns and misinformation are shown in Table 3.42-44

Counter messages to common vaccine-related concerns and misinformation

Know the barriers to vaccination. The role of the psychiatrist is to help patients, particularly those with SMIs, overcome logistical barriers and address hesitancy, which are both essential for vaccine uptake. Psychiatrists can help identify actual barriers (eg, transportation, digital access for information and scheduling) and perceived barriers, improve information access, and help patients obtain self-efficacy to take the actions needed to get vaccinated, particularly by collaborating with and communicating these concerns to other social services (Table 4).41

Access barriers to vaccination among patients with SMI

Monitor for vaccination series completion. Especially for vaccines that require more than a single dose over time, patients need more reminders, nudges, practical support, and encouragement to complete vaccination. A surprising degree of confusion regarding the timing of protection and benefit from the second COVID-19 injection (for the 2-injection vaccines) was uncovered in a recent survey of >1,000 US adults who had received their vaccinations in February 2021.45 Attentive monitoring of vaccination series completion by psychiatrists can thus increase the likelihood that a patient will follow through (Table 4).41 This can be as simple as asking about completion of the series during appointments, but further aided by communicating to the larger care team (social workers, care managers, care coordinators) when identifying that the patient may need further assistance.

The Figure2,6,7,19,40 summarizes the steps that psychiatrists can take to help patients get vaccinated by assessing attitudes towards vaccination (vaccine hesitancy), helping to remove barriers to vaccination, and ensuring via patient follow-up that a vaccine series is completed.

Practical steps for psychiatrists to help their patients get vaccinated

Continue to: Active involvement is key

 

 

Active involvement is key

The active involvement of psychiatrists in COVID-19 vaccination efforts can protect patients from the virus, reduce health disparities among patients with SMI, and promote herd immunity, helping to end the pandemic. Psychiatry practices can serve as ideal platforms to deliver evidence-based COVID-19 vaccine information and encourage vaccine uptake, particularly for marginalized populations.

Vaccination programs in mental health practices can even be conceptualized as a moral mandate in the spirit of addressing distributive injustice. The population management challenges of individual-level barriers and follow-through could be dramatically reduced—if not nearly eliminated—through policy-level changes that allow vaccinations to be administered in places where patients with SMI are already engaged: that is, “shots in arms” in mental health settings. As noted, some studies have shown that mental health settings can play a key role in other preventive care campaigns, such as the annual influenza and hepatitis vaccinations, and thus the incorporation of preventive care need not be limited to just COVID-19 vaccination efforts.

The COVID-19 pandemic is an opportunity to rethink the role of psychiatrists and psychiatric offices and clinics in preventive health care. The health risks and disparities of patients with SMI require the proactive involvement of psychiatrists at both the level of their individual patients and at the federal and state levels to advocate for policy changes that can benefit these populations. Overall, psychiatrists occupy a special role within the medical establishment that enables them to uniquely advocate for patients with SMI and ensure they are not forgotten during the COVID-19 pandemic.

 

Bottom Line

Psychiatrists could apply behavior management techniques such as motivational interviewing and nudging to address vaccine hesitancy in their patients and move them to accepting the COVID-19 vaccination. This could be particularly valuable for patients with serious mental illness, who face increased risks from COVID-19 and additional barriers to getting vaccinated.

Related Resources

References

1. Mazereel V, Van Assche K, Detraux J, et al. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021;8(5):444-450.

2. Freudenreich O, Van Alphen MU, Lim C. The ABCs of successful vaccinations: a role for psychiatry. Current Psychiatry. 2021;20(3):48-50.

3. World Health Organization (WHO). Ten threats to global health in 2019. Accessed July 2, 2021. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

4. MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161-4164.

5. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550-1562.

6. Betsch C, Korn L, Holtmann C. Don’t try to convert the antivaccinators, instead target the fence-sitters. Proc Natl Acad Sci. 2015;112(49):E6725-E6726.

7. Rahman T, Hartz SM, Xiong W, et al. Extreme overvalued beliefs. J Am Acad Psychiatry Law. 2020;48(3):319-326.

8. Leask J. Target the fence-sitters. Nature. 2011;473(7348):443-445.

9. United States Census Bureau. Household Pulse Survey COVID-19 Vaccination Tracker. Updated June 30, 2021. Accessed July 2, 2021. https://www.census.gov/library/visualizations/interactive/household-pulse-survey-covid-19-vaccination-tracker.html

10. United States Census Bureau. Measuring household experiences during the coronavirus pandemic. Updated May 5, 2021. Accessed July 2, 2021. https://www.census.gov/data/experimental-data-products/household-pulse-survey.html

11. Jefsen OH, Kølbæk P, Gil Y, et al. COVID-19 vaccine willingness among patients with mental illness compared with the general population. Acta Neuropsychiatrica. 2021:1-24. doi:10.1017/neu.2021.15

12. Miles LW, Williams N, Luthy KE, et al. Adult vaccination rates in the mentally ill population: an outpatient improvement project. J Am Psychiatr Nurses Assoc. 2020;26(2):172-180.

13. Lewandowsky S, Ecker UK, Seifert CM, et al. Misinformation and its correction: continued influence and successful debiasing. Psychol Sci Public Interest. 2012;13(3):106-131.

14. Druss BG, Rosenheck RA. Locus of mental health treatment in an integrated service system. Psychiatr Serv. 2000;51(7):890-892.

15. Freudenreich O, Kontos N, Querques J. COVID-19 and patients with serious mental illness. Current Psychiatry. 2020;19(9):24-35.

16. Hamel L, Kirzinger A, Muñana C, et al. KFF COVID-19 vaccine monitor: December 2020. Accessed July 2, 2021. https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/

17. Kai J, Crosland A. Perspectives of people with enduring mental ill health from a community-based qualitative study. Br J Gen Pract. 2001;51(470):730-736.

18. Mather G, Baker D, Laugharne R. Patient trust in psychiatrists. Psychosis. 2012;4(2):161-167.

19. Miller WR, Rollnick S. Motivational interviewing: helping people change. Guilford Press; 2012.

20. Reno JE, O’Leary S, Garrett K, et al. Improving provider communication about HPV vaccines for vaccine-hesitant parents through the use of motivational interviewing. J Health Commun. 2018;23(4):313-320.

21. Baddeley M. Behavioural economics: a very short introduction. Volume 505. Oxford University Press; 2017.

22. Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380-386.

23. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52.

24. Lorenz RA, Norris MM, Norton LC, et al. Factors associated with influenza vaccination decisions among patients with mental illness. Int J Psychiatry Med. 2013;46(1):1-13.

25. Bitan DT. Patients with schizophrenia are under‐vaccinated for COVID‐19: a report from Israel. World Psychiatry. 2021;20(2):300.

26. Robotham D, Satkunanathan S, Doughty L, et al. Do we still have a digital divide in mental health? A five-year survey follow-up. J Med Internet Res. 2016;18(11):e309.

27. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138.

28. Carrà G, Bartoli F, Carretta D, et al. The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis. Soc Psychiatry Psychiatr Epidemiol. 2014;49(11):1739-1746.

29. Lin MT, Burgess JF, Carey K. The association between serious psychological distress and emergency department utilization among young adults in the USA. Soc Psychiatry Psychiatr Epidemiol. 2012;47(6):939-947.

30. DeCoux M. Acute versus primary care: the health care decision making process for individuals with severe mental illness. Issues Ment Health Nurs. 2005;26(9):935-951.

31. Hoffman L, Wisniewski H, Hays R, et al. Digital opportunities for outcomes in recovery services (DOORS): a pragmatic hands-on group approach toward increasing digital health and smartphone competencies, autonomy, relatedness, and alliance for those with serious mental illness. J Psychiatr Pract. 2020;26(2):80-88.

32. Rosenberg SD, Goldberg RW, Dixon LB, et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr Serv. 2010;61(9):885-891.

33. Slade EP, Rosenberg S, Dixon LB, et al. Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness. Psychiatr Serv. 2013;64(2):127-133.

34. Brewer NT, Chapman GB, Rothman AJ, et al. Increasing vaccination: putting psychological science into action. Psychol Sci Public Interest. 2017;18(3):149-207.

35. Nabet B, Gable J, Eder J, et al. PolicyLab evidence to action brief: addressing vaccine hesitancy to protect children & communities against preventable diseases. Children’s Hospital of Philadelphia. Published Spring 2017. Accessed July 2, 2021. https://policylab.chop.edu/sites/default/files/pdf/publications/Addressing_Vaccine_Hesitancy.pdf

36. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132(6):1037-1046.

37. Betsch C, Böhm R, Korn L, et al. On the benefits of explaining herd immunity in vaccine advocacy. Nat Hum Behav. 2017;1(3):1-6.

38. Shen F, Sheer VC, Li R. Impact of narratives on persuasion in health communication: a meta-analysis. J Advert. 2015;44(2):105-113.

39. Parkerson N, Leader A. Vaccine hesitancy in the era of COVID. Population Health Leadership Series: PopTalk webinars. Paper 26. Published February 10, 2021. https://jdc.jefferson.edu/phlspoptalk/26/

40. Dempsey AF, O’Leary ST. Human papillomavirus vaccination: narrative review of studies on how providers’ vaccine communication affects attitudes and uptake. Acad Pediatr. 2018;18(2):S23-S27.

41. Chou W, Burgdorf C, Gaysynsky A, et al. COVID-19 vaccination communication: applying behavioral and social science to address vaccine hesitancy and foster vaccine confidence. National Institutes of Health. Published 2020. https://obssr.od.nih.gov/sites/obssr/files/inline-files/OBSSR_VaccineWhitePaper_FINAL_508.pdf

42. International Society for Vaccines and the MJH Life Sciences COVID-19 coalition. Building confidence in COVID-19 vaccination: a toolbox of talks from leaders in the field. March 9, 2021. https://globalmeet.webcasts.com/starthere.jsp?ei=1435659&tp_key=59ed660099

43. Centers for Disease Control and Prevention. Frequently asked questions about COVID-19 vaccination. Accessed July 2, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html

44. Singh BR, Gandharava S, Gandharva R. Covid-19 vaccines and community immunity. Infectious Diseases Research. 2021;2(1):5.

45. Goldfarb JL, Kreps S, Brownstein JS, et al. Beyond the first dose - Covid-19 vaccine follow-through and continued protective measures. N Engl J Med. 2021;85(2):101-103.

Article PDF
Author and Disclosure Information

Carol Lim, MD, MPH
Fellow in Public and Community Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Manjola U. Van Alphen, MD, PhD, MBA
Chief Medical Officer
North Suffolk Mental Health Association
Instructor in Psychiatry
MGH Schizophrenia Clinical and Research Program
Harvard Medical School
Boston, Massachusetts

Oliver Freudenreich, MD, FACLP
Co-Director
MGH Schizophrenia Clinical and Research Program
Director
MGH Fellowship in Public and Community Psychiatry
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received research grants (to institution) and consultant honoraria (advisory board) from Janssen (area: schizophrenia, long-acting injectable antipsychotics). Drs. Lim and Van Alphen report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Issue
Current Psychiatry - 20(8)
Publications
Topics
Page Number
10-11,17-21,26-28,38
Sections
Author and Disclosure Information

Carol Lim, MD, MPH
Fellow in Public and Community Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Manjola U. Van Alphen, MD, PhD, MBA
Chief Medical Officer
North Suffolk Mental Health Association
Instructor in Psychiatry
MGH Schizophrenia Clinical and Research Program
Harvard Medical School
Boston, Massachusetts

Oliver Freudenreich, MD, FACLP
Co-Director
MGH Schizophrenia Clinical and Research Program
Director
MGH Fellowship in Public and Community Psychiatry
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received research grants (to institution) and consultant honoraria (advisory board) from Janssen (area: schizophrenia, long-acting injectable antipsychotics). Drs. Lim and Van Alphen report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Author and Disclosure Information

Carol Lim, MD, MPH
Fellow in Public and Community Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Manjola U. Van Alphen, MD, PhD, MBA
Chief Medical Officer
North Suffolk Mental Health Association
Instructor in Psychiatry
MGH Schizophrenia Clinical and Research Program
Harvard Medical School
Boston, Massachusetts

Oliver Freudenreich, MD, FACLP
Co-Director
MGH Schizophrenia Clinical and Research Program
Director
MGH Fellowship in Public and Community Psychiatry
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received research grants (to institution) and consultant honoraria (advisory board) from Janssen (area: schizophrenia, long-acting injectable antipsychotics). Drs. Lim and Van Alphen report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Article PDF
Article PDF

After more than 600,000 deaths in the United States from the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), several safe and effective vaccines against the virus have become available. Vaccines are the most effective preventive measure against COVID-19 and the most promising way to achieve herd immunity to end the current pandemic. However, obstacles to reaching this goal include vaccine skepticism, structural barriers, or simple inertia to get vaccinated. These challenges provide opportunities for psychiatrists to use their medical knowledge and expertise, applying behavior management techniques such as motivational interviewing and nudging to encourage their patients to get vaccinated. In particular, marginalized patients with serious mental illness (SMI), who are subject to disproportionately high rates of COVID-19 infection and more severe outcomes,1 have much to gain if psychiatrists become involved in the COVID-19 vaccination campaign.

In this article, we define vaccine hesitancy and highlight what makes psychiatrists ideal vaccine ambassadors, given their unique skill set and longitudinal, trust-based connection with their patients. We expand on the particular vulnerabilities of patients with SMI, including structural barriers to vaccination that lead to health disparities and inequity. Finally, building on “The ABCs of successful vaccinations” framework published in Current Psychiatry March 2021,2 we outline how psychiatrists can address vaccine misconceptions, employ effective communication strategies to build vaccine confidence, and help patients overcome structural barriers and get the COVID-19 vaccination. While we are currently focused on ending the COVID-19 pandemic, our broader mission as psychiatrists should be to become ambassadors for other vaccinations as well, such as the annual influenza vaccine.

What is vaccine hesitancy?

The World Health Organization (WHO) defines vaccine hesitancy as a “delay in acceptance or refusal of vaccines despite availability of vaccine services.”3,4 Vaccine hesitancy occurs on a continuum ranging from uncertainty about accepting a vaccine to absolute refusal.4,5 It involves a complex decision-making process driven by contextual, individual, and social influences, and vaccine-specific issues.4 In the “3C” model developed by the WHO Strategic Advisory Group of Experts (SAGE) Working Group, vaccine hesitancy is influenced by confidence (trust in vaccines, in the health care system, and in policy makers), complacency (lower perceived risk), and convenience (availability, affordability, accessibility, language and health literacy, appeal of vaccination program).4

In 2019, the WHO named vaccine hesitancy as one of the top 10 global health threats.3 Hesitancy to receive COVID-19 vaccines may be particularly high because of their rapid development. In addition, the tumultuous political environment that often featured inconsistent messaging about the virus, its dangers, and its transmission since the early days of the pandemic created widespread public confusion and doubt as scientific understandings evolved. “Anti-vaxxer” movements that completely rejected vaccine efficacy disseminated misinformation online. Followers of these movements may have such extreme overvalued ideas that any effort to persuade them otherwise with scientific evidence will accomplish very little.6,7 Therefore, focusing on individuals who are “sitting on the fence” about getting vaccinated can be more productive because they represent a much larger group than those who adamantly refuse vaccines, and they may be more amenable to changing beliefs and behaviors.8

The US Census Bureau’s Household Pulse Survey asked, “How likely are you to accept the vaccine?”9 As of late June 2021, 11.4% of US adults reported they would “definitely not get a vaccine” or “probably not get a vaccine,” and that number increases to 16.9% when including those who are “unsure,” although there is wide geographical variability.10

A recent study in Denmark showed that willingness to receive the COVID-19 vaccine was slightly lower among patients with mental illness (84.8%) compared with the general population (89.5%).11 Given the small difference, vaccine hesitancy was not considered to be a major barrier for vaccination among patients with mental illness in Denmark. This is similar to the findings of a pre-pandemic study at a community mental health clinic in the United States involving other vaccinations, which suggested that 84% of patients with SMI perceived vaccinations as safe, effective, and important.12 In this clinic, identified barriers to vaccinations in general among patients with SMI included lack of awareness and knowledge (42.2%), accessibility (16.3%), personal cost (13.3%), fears about immunization (10.4%), and lack of recommendations by primary care providers (PCPs) (1.5%).12

It is critical to distinguish attitude-driven vaccine hesitancy from a lack of education and opportunity to receive a vaccine. Particularly disadvantaged communities may be mislabeled as “vaccine hesitant” when in fact they may not have the ability to be as proactive as other population groups (eg, difficulty scheduling appointments over the Internet).

Continue to: What makes psychiatrists ideal vaccine ambassadors?

 

 

What makes psychiatrists ideal vaccine ambassadors?

There are several reasons psychiatrists can be well-positioned to contribute to the success of vaccination campaigns (Table 1). These include their frequent contact with patients and their care teams, the high trust those patients have in them, and their medical expertise and skills in applied behavioral and social science techniques, including motivational interviewing and nudging. Vaccination efforts and outreach are more effective when led by the clinician with whom the patient has the most contact because resolving vaccine hesitancy is not a one-time discussion but requires ongoing communication, persistence, and consistency.13 Patients may contact their psychiatrists more frequently than their other clinicians, including PCPs. For this reason, psychiatrists can serve as the gateway to health care, particularly for patients with SMI.14 In addition, interruptions in nonemergency services caused by the COVID-19 pandemic may affect vaccine delivery because patients may have been unable to see their PCPs regularly during the pandemic.15

What makes psychiatrists ideal vaccine ambassadors?

Psychiatrists’ medical expertise and their ability to develop rapport with their patients promote trust-building. Receiving credible information from a trusted source such as a patient’s psychiatrist can be impactful. A recent poll suggested that individual health care clinicians have been consistently identified as the most trusted sources for vaccine information, including for the COVID-19 vaccines.16 There is also higher trust when there is greater continuity of care both in terms of length of time the patient has known the clinician and the number of consultations,17 an inherent part of psychiatric practice. In addition, research has shown that patients trust their psychiatrists as much as they trust their general practitioners.18

Psychiatrists are experts in behavior change, promoting healthy behaviors through motivational interviewing and nudging. They also have experience with managing patients who hold overvalued ideas as well as dealing with uncertainty, given their scientific and medical training.

Motivational interviewing is a patient-centered, collaborative approach widely used by psychiatrists to treat unhealthy behaviors such as substance use. Clinicians elicit and strengthen the patient’s desire and motivation for change while respecting their autonomy. Instead of presenting persuasive facts, the clinician creates a welcoming, nonthreatening, safe environment by engaging patients in open dialogue, reflecting back the patients’ concerns with empathy, helping them realize contradictions in behavior, and supporting self-sufficiency.19 In a nonpsychiatric setting, studies have shown the effectiveness of motivational interviewing in increasing uptake of human papillomavirus vaccines and of pediatric vaccines.20

Nudging, which comes from behavioral economics and psychology, underscores the importance of structuring a choice architecture in changing the way people make their everyday decisions.21 Nudging still gives people a choice and respects autonomy, but it leads patients to more efficient and productive decision-making. Many nudges are based around giving good “default options” because people often do not make efforts to deviate from default options. In addition, social nudges are powerful, giving people a social reference point and normalizing certain behaviors.21 Psychiatrists have become skilled in nudging from working with patients with varying levels of insight and cognitive capabilities. That is, they give simple choices, prompts, and frequent feedback to reinforce “good” decisions and to discourage “bad” decisions.

Continue to: Managing overvalued ideas

 

 

Managing overvalued ideas. Psychiatrists are also well-versed in having discussions with patients who hold irrational beliefs (psychosis) or overvalued ideas. For example, psychiatrists frequently manage anorexia nervosa and hypochondria, which are rooted in overvalued ideas.7 While psychiatrists may not be able to directly confront the overvalued ideas, they can work around such ideas while waiting for more flexible moments. Similarly, managing patients with intense emotional commitment7 to commonly held anti-vaccination ideas may not be much different. Psychiatrists can work around resistance until patients may be less strongly attached to those overvalued ideas in instances when other techniques, such as motivational interviewing and nudging, may be more effective.

Managing uncertainty. Psychiatrists are experts in managing “not knowing” and uncertainty. Due to their medical scientific training, they are familiar with the process of science, and how understanding changes through trial and error. In contrast, most patients usually only see the end product (ie, a drug comes to market). Discussions with patients that acknowledge uncertainty and emphasize that changes in what is known are expected and appropriate as scientific knowledge evolves could help preempt skepticism when messages are updated.
 

Why do patients with SMI need more help?

SMI as a high-risk group. Patients with SMI are part of a “tragic” epidemiologic triad of agent-host-environment15 that places them at remarkably elevated risk for COVID-19 infection and more serious complications and death when infected.1 After age, a diagnosis of a schizophrenia spectrum disorder is the second largest predictor of mortality from COVID-19, with a 2.7-fold increase in mortality.22 This is how the elements of the triad come together: SARS-Cov-2 is a highly infectious agent affecting individuals who are vulnerable hosts because of their high frequency of medical comorbidities, including cardio­vascular disease, type 2 diabetes, and respiratory tract diseases, which are all risk factors for worse outcomes due to COVID-19.23 In addition, SMI is associated with socioeconomic risk factors for SARS-Cov-2 infection, including poverty, homelessness, and crowded settings such as jails, group homes, hospitals, and shelters, which constitute ideal environments for high transmission of the virus.

Structural barriers to vaccination. Studies have suggested lower rates of vaccination among people with SMI for various other infectious diseases compared with the general population.12 For example, in 1 outpatient mental health setting, influenza vaccination rates were 24% to 28%, which was lower than the national vaccination rate of 40.9% for the same influenza season (2010 to 2011).24 More recently, a study in Israel examining the COVID-19 vaccination rate among >25,000 patients with schizophrenia suggested under-vaccination of this cohort. The results showed that the odds of getting the COVID-19 vaccination were significantly lower in the schizophrenia group compared with the general population (odds ratio = 0.80, 95% CI: 0.77 to 0.83).25

Patients with SMI encounter considerable system-level barriers to vaccinations in general, such as reduced access to health care due to cost and a lack of transportation,12 the digital divide given their reduced access to the internet and computers for information and scheduling,26 and lack of vaccination recommendations from their PCPs.12 Studies have also shown that patients with SMI often receive suboptimal medical care because of stigmatization and discrimination.27 They also have lower rates of preventive care utilization, seeking medical services only in times of crisis and seeking mental health services more often than physical health care.28-30

Continue to: Patients with SMI face...

 

 

Patients with SMI face additional individual challenges that impede vaccine uptake, such as lack of knowledge and awareness about the virus and vaccinations, general cognitive impairment, low digital literacy skills,31 low language literacy and educational attainment, baseline delusions, and negative symptoms such as apathy, avolition, and anhedonia.1 Thus, even if they overcome the external barriers and obtain vaccine-related information, these patients may experience difficulty in understanding the content and applying this information to their personal circumstances as a result of low health literacy.

How psychiatrists can help

The concept of using mental health care sites and trained clinicians to increase medical disease prevention is not new. The rigorously tested intervention model STIRR (Screen, Test, Immunize, Reduce risk, and Refer) uses co-located nurse practitioners in community mental health centers to provide risk assessment, counseling, and blood testing for hepatitis and HIV, as well as on-site vaccinations for hepatitis to patients dually diagnosed with SMI and substance use disorders.32 Similarly, when a vaccination program was integrated into an outpatient mental health clinic offering various on-site vaccinations, vaccination rates increased by up to 25% over baseline.12 Such public health approaches of integrating medical care at the site of mental health care, where patients with SMI are most reliably engaged, can be highly cost-effective33 in terms of reducing disease burden among patients with SMI.

While the psychiatrist may not have the time and resources to directly follow through on all aspects of vaccinations, they can assume leadership and work with the larger team—including therapists and counselors, nurse practitioners, social workers, case managers, care coordinators, or PCPs with whom they regularly collaborate in caring for patients with SMI—to communicate what they have learned about patient hesitancies, share suggestions for future conversations to address these hesitancies, and relay what structural barriers the patient may need assistance to address.

Prioritization of patients with SMI for vaccine eligibility does not directly lead to vaccine uptake. Patients with SMI need extra support from their primary point of health care contact, namely their psychiatrists. Psychiatrists may bring a set of specialized skills uniquely suited to this moment to address vaccine hesitancy and overall lack of vaccine resources and awareness. Freudenreich et al2 recently proposed “The ABCs of Successful Vaccinations” framework that psychiatrists can use in their interactions with patients to encourage vaccination by focusing on:

  • attitudes towards vaccination
  • barriers to vaccination
  • completed vaccination series.

Understand attitudes toward vaccination. Decision-making may be an emotional and psychological experience that is informed by thoughts and feelings,34 and psychiatrists are uniquely positioned to tailor messages to individual patients by using motivational interviewing and applying nudging techniques.8 Given the large role of the pandemic in everyday life, it would be natural to address vaccine-related concerns in the course of routine rapport-building. Table 219,34-38 shows example phrases of COVID-19 vaccine messages that are based on communication strategies that have demonstrated success in health behavior domains (including vaccinations).39

Evidence-based communication strategies to increase vaccine uptake

Continue to: First, a strong recommendation...

 

 

First, a strong recommendation should be made using the presumptive approach.40 If vaccine hesitancy is detected, psychiatrists should next attempt to understand patients’ reasoning with open-ended questions to probe vaccine-related concerns. Motivational interviewing can then be used to target the fence sitters (rather than anti-vaxxers).6 Psychiatrists can also communicate with therapists about the need for further follow up on patients’ hesitancies.

When assuring patients of vaccine safety and efficacy, it is helpful to explain the vaccine development process, including FDA approval, extensive clinical trials, monitoring, and the distribution process. Providing clear, transparent, accurate information about the risks and benefits of the vaccines is important, as well as monitoring misinformation and developing convincing counter messages that elicit positive emotions toward the vaccines.41 Examples of messages to counter common vaccine-related concerns and misinformation are shown in Table 3.42-44

Counter messages to common vaccine-related concerns and misinformation

Know the barriers to vaccination. The role of the psychiatrist is to help patients, particularly those with SMIs, overcome logistical barriers and address hesitancy, which are both essential for vaccine uptake. Psychiatrists can help identify actual barriers (eg, transportation, digital access for information and scheduling) and perceived barriers, improve information access, and help patients obtain self-efficacy to take the actions needed to get vaccinated, particularly by collaborating with and communicating these concerns to other social services (Table 4).41

Access barriers to vaccination among patients with SMI

Monitor for vaccination series completion. Especially for vaccines that require more than a single dose over time, patients need more reminders, nudges, practical support, and encouragement to complete vaccination. A surprising degree of confusion regarding the timing of protection and benefit from the second COVID-19 injection (for the 2-injection vaccines) was uncovered in a recent survey of >1,000 US adults who had received their vaccinations in February 2021.45 Attentive monitoring of vaccination series completion by psychiatrists can thus increase the likelihood that a patient will follow through (Table 4).41 This can be as simple as asking about completion of the series during appointments, but further aided by communicating to the larger care team (social workers, care managers, care coordinators) when identifying that the patient may need further assistance.

The Figure2,6,7,19,40 summarizes the steps that psychiatrists can take to help patients get vaccinated by assessing attitudes towards vaccination (vaccine hesitancy), helping to remove barriers to vaccination, and ensuring via patient follow-up that a vaccine series is completed.

Practical steps for psychiatrists to help their patients get vaccinated

Continue to: Active involvement is key

 

 

Active involvement is key

The active involvement of psychiatrists in COVID-19 vaccination efforts can protect patients from the virus, reduce health disparities among patients with SMI, and promote herd immunity, helping to end the pandemic. Psychiatry practices can serve as ideal platforms to deliver evidence-based COVID-19 vaccine information and encourage vaccine uptake, particularly for marginalized populations.

Vaccination programs in mental health practices can even be conceptualized as a moral mandate in the spirit of addressing distributive injustice. The population management challenges of individual-level barriers and follow-through could be dramatically reduced—if not nearly eliminated—through policy-level changes that allow vaccinations to be administered in places where patients with SMI are already engaged: that is, “shots in arms” in mental health settings. As noted, some studies have shown that mental health settings can play a key role in other preventive care campaigns, such as the annual influenza and hepatitis vaccinations, and thus the incorporation of preventive care need not be limited to just COVID-19 vaccination efforts.

The COVID-19 pandemic is an opportunity to rethink the role of psychiatrists and psychiatric offices and clinics in preventive health care. The health risks and disparities of patients with SMI require the proactive involvement of psychiatrists at both the level of their individual patients and at the federal and state levels to advocate for policy changes that can benefit these populations. Overall, psychiatrists occupy a special role within the medical establishment that enables them to uniquely advocate for patients with SMI and ensure they are not forgotten during the COVID-19 pandemic.

 

Bottom Line

Psychiatrists could apply behavior management techniques such as motivational interviewing and nudging to address vaccine hesitancy in their patients and move them to accepting the COVID-19 vaccination. This could be particularly valuable for patients with serious mental illness, who face increased risks from COVID-19 and additional barriers to getting vaccinated.

Related Resources

After more than 600,000 deaths in the United States from the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), several safe and effective vaccines against the virus have become available. Vaccines are the most effective preventive measure against COVID-19 and the most promising way to achieve herd immunity to end the current pandemic. However, obstacles to reaching this goal include vaccine skepticism, structural barriers, or simple inertia to get vaccinated. These challenges provide opportunities for psychiatrists to use their medical knowledge and expertise, applying behavior management techniques such as motivational interviewing and nudging to encourage their patients to get vaccinated. In particular, marginalized patients with serious mental illness (SMI), who are subject to disproportionately high rates of COVID-19 infection and more severe outcomes,1 have much to gain if psychiatrists become involved in the COVID-19 vaccination campaign.

In this article, we define vaccine hesitancy and highlight what makes psychiatrists ideal vaccine ambassadors, given their unique skill set and longitudinal, trust-based connection with their patients. We expand on the particular vulnerabilities of patients with SMI, including structural barriers to vaccination that lead to health disparities and inequity. Finally, building on “The ABCs of successful vaccinations” framework published in Current Psychiatry March 2021,2 we outline how psychiatrists can address vaccine misconceptions, employ effective communication strategies to build vaccine confidence, and help patients overcome structural barriers and get the COVID-19 vaccination. While we are currently focused on ending the COVID-19 pandemic, our broader mission as psychiatrists should be to become ambassadors for other vaccinations as well, such as the annual influenza vaccine.

What is vaccine hesitancy?

The World Health Organization (WHO) defines vaccine hesitancy as a “delay in acceptance or refusal of vaccines despite availability of vaccine services.”3,4 Vaccine hesitancy occurs on a continuum ranging from uncertainty about accepting a vaccine to absolute refusal.4,5 It involves a complex decision-making process driven by contextual, individual, and social influences, and vaccine-specific issues.4 In the “3C” model developed by the WHO Strategic Advisory Group of Experts (SAGE) Working Group, vaccine hesitancy is influenced by confidence (trust in vaccines, in the health care system, and in policy makers), complacency (lower perceived risk), and convenience (availability, affordability, accessibility, language and health literacy, appeal of vaccination program).4

In 2019, the WHO named vaccine hesitancy as one of the top 10 global health threats.3 Hesitancy to receive COVID-19 vaccines may be particularly high because of their rapid development. In addition, the tumultuous political environment that often featured inconsistent messaging about the virus, its dangers, and its transmission since the early days of the pandemic created widespread public confusion and doubt as scientific understandings evolved. “Anti-vaxxer” movements that completely rejected vaccine efficacy disseminated misinformation online. Followers of these movements may have such extreme overvalued ideas that any effort to persuade them otherwise with scientific evidence will accomplish very little.6,7 Therefore, focusing on individuals who are “sitting on the fence” about getting vaccinated can be more productive because they represent a much larger group than those who adamantly refuse vaccines, and they may be more amenable to changing beliefs and behaviors.8

The US Census Bureau’s Household Pulse Survey asked, “How likely are you to accept the vaccine?”9 As of late June 2021, 11.4% of US adults reported they would “definitely not get a vaccine” or “probably not get a vaccine,” and that number increases to 16.9% when including those who are “unsure,” although there is wide geographical variability.10

A recent study in Denmark showed that willingness to receive the COVID-19 vaccine was slightly lower among patients with mental illness (84.8%) compared with the general population (89.5%).11 Given the small difference, vaccine hesitancy was not considered to be a major barrier for vaccination among patients with mental illness in Denmark. This is similar to the findings of a pre-pandemic study at a community mental health clinic in the United States involving other vaccinations, which suggested that 84% of patients with SMI perceived vaccinations as safe, effective, and important.12 In this clinic, identified barriers to vaccinations in general among patients with SMI included lack of awareness and knowledge (42.2%), accessibility (16.3%), personal cost (13.3%), fears about immunization (10.4%), and lack of recommendations by primary care providers (PCPs) (1.5%).12

It is critical to distinguish attitude-driven vaccine hesitancy from a lack of education and opportunity to receive a vaccine. Particularly disadvantaged communities may be mislabeled as “vaccine hesitant” when in fact they may not have the ability to be as proactive as other population groups (eg, difficulty scheduling appointments over the Internet).

Continue to: What makes psychiatrists ideal vaccine ambassadors?

 

 

What makes psychiatrists ideal vaccine ambassadors?

There are several reasons psychiatrists can be well-positioned to contribute to the success of vaccination campaigns (Table 1). These include their frequent contact with patients and their care teams, the high trust those patients have in them, and their medical expertise and skills in applied behavioral and social science techniques, including motivational interviewing and nudging. Vaccination efforts and outreach are more effective when led by the clinician with whom the patient has the most contact because resolving vaccine hesitancy is not a one-time discussion but requires ongoing communication, persistence, and consistency.13 Patients may contact their psychiatrists more frequently than their other clinicians, including PCPs. For this reason, psychiatrists can serve as the gateway to health care, particularly for patients with SMI.14 In addition, interruptions in nonemergency services caused by the COVID-19 pandemic may affect vaccine delivery because patients may have been unable to see their PCPs regularly during the pandemic.15

What makes psychiatrists ideal vaccine ambassadors?

Psychiatrists’ medical expertise and their ability to develop rapport with their patients promote trust-building. Receiving credible information from a trusted source such as a patient’s psychiatrist can be impactful. A recent poll suggested that individual health care clinicians have been consistently identified as the most trusted sources for vaccine information, including for the COVID-19 vaccines.16 There is also higher trust when there is greater continuity of care both in terms of length of time the patient has known the clinician and the number of consultations,17 an inherent part of psychiatric practice. In addition, research has shown that patients trust their psychiatrists as much as they trust their general practitioners.18

Psychiatrists are experts in behavior change, promoting healthy behaviors through motivational interviewing and nudging. They also have experience with managing patients who hold overvalued ideas as well as dealing with uncertainty, given their scientific and medical training.

Motivational interviewing is a patient-centered, collaborative approach widely used by psychiatrists to treat unhealthy behaviors such as substance use. Clinicians elicit and strengthen the patient’s desire and motivation for change while respecting their autonomy. Instead of presenting persuasive facts, the clinician creates a welcoming, nonthreatening, safe environment by engaging patients in open dialogue, reflecting back the patients’ concerns with empathy, helping them realize contradictions in behavior, and supporting self-sufficiency.19 In a nonpsychiatric setting, studies have shown the effectiveness of motivational interviewing in increasing uptake of human papillomavirus vaccines and of pediatric vaccines.20

Nudging, which comes from behavioral economics and psychology, underscores the importance of structuring a choice architecture in changing the way people make their everyday decisions.21 Nudging still gives people a choice and respects autonomy, but it leads patients to more efficient and productive decision-making. Many nudges are based around giving good “default options” because people often do not make efforts to deviate from default options. In addition, social nudges are powerful, giving people a social reference point and normalizing certain behaviors.21 Psychiatrists have become skilled in nudging from working with patients with varying levels of insight and cognitive capabilities. That is, they give simple choices, prompts, and frequent feedback to reinforce “good” decisions and to discourage “bad” decisions.

Continue to: Managing overvalued ideas

 

 

Managing overvalued ideas. Psychiatrists are also well-versed in having discussions with patients who hold irrational beliefs (psychosis) or overvalued ideas. For example, psychiatrists frequently manage anorexia nervosa and hypochondria, which are rooted in overvalued ideas.7 While psychiatrists may not be able to directly confront the overvalued ideas, they can work around such ideas while waiting for more flexible moments. Similarly, managing patients with intense emotional commitment7 to commonly held anti-vaccination ideas may not be much different. Psychiatrists can work around resistance until patients may be less strongly attached to those overvalued ideas in instances when other techniques, such as motivational interviewing and nudging, may be more effective.

Managing uncertainty. Psychiatrists are experts in managing “not knowing” and uncertainty. Due to their medical scientific training, they are familiar with the process of science, and how understanding changes through trial and error. In contrast, most patients usually only see the end product (ie, a drug comes to market). Discussions with patients that acknowledge uncertainty and emphasize that changes in what is known are expected and appropriate as scientific knowledge evolves could help preempt skepticism when messages are updated.
 

Why do patients with SMI need more help?

SMI as a high-risk group. Patients with SMI are part of a “tragic” epidemiologic triad of agent-host-environment15 that places them at remarkably elevated risk for COVID-19 infection and more serious complications and death when infected.1 After age, a diagnosis of a schizophrenia spectrum disorder is the second largest predictor of mortality from COVID-19, with a 2.7-fold increase in mortality.22 This is how the elements of the triad come together: SARS-Cov-2 is a highly infectious agent affecting individuals who are vulnerable hosts because of their high frequency of medical comorbidities, including cardio­vascular disease, type 2 diabetes, and respiratory tract diseases, which are all risk factors for worse outcomes due to COVID-19.23 In addition, SMI is associated with socioeconomic risk factors for SARS-Cov-2 infection, including poverty, homelessness, and crowded settings such as jails, group homes, hospitals, and shelters, which constitute ideal environments for high transmission of the virus.

Structural barriers to vaccination. Studies have suggested lower rates of vaccination among people with SMI for various other infectious diseases compared with the general population.12 For example, in 1 outpatient mental health setting, influenza vaccination rates were 24% to 28%, which was lower than the national vaccination rate of 40.9% for the same influenza season (2010 to 2011).24 More recently, a study in Israel examining the COVID-19 vaccination rate among >25,000 patients with schizophrenia suggested under-vaccination of this cohort. The results showed that the odds of getting the COVID-19 vaccination were significantly lower in the schizophrenia group compared with the general population (odds ratio = 0.80, 95% CI: 0.77 to 0.83).25

Patients with SMI encounter considerable system-level barriers to vaccinations in general, such as reduced access to health care due to cost and a lack of transportation,12 the digital divide given their reduced access to the internet and computers for information and scheduling,26 and lack of vaccination recommendations from their PCPs.12 Studies have also shown that patients with SMI often receive suboptimal medical care because of stigmatization and discrimination.27 They also have lower rates of preventive care utilization, seeking medical services only in times of crisis and seeking mental health services more often than physical health care.28-30

Continue to: Patients with SMI face...

 

 

Patients with SMI face additional individual challenges that impede vaccine uptake, such as lack of knowledge and awareness about the virus and vaccinations, general cognitive impairment, low digital literacy skills,31 low language literacy and educational attainment, baseline delusions, and negative symptoms such as apathy, avolition, and anhedonia.1 Thus, even if they overcome the external barriers and obtain vaccine-related information, these patients may experience difficulty in understanding the content and applying this information to their personal circumstances as a result of low health literacy.

How psychiatrists can help

The concept of using mental health care sites and trained clinicians to increase medical disease prevention is not new. The rigorously tested intervention model STIRR (Screen, Test, Immunize, Reduce risk, and Refer) uses co-located nurse practitioners in community mental health centers to provide risk assessment, counseling, and blood testing for hepatitis and HIV, as well as on-site vaccinations for hepatitis to patients dually diagnosed with SMI and substance use disorders.32 Similarly, when a vaccination program was integrated into an outpatient mental health clinic offering various on-site vaccinations, vaccination rates increased by up to 25% over baseline.12 Such public health approaches of integrating medical care at the site of mental health care, where patients with SMI are most reliably engaged, can be highly cost-effective33 in terms of reducing disease burden among patients with SMI.

While the psychiatrist may not have the time and resources to directly follow through on all aspects of vaccinations, they can assume leadership and work with the larger team—including therapists and counselors, nurse practitioners, social workers, case managers, care coordinators, or PCPs with whom they regularly collaborate in caring for patients with SMI—to communicate what they have learned about patient hesitancies, share suggestions for future conversations to address these hesitancies, and relay what structural barriers the patient may need assistance to address.

Prioritization of patients with SMI for vaccine eligibility does not directly lead to vaccine uptake. Patients with SMI need extra support from their primary point of health care contact, namely their psychiatrists. Psychiatrists may bring a set of specialized skills uniquely suited to this moment to address vaccine hesitancy and overall lack of vaccine resources and awareness. Freudenreich et al2 recently proposed “The ABCs of Successful Vaccinations” framework that psychiatrists can use in their interactions with patients to encourage vaccination by focusing on:

  • attitudes towards vaccination
  • barriers to vaccination
  • completed vaccination series.

Understand attitudes toward vaccination. Decision-making may be an emotional and psychological experience that is informed by thoughts and feelings,34 and psychiatrists are uniquely positioned to tailor messages to individual patients by using motivational interviewing and applying nudging techniques.8 Given the large role of the pandemic in everyday life, it would be natural to address vaccine-related concerns in the course of routine rapport-building. Table 219,34-38 shows example phrases of COVID-19 vaccine messages that are based on communication strategies that have demonstrated success in health behavior domains (including vaccinations).39

Evidence-based communication strategies to increase vaccine uptake

Continue to: First, a strong recommendation...

 

 

First, a strong recommendation should be made using the presumptive approach.40 If vaccine hesitancy is detected, psychiatrists should next attempt to understand patients’ reasoning with open-ended questions to probe vaccine-related concerns. Motivational interviewing can then be used to target the fence sitters (rather than anti-vaxxers).6 Psychiatrists can also communicate with therapists about the need for further follow up on patients’ hesitancies.

When assuring patients of vaccine safety and efficacy, it is helpful to explain the vaccine development process, including FDA approval, extensive clinical trials, monitoring, and the distribution process. Providing clear, transparent, accurate information about the risks and benefits of the vaccines is important, as well as monitoring misinformation and developing convincing counter messages that elicit positive emotions toward the vaccines.41 Examples of messages to counter common vaccine-related concerns and misinformation are shown in Table 3.42-44

Counter messages to common vaccine-related concerns and misinformation

Know the barriers to vaccination. The role of the psychiatrist is to help patients, particularly those with SMIs, overcome logistical barriers and address hesitancy, which are both essential for vaccine uptake. Psychiatrists can help identify actual barriers (eg, transportation, digital access for information and scheduling) and perceived barriers, improve information access, and help patients obtain self-efficacy to take the actions needed to get vaccinated, particularly by collaborating with and communicating these concerns to other social services (Table 4).41

Access barriers to vaccination among patients with SMI

Monitor for vaccination series completion. Especially for vaccines that require more than a single dose over time, patients need more reminders, nudges, practical support, and encouragement to complete vaccination. A surprising degree of confusion regarding the timing of protection and benefit from the second COVID-19 injection (for the 2-injection vaccines) was uncovered in a recent survey of >1,000 US adults who had received their vaccinations in February 2021.45 Attentive monitoring of vaccination series completion by psychiatrists can thus increase the likelihood that a patient will follow through (Table 4).41 This can be as simple as asking about completion of the series during appointments, but further aided by communicating to the larger care team (social workers, care managers, care coordinators) when identifying that the patient may need further assistance.

The Figure2,6,7,19,40 summarizes the steps that psychiatrists can take to help patients get vaccinated by assessing attitudes towards vaccination (vaccine hesitancy), helping to remove barriers to vaccination, and ensuring via patient follow-up that a vaccine series is completed.

Practical steps for psychiatrists to help their patients get vaccinated

Continue to: Active involvement is key

 

 

Active involvement is key

The active involvement of psychiatrists in COVID-19 vaccination efforts can protect patients from the virus, reduce health disparities among patients with SMI, and promote herd immunity, helping to end the pandemic. Psychiatry practices can serve as ideal platforms to deliver evidence-based COVID-19 vaccine information and encourage vaccine uptake, particularly for marginalized populations.

Vaccination programs in mental health practices can even be conceptualized as a moral mandate in the spirit of addressing distributive injustice. The population management challenges of individual-level barriers and follow-through could be dramatically reduced—if not nearly eliminated—through policy-level changes that allow vaccinations to be administered in places where patients with SMI are already engaged: that is, “shots in arms” in mental health settings. As noted, some studies have shown that mental health settings can play a key role in other preventive care campaigns, such as the annual influenza and hepatitis vaccinations, and thus the incorporation of preventive care need not be limited to just COVID-19 vaccination efforts.

The COVID-19 pandemic is an opportunity to rethink the role of psychiatrists and psychiatric offices and clinics in preventive health care. The health risks and disparities of patients with SMI require the proactive involvement of psychiatrists at both the level of their individual patients and at the federal and state levels to advocate for policy changes that can benefit these populations. Overall, psychiatrists occupy a special role within the medical establishment that enables them to uniquely advocate for patients with SMI and ensure they are not forgotten during the COVID-19 pandemic.

 

Bottom Line

Psychiatrists could apply behavior management techniques such as motivational interviewing and nudging to address vaccine hesitancy in their patients and move them to accepting the COVID-19 vaccination. This could be particularly valuable for patients with serious mental illness, who face increased risks from COVID-19 and additional barriers to getting vaccinated.

Related Resources

References

1. Mazereel V, Van Assche K, Detraux J, et al. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021;8(5):444-450.

2. Freudenreich O, Van Alphen MU, Lim C. The ABCs of successful vaccinations: a role for psychiatry. Current Psychiatry. 2021;20(3):48-50.

3. World Health Organization (WHO). Ten threats to global health in 2019. Accessed July 2, 2021. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

4. MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161-4164.

5. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550-1562.

6. Betsch C, Korn L, Holtmann C. Don’t try to convert the antivaccinators, instead target the fence-sitters. Proc Natl Acad Sci. 2015;112(49):E6725-E6726.

7. Rahman T, Hartz SM, Xiong W, et al. Extreme overvalued beliefs. J Am Acad Psychiatry Law. 2020;48(3):319-326.

8. Leask J. Target the fence-sitters. Nature. 2011;473(7348):443-445.

9. United States Census Bureau. Household Pulse Survey COVID-19 Vaccination Tracker. Updated June 30, 2021. Accessed July 2, 2021. https://www.census.gov/library/visualizations/interactive/household-pulse-survey-covid-19-vaccination-tracker.html

10. United States Census Bureau. Measuring household experiences during the coronavirus pandemic. Updated May 5, 2021. Accessed July 2, 2021. https://www.census.gov/data/experimental-data-products/household-pulse-survey.html

11. Jefsen OH, Kølbæk P, Gil Y, et al. COVID-19 vaccine willingness among patients with mental illness compared with the general population. Acta Neuropsychiatrica. 2021:1-24. doi:10.1017/neu.2021.15

12. Miles LW, Williams N, Luthy KE, et al. Adult vaccination rates in the mentally ill population: an outpatient improvement project. J Am Psychiatr Nurses Assoc. 2020;26(2):172-180.

13. Lewandowsky S, Ecker UK, Seifert CM, et al. Misinformation and its correction: continued influence and successful debiasing. Psychol Sci Public Interest. 2012;13(3):106-131.

14. Druss BG, Rosenheck RA. Locus of mental health treatment in an integrated service system. Psychiatr Serv. 2000;51(7):890-892.

15. Freudenreich O, Kontos N, Querques J. COVID-19 and patients with serious mental illness. Current Psychiatry. 2020;19(9):24-35.

16. Hamel L, Kirzinger A, Muñana C, et al. KFF COVID-19 vaccine monitor: December 2020. Accessed July 2, 2021. https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/

17. Kai J, Crosland A. Perspectives of people with enduring mental ill health from a community-based qualitative study. Br J Gen Pract. 2001;51(470):730-736.

18. Mather G, Baker D, Laugharne R. Patient trust in psychiatrists. Psychosis. 2012;4(2):161-167.

19. Miller WR, Rollnick S. Motivational interviewing: helping people change. Guilford Press; 2012.

20. Reno JE, O’Leary S, Garrett K, et al. Improving provider communication about HPV vaccines for vaccine-hesitant parents through the use of motivational interviewing. J Health Commun. 2018;23(4):313-320.

21. Baddeley M. Behavioural economics: a very short introduction. Volume 505. Oxford University Press; 2017.

22. Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380-386.

23. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52.

24. Lorenz RA, Norris MM, Norton LC, et al. Factors associated with influenza vaccination decisions among patients with mental illness. Int J Psychiatry Med. 2013;46(1):1-13.

25. Bitan DT. Patients with schizophrenia are under‐vaccinated for COVID‐19: a report from Israel. World Psychiatry. 2021;20(2):300.

26. Robotham D, Satkunanathan S, Doughty L, et al. Do we still have a digital divide in mental health? A five-year survey follow-up. J Med Internet Res. 2016;18(11):e309.

27. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138.

28. Carrà G, Bartoli F, Carretta D, et al. The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis. Soc Psychiatry Psychiatr Epidemiol. 2014;49(11):1739-1746.

29. Lin MT, Burgess JF, Carey K. The association between serious psychological distress and emergency department utilization among young adults in the USA. Soc Psychiatry Psychiatr Epidemiol. 2012;47(6):939-947.

30. DeCoux M. Acute versus primary care: the health care decision making process for individuals with severe mental illness. Issues Ment Health Nurs. 2005;26(9):935-951.

31. Hoffman L, Wisniewski H, Hays R, et al. Digital opportunities for outcomes in recovery services (DOORS): a pragmatic hands-on group approach toward increasing digital health and smartphone competencies, autonomy, relatedness, and alliance for those with serious mental illness. J Psychiatr Pract. 2020;26(2):80-88.

32. Rosenberg SD, Goldberg RW, Dixon LB, et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr Serv. 2010;61(9):885-891.

33. Slade EP, Rosenberg S, Dixon LB, et al. Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness. Psychiatr Serv. 2013;64(2):127-133.

34. Brewer NT, Chapman GB, Rothman AJ, et al. Increasing vaccination: putting psychological science into action. Psychol Sci Public Interest. 2017;18(3):149-207.

35. Nabet B, Gable J, Eder J, et al. PolicyLab evidence to action brief: addressing vaccine hesitancy to protect children & communities against preventable diseases. Children’s Hospital of Philadelphia. Published Spring 2017. Accessed July 2, 2021. https://policylab.chop.edu/sites/default/files/pdf/publications/Addressing_Vaccine_Hesitancy.pdf

36. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132(6):1037-1046.

37. Betsch C, Böhm R, Korn L, et al. On the benefits of explaining herd immunity in vaccine advocacy. Nat Hum Behav. 2017;1(3):1-6.

38. Shen F, Sheer VC, Li R. Impact of narratives on persuasion in health communication: a meta-analysis. J Advert. 2015;44(2):105-113.

39. Parkerson N, Leader A. Vaccine hesitancy in the era of COVID. Population Health Leadership Series: PopTalk webinars. Paper 26. Published February 10, 2021. https://jdc.jefferson.edu/phlspoptalk/26/

40. Dempsey AF, O’Leary ST. Human papillomavirus vaccination: narrative review of studies on how providers’ vaccine communication affects attitudes and uptake. Acad Pediatr. 2018;18(2):S23-S27.

41. Chou W, Burgdorf C, Gaysynsky A, et al. COVID-19 vaccination communication: applying behavioral and social science to address vaccine hesitancy and foster vaccine confidence. National Institutes of Health. Published 2020. https://obssr.od.nih.gov/sites/obssr/files/inline-files/OBSSR_VaccineWhitePaper_FINAL_508.pdf

42. International Society for Vaccines and the MJH Life Sciences COVID-19 coalition. Building confidence in COVID-19 vaccination: a toolbox of talks from leaders in the field. March 9, 2021. https://globalmeet.webcasts.com/starthere.jsp?ei=1435659&tp_key=59ed660099

43. Centers for Disease Control and Prevention. Frequently asked questions about COVID-19 vaccination. Accessed July 2, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html

44. Singh BR, Gandharava S, Gandharva R. Covid-19 vaccines and community immunity. Infectious Diseases Research. 2021;2(1):5.

45. Goldfarb JL, Kreps S, Brownstein JS, et al. Beyond the first dose - Covid-19 vaccine follow-through and continued protective measures. N Engl J Med. 2021;85(2):101-103.

References

1. Mazereel V, Van Assche K, Detraux J, et al. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021;8(5):444-450.

2. Freudenreich O, Van Alphen MU, Lim C. The ABCs of successful vaccinations: a role for psychiatry. Current Psychiatry. 2021;20(3):48-50.

3. World Health Organization (WHO). Ten threats to global health in 2019. Accessed July 2, 2021. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

4. MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161-4164.

5. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550-1562.

6. Betsch C, Korn L, Holtmann C. Don’t try to convert the antivaccinators, instead target the fence-sitters. Proc Natl Acad Sci. 2015;112(49):E6725-E6726.

7. Rahman T, Hartz SM, Xiong W, et al. Extreme overvalued beliefs. J Am Acad Psychiatry Law. 2020;48(3):319-326.

8. Leask J. Target the fence-sitters. Nature. 2011;473(7348):443-445.

9. United States Census Bureau. Household Pulse Survey COVID-19 Vaccination Tracker. Updated June 30, 2021. Accessed July 2, 2021. https://www.census.gov/library/visualizations/interactive/household-pulse-survey-covid-19-vaccination-tracker.html

10. United States Census Bureau. Measuring household experiences during the coronavirus pandemic. Updated May 5, 2021. Accessed July 2, 2021. https://www.census.gov/data/experimental-data-products/household-pulse-survey.html

11. Jefsen OH, Kølbæk P, Gil Y, et al. COVID-19 vaccine willingness among patients with mental illness compared with the general population. Acta Neuropsychiatrica. 2021:1-24. doi:10.1017/neu.2021.15

12. Miles LW, Williams N, Luthy KE, et al. Adult vaccination rates in the mentally ill population: an outpatient improvement project. J Am Psychiatr Nurses Assoc. 2020;26(2):172-180.

13. Lewandowsky S, Ecker UK, Seifert CM, et al. Misinformation and its correction: continued influence and successful debiasing. Psychol Sci Public Interest. 2012;13(3):106-131.

14. Druss BG, Rosenheck RA. Locus of mental health treatment in an integrated service system. Psychiatr Serv. 2000;51(7):890-892.

15. Freudenreich O, Kontos N, Querques J. COVID-19 and patients with serious mental illness. Current Psychiatry. 2020;19(9):24-35.

16. Hamel L, Kirzinger A, Muñana C, et al. KFF COVID-19 vaccine monitor: December 2020. Accessed July 2, 2021. https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/

17. Kai J, Crosland A. Perspectives of people with enduring mental ill health from a community-based qualitative study. Br J Gen Pract. 2001;51(470):730-736.

18. Mather G, Baker D, Laugharne R. Patient trust in psychiatrists. Psychosis. 2012;4(2):161-167.

19. Miller WR, Rollnick S. Motivational interviewing: helping people change. Guilford Press; 2012.

20. Reno JE, O’Leary S, Garrett K, et al. Improving provider communication about HPV vaccines for vaccine-hesitant parents through the use of motivational interviewing. J Health Commun. 2018;23(4):313-320.

21. Baddeley M. Behavioural economics: a very short introduction. Volume 505. Oxford University Press; 2017.

22. Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380-386.

23. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52.

24. Lorenz RA, Norris MM, Norton LC, et al. Factors associated with influenza vaccination decisions among patients with mental illness. Int J Psychiatry Med. 2013;46(1):1-13.

25. Bitan DT. Patients with schizophrenia are under‐vaccinated for COVID‐19: a report from Israel. World Psychiatry. 2021;20(2):300.

26. Robotham D, Satkunanathan S, Doughty L, et al. Do we still have a digital divide in mental health? A five-year survey follow-up. J Med Internet Res. 2016;18(11):e309.

27. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138.

28. Carrà G, Bartoli F, Carretta D, et al. The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis. Soc Psychiatry Psychiatr Epidemiol. 2014;49(11):1739-1746.

29. Lin MT, Burgess JF, Carey K. The association between serious psychological distress and emergency department utilization among young adults in the USA. Soc Psychiatry Psychiatr Epidemiol. 2012;47(6):939-947.

30. DeCoux M. Acute versus primary care: the health care decision making process for individuals with severe mental illness. Issues Ment Health Nurs. 2005;26(9):935-951.

31. Hoffman L, Wisniewski H, Hays R, et al. Digital opportunities for outcomes in recovery services (DOORS): a pragmatic hands-on group approach toward increasing digital health and smartphone competencies, autonomy, relatedness, and alliance for those with serious mental illness. J Psychiatr Pract. 2020;26(2):80-88.

32. Rosenberg SD, Goldberg RW, Dixon LB, et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr Serv. 2010;61(9):885-891.

33. Slade EP, Rosenberg S, Dixon LB, et al. Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness. Psychiatr Serv. 2013;64(2):127-133.

34. Brewer NT, Chapman GB, Rothman AJ, et al. Increasing vaccination: putting psychological science into action. Psychol Sci Public Interest. 2017;18(3):149-207.

35. Nabet B, Gable J, Eder J, et al. PolicyLab evidence to action brief: addressing vaccine hesitancy to protect children & communities against preventable diseases. Children’s Hospital of Philadelphia. Published Spring 2017. Accessed July 2, 2021. https://policylab.chop.edu/sites/default/files/pdf/publications/Addressing_Vaccine_Hesitancy.pdf

36. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132(6):1037-1046.

37. Betsch C, Böhm R, Korn L, et al. On the benefits of explaining herd immunity in vaccine advocacy. Nat Hum Behav. 2017;1(3):1-6.

38. Shen F, Sheer VC, Li R. Impact of narratives on persuasion in health communication: a meta-analysis. J Advert. 2015;44(2):105-113.

39. Parkerson N, Leader A. Vaccine hesitancy in the era of COVID. Population Health Leadership Series: PopTalk webinars. Paper 26. Published February 10, 2021. https://jdc.jefferson.edu/phlspoptalk/26/

40. Dempsey AF, O’Leary ST. Human papillomavirus vaccination: narrative review of studies on how providers’ vaccine communication affects attitudes and uptake. Acad Pediatr. 2018;18(2):S23-S27.

41. Chou W, Burgdorf C, Gaysynsky A, et al. COVID-19 vaccination communication: applying behavioral and social science to address vaccine hesitancy and foster vaccine confidence. National Institutes of Health. Published 2020. https://obssr.od.nih.gov/sites/obssr/files/inline-files/OBSSR_VaccineWhitePaper_FINAL_508.pdf

42. International Society for Vaccines and the MJH Life Sciences COVID-19 coalition. Building confidence in COVID-19 vaccination: a toolbox of talks from leaders in the field. March 9, 2021. https://globalmeet.webcasts.com/starthere.jsp?ei=1435659&tp_key=59ed660099

43. Centers for Disease Control and Prevention. Frequently asked questions about COVID-19 vaccination. Accessed July 2, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html

44. Singh BR, Gandharava S, Gandharva R. Covid-19 vaccines and community immunity. Infectious Diseases Research. 2021;2(1):5.

45. Goldfarb JL, Kreps S, Brownstein JS, et al. Beyond the first dose - Covid-19 vaccine follow-through and continued protective measures. N Engl J Med. 2021;85(2):101-103.

Issue
Current Psychiatry - 20(8)
Issue
Current Psychiatry - 20(8)
Page Number
10-11,17-21,26-28,38
Page Number
10-11,17-21,26-28,38
Publications
Publications
Topics
Article Type
Display Headline
Becoming vaccine ambassadors: A new role for psychiatrists
Display Headline
Becoming vaccine ambassadors: A new role for psychiatrists
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

The ABCs of successful vaccinations: A role for psychiatry

Article Type
Changed
Thu, 08/26/2021 - 15:50
Display Headline
The ABCs of successful vaccinations: A role for psychiatry

While the implementation of mass vaccinations is a public health task, individual clinicians are critical for the success of any vaccination campaign. Psychiatrists may be well positioned to help increase vaccine uptake among psychiatric patients. They see their patients more frequently than primary care physicians do, which allows for patient engagement over time regarding vaccinations. Also, as physicians, psychiatrists are a trusted source of medical information, and they are well-versed in using the tools of nudging and motivational interviewing to manage ambivalence about receiving a vaccine (vaccine hesitancy).1

The “ABCs of successful vaccinations” (Figure) provide a framework that psychiatrists can use when speaking with their patients about vaccinations. The ABCs assess psychological factors that hinder acceptance of vaccination (A = Attitudes toward vaccination), practical challenges in vaccine access for patients who are willing to get vaccinated (B = Barriers to vaccination), and the actual outcome of “shot in the arm” (C = Completed vaccination series). The Figure provides examples of each area of focus.

The ABCs of successful vaccinations

How to talk to patients about vaccines

“Attitudes toward vaccination” is an area in which psychiatrists can potentially move patients from hesitancy to vaccine confidence and acceptance. First, express confidence in the vaccine (ie, make a clear statement: “You are an excellent candidate for this vaccine.”). Then, begin a discussion using presumptive language: “You must be ready to receive the vaccine.” In individuals who hesitate, elicit their concern: “What would make vaccination more acceptable?” In those who agree in principle about the benefits of vaccinations, ask about any impediments: “What would get in the way of getting vaccinated?” While some patients may require more information about the vaccine, others may need more time or mostly concrete help, such as assistance with scheduling a vaccine appointment. Do not to forget to follow up to see if a planned and complete vaccination series has taken place. The CDC offers an excellent online toolkit to help clinicians discuss vaccinations with their patients.2

Psychiatric patients, particularly those from disadvantaged and marginalized populations, have much to gain if psychiatrists are involved in preventive health care, including the coronavirus vaccination drive or the annual flu vaccination campaign.

References

1. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550-1562.
2. Centers for Disease Control and Prevention. COVID-19 vaccination toolkits. Accessed February 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/toolkits.html

Article PDF
Author and Disclosure Information

Dr. Freudenreich is Co-Director, Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts. Dr. Van Alphen is CMO of North Suffolk Mental Health Association, Chelsea, Massachusetts. Dr. Lim is a Fellow in Public and Community Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.

Disclosures
The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Issue
Current Psychiatry - 20(3)
Publications
Topics
Page Number
48-49
Sections
Author and Disclosure Information

Dr. Freudenreich is Co-Director, Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts. Dr. Van Alphen is CMO of North Suffolk Mental Health Association, Chelsea, Massachusetts. Dr. Lim is a Fellow in Public and Community Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.

Disclosures
The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Author and Disclosure Information

Dr. Freudenreich is Co-Director, Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts. Dr. Van Alphen is CMO of North Suffolk Mental Health Association, Chelsea, Massachusetts. Dr. Lim is a Fellow in Public and Community Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.

Disclosures
The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Article PDF
Article PDF

While the implementation of mass vaccinations is a public health task, individual clinicians are critical for the success of any vaccination campaign. Psychiatrists may be well positioned to help increase vaccine uptake among psychiatric patients. They see their patients more frequently than primary care physicians do, which allows for patient engagement over time regarding vaccinations. Also, as physicians, psychiatrists are a trusted source of medical information, and they are well-versed in using the tools of nudging and motivational interviewing to manage ambivalence about receiving a vaccine (vaccine hesitancy).1

The “ABCs of successful vaccinations” (Figure) provide a framework that psychiatrists can use when speaking with their patients about vaccinations. The ABCs assess psychological factors that hinder acceptance of vaccination (A = Attitudes toward vaccination), practical challenges in vaccine access for patients who are willing to get vaccinated (B = Barriers to vaccination), and the actual outcome of “shot in the arm” (C = Completed vaccination series). The Figure provides examples of each area of focus.

The ABCs of successful vaccinations

How to talk to patients about vaccines

“Attitudes toward vaccination” is an area in which psychiatrists can potentially move patients from hesitancy to vaccine confidence and acceptance. First, express confidence in the vaccine (ie, make a clear statement: “You are an excellent candidate for this vaccine.”). Then, begin a discussion using presumptive language: “You must be ready to receive the vaccine.” In individuals who hesitate, elicit their concern: “What would make vaccination more acceptable?” In those who agree in principle about the benefits of vaccinations, ask about any impediments: “What would get in the way of getting vaccinated?” While some patients may require more information about the vaccine, others may need more time or mostly concrete help, such as assistance with scheduling a vaccine appointment. Do not to forget to follow up to see if a planned and complete vaccination series has taken place. The CDC offers an excellent online toolkit to help clinicians discuss vaccinations with their patients.2

Psychiatric patients, particularly those from disadvantaged and marginalized populations, have much to gain if psychiatrists are involved in preventive health care, including the coronavirus vaccination drive or the annual flu vaccination campaign.

While the implementation of mass vaccinations is a public health task, individual clinicians are critical for the success of any vaccination campaign. Psychiatrists may be well positioned to help increase vaccine uptake among psychiatric patients. They see their patients more frequently than primary care physicians do, which allows for patient engagement over time regarding vaccinations. Also, as physicians, psychiatrists are a trusted source of medical information, and they are well-versed in using the tools of nudging and motivational interviewing to manage ambivalence about receiving a vaccine (vaccine hesitancy).1

The “ABCs of successful vaccinations” (Figure) provide a framework that psychiatrists can use when speaking with their patients about vaccinations. The ABCs assess psychological factors that hinder acceptance of vaccination (A = Attitudes toward vaccination), practical challenges in vaccine access for patients who are willing to get vaccinated (B = Barriers to vaccination), and the actual outcome of “shot in the arm” (C = Completed vaccination series). The Figure provides examples of each area of focus.

The ABCs of successful vaccinations

How to talk to patients about vaccines

“Attitudes toward vaccination” is an area in which psychiatrists can potentially move patients from hesitancy to vaccine confidence and acceptance. First, express confidence in the vaccine (ie, make a clear statement: “You are an excellent candidate for this vaccine.”). Then, begin a discussion using presumptive language: “You must be ready to receive the vaccine.” In individuals who hesitate, elicit their concern: “What would make vaccination more acceptable?” In those who agree in principle about the benefits of vaccinations, ask about any impediments: “What would get in the way of getting vaccinated?” While some patients may require more information about the vaccine, others may need more time or mostly concrete help, such as assistance with scheduling a vaccine appointment. Do not to forget to follow up to see if a planned and complete vaccination series has taken place. The CDC offers an excellent online toolkit to help clinicians discuss vaccinations with their patients.2

Psychiatric patients, particularly those from disadvantaged and marginalized populations, have much to gain if psychiatrists are involved in preventive health care, including the coronavirus vaccination drive or the annual flu vaccination campaign.

References

1. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550-1562.
2. Centers for Disease Control and Prevention. COVID-19 vaccination toolkits. Accessed February 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/toolkits.html

References

1. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550-1562.
2. Centers for Disease Control and Prevention. COVID-19 vaccination toolkits. Accessed February 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/toolkits.html

Issue
Current Psychiatry - 20(3)
Issue
Current Psychiatry - 20(3)
Page Number
48-49
Page Number
48-49
Publications
Publications
Topics
Article Type
Display Headline
The ABCs of successful vaccinations: A role for psychiatry
Display Headline
The ABCs of successful vaccinations: A role for psychiatry
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Article PDF Media

Long-acting injectable antipsychotics during COVID-19

Article Type
Changed
Thu, 08/26/2021 - 15:51
Display Headline
Long-acting injectable antipsychotics during COVID-19

Long-acting injectable antipsychotics (LAIs) are an essential tool in the treatment of patients with psychotic disorders, allowing for periods of stable drug plasma concentration and confirmed adherence.1 The current coronavirus disease 2019 (COVID-19) pandemic presents unique challenges for administering LAIs and requires a thoughtful and prospective approach in order to ensure continuity of psychiatric care while minimizing the risk of infection with COVID-19. Ideally, patients should be seen in person as infrequently as clinically prudent during this public health emergency; however, LAI administration necessitates direct physical contact between patient and clinician.

Patients with serious mental illness (SMI), who comprise the majority of individuals who receive LAIs, are at heightened risk for cardiovascular and pulmonary comorbidities. These factors are the primary reason the life expectancy of a patient with SMI is nearly 30 years shorter than that of the general population.2-5 The risk of health care workers becoming infected or inadvertently spreading COVID-19 is heightened when working with patients in group living environments (ie, a shelter or group home), who have both increased exposure and increased risk of further transmission.6 Additional patient populations, including older adults, immunocompromised individuals, and those with preexisting conditions, are at heightened risk for serious complications if they were to contract COVID-19.7,8

Thus, the questions of whether LAIs should be administered, and how to do so safely (both during the ongoing, acute phase of the pandemic as well as during the subsequent recovery period until the pandemic abates) need to be carefully considered. In this article, we provide concrete advice for clinicians and clinics on these topics, with the goal of maintaining patients’ psychiatric stability while protecting patients, health care workers, and the broader society from COVID-19 infection. Table 1 summarizes the questions regarding LAIs that clinicians need to address during this crisis. While we focus on outpatient care, inpatient teams should keep these considerations in mind if they are starting and discharging a patient on an LAI. More than ever, close collaboration and communication between inpatient and outpatient teams is critical.

Considerations for LAI administration during COVID-19

Should an LAI be continued?

An important first step to approaching this challenge is to create a spreadsheet for all patients receiving LAIs. Focusing on a population-based approach is helpful to be systematic and ensure that no patients fall through the cracks during this public health emergency.9 Once all patients have been identified, the treatment team should review each patient to determine if continuing to administer the antipsychotic as an LAI formulation is essential, taking into account the patient’s current psychiatric status, historical medication adherence, potential severity and dangerousness of decompensation if nonadherent, and structures to support stability. For example, can a patient move in with family who can monitor medication adherence during the pandemic? Is it possible for the group home to assume medication administration? Additional consideration should be given to the living environment and health-vulnerability of the patient and the individuals living with them.

If the risk calculation does not point strongly towards a need for continuing the LAI, it may be prudent to temporarily transition the patient to the corresponding oral antipsychotic preparation. Table 2 lists all LAIs available in the United States and their approximate equivalent oral dosing. It is important to note that such transitions are not without clinical risk, to emphasize to the patient that the transition is intended as a temporary measure, and to discuss a proposed timeline for re-initiating the LAI. Also, emphasize to the patient and family that this transition does not diminish the previous reasoning for needing an LAI, but is a temporary measure taken in light of weighing the risks and benefits during a pandemic.

Long-acting injectable antipsychotics and equivalent oral dosing

Which LAI should be administered?

If continuing the LAI is determined to be clinically necessary, consider switching the patient to a longer-acting preparation to maximize intervals between administrations and minimize the potential for infection. From a public health perspective, the longest clinically prudent interval between injections may be the most important consideration, provided the patient can receive a dose necessary to retain stability, and the LAI should be chosen accordingly. Deltoid injections may be able to be administered with reduced contact, or on a “drive-up” basis.10 Consider transitioning a patient who is receiving olanzapine pamoate to an alternate LAI or oral formulation, because the 3-hour observation period that is required after olanzapine pamoate administration is particularly problematic. While it may not be ideal to make medication changes during a pandemic, it is worth carefully weighing the patient’s stability and historical experience with other LAIs to determine if a safer/longer-spaced option is worth trying.11

We recommend only switching among similar antipsychotics (ie, risperidone to paliperidone), or between different preparations of the same drug (ie, Abilify Maintena to Aristada), if possible, as these are the lowest risk transitions with regards to relapse. Table 3 provides examples.

Considerations for longer-interval LAIs

Continue to: When should the LAI be administered?

 

 

When should the LAI be administered?

The pharmacokinetics of LAIs allow for some flexibility in terms of when an LAI needs to be administered. The package inserts of all second-generation LAIs include missed-dose guidelines. These guidelines provide information on how long one can wait before the next injection is due, and what additional measures must be taken when beyond that date. Delaying an injection may be prudent, and the missed dose guidelines will indicate when one must consider supplementing with oral medications. For patients who are in quarantine, it may be better to delay an injection until the patient ends their quarantine than to deliver the dose during quarantine. Administering an injection earlier also is usually safe; off-cycle visits may help minimize patient contact (ie, if the patient happens to be coming into the vicinity of the clinic, or requires phlebotomy for therapeutic drug monitoring), and assist in planning for possible resurgences. When appropriate, and after considering the risk of worsening adverse effects, administering a higher dose than the usual maintenance dose would provide a buffer if the next injection was to be delayed. Therapeutic drug monitoring can help to optimize dosing and avoid low plasma drug levels, which may be not be sufficient, particularly during this time of stress.12 To provide optimal protection against relapse, consider administering a dose that puts patients at the higher range of plasma drug levels.

Where can the LAI be administered, and who can give it?

For patients who usually travel to a clinic, consider arranging for a more local injection (ie, at the patient’s primary care clinic in their hometown, or at a local mental health center), and explore if the patient may be able to receive their injection in their home through a visiting nurse association (VNA). In many states (approximately 30 currently), clinicians at pharmacies are also able to administer patient injections. Clinics would do well to at least plan for alternate staffing models in the event of staff illness. A pool of individuals should be available to give injections; consider training additional staff members (including MDs who may have never previously administered an LAI but could be quickly instructed to do so) to administer LAIs. Theoretically, during a public health emergency, family members, particularly those who have a background in health care, could be trained to give an injection and provided education on LAI storage and post-injection monitoring. This approach would not be consistent with FDA labeling, however, and should only be considered as a last resort.

What safety measures can be put in place?

Face-to-face time for injection administration should be kept as brief as possible. Before the encounter, obtain the patient’s clinical information, ideally through telehealth or from an acceptable distance. Medication should be drawn ahead of time, and not in an enclosed space with the patient present. Strongly consider abandoning the traditional enclosed room for the injection, and instead use larger spaces, doorways, or outside, if feasible. As previously noted, some clinics and clinicians have used a drive-up approach for LAI administration, particularly for deltoid injections.10 Individuals who administer the injections should wear personal protective equipment, and the clinic should obtain an adequate supply of this equipment well in advance.

Lessons learned at our clinic

In our community mental health center clinic, planning around these questions has allowed us to provide safe and continuous psychiatric care with LAIs during this public health emergency while reducing the risk of infection. We have worked to transfer LAI administration to VNAs and transition patients to longer-lasting formulations or oral medications where appropriate, which has resulted in an approximately 50% decrease in in-person visits. Reducing the number of in-person visits does not need to result in less frequent clinical follow-up. Telepsychiatry visits can make up for lost in-person visits and have generally been well accepted.

As we are preparing for the next phase, routine medical health monitoring (eg, metabolic monitoring, monitoring for tardive dyskinesia) that has not been at the forefront of concerns should be carefully reintroduced. Challenges encountered have included difficulty in having VNA accept patients for short-term LAI visits, changes to where on the body the injection is delivered, and patients with SMI and their families being reluctant to depart from previous routines and administration schedules.

Continue to: There is great value...

 

 

There is great value in the collective lessons learned during this public health emergency (eg, the need for a flexible, population health-based approach; acceptability of combination telehealth and in-person visits) that can lead to more person-centered and accessible care for patients with SMI.

Acknowledgments

The authors thank North Suffolk Mental Health Association, the Freedom Trail Clinic, and their patients.

Bottom Line

When caring for a patient with a psychotic illness during the coronavirus disease 2019 (COVID-19) pandemic, evaluate whether it is necessary to continue a longacting injectable antipsychotic (LAI). If yes, reconsider which LAI should be administered, when and where it should be given, and by whom. Implement safety measures to minimize the risk of COVID-19 exposure and transmission.

Related Resources

Drug Brand Names

Aripiprazole • Abilify
Aripiprazole for extended- release injectable suspension • Abilify Maintena
Aripiprazole lauroxil • Aristada
Haloperidol • Haldol
Haloperidol injection • Haldol decanoate
Olanzapine • Zyprexa
Olanzapine for extended-release injectable suspension • Zyprexa Relprevv
Paliperidone • Invega
Paliperidone palmitate extended-release injectable suspension • Invega Sustenna
Paliperidone palmitate extended-release injectable suspension • Invega Trinza
Risperidone • Risperdal
Risperidone for extended- release injectable suspension • Perseris
Risperidone injection • Risperdal Consta

References

1. Freudenreich O. Long-acting injectable antipsychotics. In: Freudenreich O. Psychotic disorders: a practical guide. Springer; 2020:249-261.
2. Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172-1181.
3. Reilly S, Olier I, Planner C, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. BMJ Open. 2015;5(12):e009010.
4. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-217.
5. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-194.
6. Baggett TP, Keyes H, Sporn N, et al. Prevalence of SARS-CoV-2 infection in residents of a large homeless shelter in Boston. JAMA. 2020;323(21):2191-2192.
7. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.
8. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985
9. Etches V, Frank J, Di Ruggiero E, et al. Measuring population health: a review of indicators. Annu Rev Public Health. 2006;27:29-55.
10. Chepke C. Drive-up pharmacotherapy during the COVID-19 pandemic. Current Psychiatry. 2020;19(5):29-30.
11. Sajatovic M, Ross R, Legacy SN, et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475-1492.
12. Schoretsanitis G, Kane JM, Correll CU, et al; American Society of Clinical Psychopharmacology, Pharmakopsychiatrie TTDMTFOTAFNU. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):19cs13169. doi: 10.4088/JCP.19cs13169

Article PDF
Author and Disclosure Information

Kristina Schnitzer, MD
Fellow, Public and Community Psychiatry
Massachusetts General Hospital
Boston, Massachusetts

Sarah MacLaurin, PMHNP-BC
Freedom Trail Clinic of North Suffolk Mental Health Association
Massachusetts General Hospital
Boston, Massachusetts

Oliver Freudenreich, MD, FACLP
Co-Director, MGH Schizophrenia Clinical and Research Program
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received grant or research support from Alkermes, Avanir, Janssen, Otsuka, and Saladax, and has served as a consultant to Alkermes, Janssen, Neurocrine, Novartis, and Roche. Drs. Schnitzer and MacLaurin report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Issue
Current Psychiatry - 20(2)
Publications
Topics
Page Number
8-13
Sections
Author and Disclosure Information

Kristina Schnitzer, MD
Fellow, Public and Community Psychiatry
Massachusetts General Hospital
Boston, Massachusetts

Sarah MacLaurin, PMHNP-BC
Freedom Trail Clinic of North Suffolk Mental Health Association
Massachusetts General Hospital
Boston, Massachusetts

Oliver Freudenreich, MD, FACLP
Co-Director, MGH Schizophrenia Clinical and Research Program
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received grant or research support from Alkermes, Avanir, Janssen, Otsuka, and Saladax, and has served as a consultant to Alkermes, Janssen, Neurocrine, Novartis, and Roche. Drs. Schnitzer and MacLaurin report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Author and Disclosure Information

Kristina Schnitzer, MD
Fellow, Public and Community Psychiatry
Massachusetts General Hospital
Boston, Massachusetts

Sarah MacLaurin, PMHNP-BC
Freedom Trail Clinic of North Suffolk Mental Health Association
Massachusetts General Hospital
Boston, Massachusetts

Oliver Freudenreich, MD, FACLP
Co-Director, MGH Schizophrenia Clinical and Research Program
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received grant or research support from Alkermes, Avanir, Janssen, Otsuka, and Saladax, and has served as a consultant to Alkermes, Janssen, Neurocrine, Novartis, and Roche. Drs. Schnitzer and MacLaurin report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Article PDF
Article PDF

Long-acting injectable antipsychotics (LAIs) are an essential tool in the treatment of patients with psychotic disorders, allowing for periods of stable drug plasma concentration and confirmed adherence.1 The current coronavirus disease 2019 (COVID-19) pandemic presents unique challenges for administering LAIs and requires a thoughtful and prospective approach in order to ensure continuity of psychiatric care while minimizing the risk of infection with COVID-19. Ideally, patients should be seen in person as infrequently as clinically prudent during this public health emergency; however, LAI administration necessitates direct physical contact between patient and clinician.

Patients with serious mental illness (SMI), who comprise the majority of individuals who receive LAIs, are at heightened risk for cardiovascular and pulmonary comorbidities. These factors are the primary reason the life expectancy of a patient with SMI is nearly 30 years shorter than that of the general population.2-5 The risk of health care workers becoming infected or inadvertently spreading COVID-19 is heightened when working with patients in group living environments (ie, a shelter or group home), who have both increased exposure and increased risk of further transmission.6 Additional patient populations, including older adults, immunocompromised individuals, and those with preexisting conditions, are at heightened risk for serious complications if they were to contract COVID-19.7,8

Thus, the questions of whether LAIs should be administered, and how to do so safely (both during the ongoing, acute phase of the pandemic as well as during the subsequent recovery period until the pandemic abates) need to be carefully considered. In this article, we provide concrete advice for clinicians and clinics on these topics, with the goal of maintaining patients’ psychiatric stability while protecting patients, health care workers, and the broader society from COVID-19 infection. Table 1 summarizes the questions regarding LAIs that clinicians need to address during this crisis. While we focus on outpatient care, inpatient teams should keep these considerations in mind if they are starting and discharging a patient on an LAI. More than ever, close collaboration and communication between inpatient and outpatient teams is critical.

Considerations for LAI administration during COVID-19

Should an LAI be continued?

An important first step to approaching this challenge is to create a spreadsheet for all patients receiving LAIs. Focusing on a population-based approach is helpful to be systematic and ensure that no patients fall through the cracks during this public health emergency.9 Once all patients have been identified, the treatment team should review each patient to determine if continuing to administer the antipsychotic as an LAI formulation is essential, taking into account the patient’s current psychiatric status, historical medication adherence, potential severity and dangerousness of decompensation if nonadherent, and structures to support stability. For example, can a patient move in with family who can monitor medication adherence during the pandemic? Is it possible for the group home to assume medication administration? Additional consideration should be given to the living environment and health-vulnerability of the patient and the individuals living with them.

If the risk calculation does not point strongly towards a need for continuing the LAI, it may be prudent to temporarily transition the patient to the corresponding oral antipsychotic preparation. Table 2 lists all LAIs available in the United States and their approximate equivalent oral dosing. It is important to note that such transitions are not without clinical risk, to emphasize to the patient that the transition is intended as a temporary measure, and to discuss a proposed timeline for re-initiating the LAI. Also, emphasize to the patient and family that this transition does not diminish the previous reasoning for needing an LAI, but is a temporary measure taken in light of weighing the risks and benefits during a pandemic.

Long-acting injectable antipsychotics and equivalent oral dosing

Which LAI should be administered?

If continuing the LAI is determined to be clinically necessary, consider switching the patient to a longer-acting preparation to maximize intervals between administrations and minimize the potential for infection. From a public health perspective, the longest clinically prudent interval between injections may be the most important consideration, provided the patient can receive a dose necessary to retain stability, and the LAI should be chosen accordingly. Deltoid injections may be able to be administered with reduced contact, or on a “drive-up” basis.10 Consider transitioning a patient who is receiving olanzapine pamoate to an alternate LAI or oral formulation, because the 3-hour observation period that is required after olanzapine pamoate administration is particularly problematic. While it may not be ideal to make medication changes during a pandemic, it is worth carefully weighing the patient’s stability and historical experience with other LAIs to determine if a safer/longer-spaced option is worth trying.11

We recommend only switching among similar antipsychotics (ie, risperidone to paliperidone), or between different preparations of the same drug (ie, Abilify Maintena to Aristada), if possible, as these are the lowest risk transitions with regards to relapse. Table 3 provides examples.

Considerations for longer-interval LAIs

Continue to: When should the LAI be administered?

 

 

When should the LAI be administered?

The pharmacokinetics of LAIs allow for some flexibility in terms of when an LAI needs to be administered. The package inserts of all second-generation LAIs include missed-dose guidelines. These guidelines provide information on how long one can wait before the next injection is due, and what additional measures must be taken when beyond that date. Delaying an injection may be prudent, and the missed dose guidelines will indicate when one must consider supplementing with oral medications. For patients who are in quarantine, it may be better to delay an injection until the patient ends their quarantine than to deliver the dose during quarantine. Administering an injection earlier also is usually safe; off-cycle visits may help minimize patient contact (ie, if the patient happens to be coming into the vicinity of the clinic, or requires phlebotomy for therapeutic drug monitoring), and assist in planning for possible resurgences. When appropriate, and after considering the risk of worsening adverse effects, administering a higher dose than the usual maintenance dose would provide a buffer if the next injection was to be delayed. Therapeutic drug monitoring can help to optimize dosing and avoid low plasma drug levels, which may be not be sufficient, particularly during this time of stress.12 To provide optimal protection against relapse, consider administering a dose that puts patients at the higher range of plasma drug levels.

Where can the LAI be administered, and who can give it?

For patients who usually travel to a clinic, consider arranging for a more local injection (ie, at the patient’s primary care clinic in their hometown, or at a local mental health center), and explore if the patient may be able to receive their injection in their home through a visiting nurse association (VNA). In many states (approximately 30 currently), clinicians at pharmacies are also able to administer patient injections. Clinics would do well to at least plan for alternate staffing models in the event of staff illness. A pool of individuals should be available to give injections; consider training additional staff members (including MDs who may have never previously administered an LAI but could be quickly instructed to do so) to administer LAIs. Theoretically, during a public health emergency, family members, particularly those who have a background in health care, could be trained to give an injection and provided education on LAI storage and post-injection monitoring. This approach would not be consistent with FDA labeling, however, and should only be considered as a last resort.

What safety measures can be put in place?

Face-to-face time for injection administration should be kept as brief as possible. Before the encounter, obtain the patient’s clinical information, ideally through telehealth or from an acceptable distance. Medication should be drawn ahead of time, and not in an enclosed space with the patient present. Strongly consider abandoning the traditional enclosed room for the injection, and instead use larger spaces, doorways, or outside, if feasible. As previously noted, some clinics and clinicians have used a drive-up approach for LAI administration, particularly for deltoid injections.10 Individuals who administer the injections should wear personal protective equipment, and the clinic should obtain an adequate supply of this equipment well in advance.

Lessons learned at our clinic

In our community mental health center clinic, planning around these questions has allowed us to provide safe and continuous psychiatric care with LAIs during this public health emergency while reducing the risk of infection. We have worked to transfer LAI administration to VNAs and transition patients to longer-lasting formulations or oral medications where appropriate, which has resulted in an approximately 50% decrease in in-person visits. Reducing the number of in-person visits does not need to result in less frequent clinical follow-up. Telepsychiatry visits can make up for lost in-person visits and have generally been well accepted.

As we are preparing for the next phase, routine medical health monitoring (eg, metabolic monitoring, monitoring for tardive dyskinesia) that has not been at the forefront of concerns should be carefully reintroduced. Challenges encountered have included difficulty in having VNA accept patients for short-term LAI visits, changes to where on the body the injection is delivered, and patients with SMI and their families being reluctant to depart from previous routines and administration schedules.

Continue to: There is great value...

 

 

There is great value in the collective lessons learned during this public health emergency (eg, the need for a flexible, population health-based approach; acceptability of combination telehealth and in-person visits) that can lead to more person-centered and accessible care for patients with SMI.

Acknowledgments

The authors thank North Suffolk Mental Health Association, the Freedom Trail Clinic, and their patients.

Bottom Line

When caring for a patient with a psychotic illness during the coronavirus disease 2019 (COVID-19) pandemic, evaluate whether it is necessary to continue a longacting injectable antipsychotic (LAI). If yes, reconsider which LAI should be administered, when and where it should be given, and by whom. Implement safety measures to minimize the risk of COVID-19 exposure and transmission.

Related Resources

Drug Brand Names

Aripiprazole • Abilify
Aripiprazole for extended- release injectable suspension • Abilify Maintena
Aripiprazole lauroxil • Aristada
Haloperidol • Haldol
Haloperidol injection • Haldol decanoate
Olanzapine • Zyprexa
Olanzapine for extended-release injectable suspension • Zyprexa Relprevv
Paliperidone • Invega
Paliperidone palmitate extended-release injectable suspension • Invega Sustenna
Paliperidone palmitate extended-release injectable suspension • Invega Trinza
Risperidone • Risperdal
Risperidone for extended- release injectable suspension • Perseris
Risperidone injection • Risperdal Consta

Long-acting injectable antipsychotics (LAIs) are an essential tool in the treatment of patients with psychotic disorders, allowing for periods of stable drug plasma concentration and confirmed adherence.1 The current coronavirus disease 2019 (COVID-19) pandemic presents unique challenges for administering LAIs and requires a thoughtful and prospective approach in order to ensure continuity of psychiatric care while minimizing the risk of infection with COVID-19. Ideally, patients should be seen in person as infrequently as clinically prudent during this public health emergency; however, LAI administration necessitates direct physical contact between patient and clinician.

Patients with serious mental illness (SMI), who comprise the majority of individuals who receive LAIs, are at heightened risk for cardiovascular and pulmonary comorbidities. These factors are the primary reason the life expectancy of a patient with SMI is nearly 30 years shorter than that of the general population.2-5 The risk of health care workers becoming infected or inadvertently spreading COVID-19 is heightened when working with patients in group living environments (ie, a shelter or group home), who have both increased exposure and increased risk of further transmission.6 Additional patient populations, including older adults, immunocompromised individuals, and those with preexisting conditions, are at heightened risk for serious complications if they were to contract COVID-19.7,8

Thus, the questions of whether LAIs should be administered, and how to do so safely (both during the ongoing, acute phase of the pandemic as well as during the subsequent recovery period until the pandemic abates) need to be carefully considered. In this article, we provide concrete advice for clinicians and clinics on these topics, with the goal of maintaining patients’ psychiatric stability while protecting patients, health care workers, and the broader society from COVID-19 infection. Table 1 summarizes the questions regarding LAIs that clinicians need to address during this crisis. While we focus on outpatient care, inpatient teams should keep these considerations in mind if they are starting and discharging a patient on an LAI. More than ever, close collaboration and communication between inpatient and outpatient teams is critical.

Considerations for LAI administration during COVID-19

Should an LAI be continued?

An important first step to approaching this challenge is to create a spreadsheet for all patients receiving LAIs. Focusing on a population-based approach is helpful to be systematic and ensure that no patients fall through the cracks during this public health emergency.9 Once all patients have been identified, the treatment team should review each patient to determine if continuing to administer the antipsychotic as an LAI formulation is essential, taking into account the patient’s current psychiatric status, historical medication adherence, potential severity and dangerousness of decompensation if nonadherent, and structures to support stability. For example, can a patient move in with family who can monitor medication adherence during the pandemic? Is it possible for the group home to assume medication administration? Additional consideration should be given to the living environment and health-vulnerability of the patient and the individuals living with them.

If the risk calculation does not point strongly towards a need for continuing the LAI, it may be prudent to temporarily transition the patient to the corresponding oral antipsychotic preparation. Table 2 lists all LAIs available in the United States and their approximate equivalent oral dosing. It is important to note that such transitions are not without clinical risk, to emphasize to the patient that the transition is intended as a temporary measure, and to discuss a proposed timeline for re-initiating the LAI. Also, emphasize to the patient and family that this transition does not diminish the previous reasoning for needing an LAI, but is a temporary measure taken in light of weighing the risks and benefits during a pandemic.

Long-acting injectable antipsychotics and equivalent oral dosing

Which LAI should be administered?

If continuing the LAI is determined to be clinically necessary, consider switching the patient to a longer-acting preparation to maximize intervals between administrations and minimize the potential for infection. From a public health perspective, the longest clinically prudent interval between injections may be the most important consideration, provided the patient can receive a dose necessary to retain stability, and the LAI should be chosen accordingly. Deltoid injections may be able to be administered with reduced contact, or on a “drive-up” basis.10 Consider transitioning a patient who is receiving olanzapine pamoate to an alternate LAI or oral formulation, because the 3-hour observation period that is required after olanzapine pamoate administration is particularly problematic. While it may not be ideal to make medication changes during a pandemic, it is worth carefully weighing the patient’s stability and historical experience with other LAIs to determine if a safer/longer-spaced option is worth trying.11

We recommend only switching among similar antipsychotics (ie, risperidone to paliperidone), or between different preparations of the same drug (ie, Abilify Maintena to Aristada), if possible, as these are the lowest risk transitions with regards to relapse. Table 3 provides examples.

Considerations for longer-interval LAIs

Continue to: When should the LAI be administered?

 

 

When should the LAI be administered?

The pharmacokinetics of LAIs allow for some flexibility in terms of when an LAI needs to be administered. The package inserts of all second-generation LAIs include missed-dose guidelines. These guidelines provide information on how long one can wait before the next injection is due, and what additional measures must be taken when beyond that date. Delaying an injection may be prudent, and the missed dose guidelines will indicate when one must consider supplementing with oral medications. For patients who are in quarantine, it may be better to delay an injection until the patient ends their quarantine than to deliver the dose during quarantine. Administering an injection earlier also is usually safe; off-cycle visits may help minimize patient contact (ie, if the patient happens to be coming into the vicinity of the clinic, or requires phlebotomy for therapeutic drug monitoring), and assist in planning for possible resurgences. When appropriate, and after considering the risk of worsening adverse effects, administering a higher dose than the usual maintenance dose would provide a buffer if the next injection was to be delayed. Therapeutic drug monitoring can help to optimize dosing and avoid low plasma drug levels, which may be not be sufficient, particularly during this time of stress.12 To provide optimal protection against relapse, consider administering a dose that puts patients at the higher range of plasma drug levels.

Where can the LAI be administered, and who can give it?

For patients who usually travel to a clinic, consider arranging for a more local injection (ie, at the patient’s primary care clinic in their hometown, or at a local mental health center), and explore if the patient may be able to receive their injection in their home through a visiting nurse association (VNA). In many states (approximately 30 currently), clinicians at pharmacies are also able to administer patient injections. Clinics would do well to at least plan for alternate staffing models in the event of staff illness. A pool of individuals should be available to give injections; consider training additional staff members (including MDs who may have never previously administered an LAI but could be quickly instructed to do so) to administer LAIs. Theoretically, during a public health emergency, family members, particularly those who have a background in health care, could be trained to give an injection and provided education on LAI storage and post-injection monitoring. This approach would not be consistent with FDA labeling, however, and should only be considered as a last resort.

What safety measures can be put in place?

Face-to-face time for injection administration should be kept as brief as possible. Before the encounter, obtain the patient’s clinical information, ideally through telehealth or from an acceptable distance. Medication should be drawn ahead of time, and not in an enclosed space with the patient present. Strongly consider abandoning the traditional enclosed room for the injection, and instead use larger spaces, doorways, or outside, if feasible. As previously noted, some clinics and clinicians have used a drive-up approach for LAI administration, particularly for deltoid injections.10 Individuals who administer the injections should wear personal protective equipment, and the clinic should obtain an adequate supply of this equipment well in advance.

Lessons learned at our clinic

In our community mental health center clinic, planning around these questions has allowed us to provide safe and continuous psychiatric care with LAIs during this public health emergency while reducing the risk of infection. We have worked to transfer LAI administration to VNAs and transition patients to longer-lasting formulations or oral medications where appropriate, which has resulted in an approximately 50% decrease in in-person visits. Reducing the number of in-person visits does not need to result in less frequent clinical follow-up. Telepsychiatry visits can make up for lost in-person visits and have generally been well accepted.

As we are preparing for the next phase, routine medical health monitoring (eg, metabolic monitoring, monitoring for tardive dyskinesia) that has not been at the forefront of concerns should be carefully reintroduced. Challenges encountered have included difficulty in having VNA accept patients for short-term LAI visits, changes to where on the body the injection is delivered, and patients with SMI and their families being reluctant to depart from previous routines and administration schedules.

Continue to: There is great value...

 

 

There is great value in the collective lessons learned during this public health emergency (eg, the need for a flexible, population health-based approach; acceptability of combination telehealth and in-person visits) that can lead to more person-centered and accessible care for patients with SMI.

Acknowledgments

The authors thank North Suffolk Mental Health Association, the Freedom Trail Clinic, and their patients.

Bottom Line

When caring for a patient with a psychotic illness during the coronavirus disease 2019 (COVID-19) pandemic, evaluate whether it is necessary to continue a longacting injectable antipsychotic (LAI). If yes, reconsider which LAI should be administered, when and where it should be given, and by whom. Implement safety measures to minimize the risk of COVID-19 exposure and transmission.

Related Resources

Drug Brand Names

Aripiprazole • Abilify
Aripiprazole for extended- release injectable suspension • Abilify Maintena
Aripiprazole lauroxil • Aristada
Haloperidol • Haldol
Haloperidol injection • Haldol decanoate
Olanzapine • Zyprexa
Olanzapine for extended-release injectable suspension • Zyprexa Relprevv
Paliperidone • Invega
Paliperidone palmitate extended-release injectable suspension • Invega Sustenna
Paliperidone palmitate extended-release injectable suspension • Invega Trinza
Risperidone • Risperdal
Risperidone for extended- release injectable suspension • Perseris
Risperidone injection • Risperdal Consta

References

1. Freudenreich O. Long-acting injectable antipsychotics. In: Freudenreich O. Psychotic disorders: a practical guide. Springer; 2020:249-261.
2. Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172-1181.
3. Reilly S, Olier I, Planner C, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. BMJ Open. 2015;5(12):e009010.
4. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-217.
5. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-194.
6. Baggett TP, Keyes H, Sporn N, et al. Prevalence of SARS-CoV-2 infection in residents of a large homeless shelter in Boston. JAMA. 2020;323(21):2191-2192.
7. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.
8. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985
9. Etches V, Frank J, Di Ruggiero E, et al. Measuring population health: a review of indicators. Annu Rev Public Health. 2006;27:29-55.
10. Chepke C. Drive-up pharmacotherapy during the COVID-19 pandemic. Current Psychiatry. 2020;19(5):29-30.
11. Sajatovic M, Ross R, Legacy SN, et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475-1492.
12. Schoretsanitis G, Kane JM, Correll CU, et al; American Society of Clinical Psychopharmacology, Pharmakopsychiatrie TTDMTFOTAFNU. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):19cs13169. doi: 10.4088/JCP.19cs13169

References

1. Freudenreich O. Long-acting injectable antipsychotics. In: Freudenreich O. Psychotic disorders: a practical guide. Springer; 2020:249-261.
2. Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172-1181.
3. Reilly S, Olier I, Planner C, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. BMJ Open. 2015;5(12):e009010.
4. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-217.
5. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-194.
6. Baggett TP, Keyes H, Sporn N, et al. Prevalence of SARS-CoV-2 infection in residents of a large homeless shelter in Boston. JAMA. 2020;323(21):2191-2192.
7. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.
8. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985
9. Etches V, Frank J, Di Ruggiero E, et al. Measuring population health: a review of indicators. Annu Rev Public Health. 2006;27:29-55.
10. Chepke C. Drive-up pharmacotherapy during the COVID-19 pandemic. Current Psychiatry. 2020;19(5):29-30.
11. Sajatovic M, Ross R, Legacy SN, et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475-1492.
12. Schoretsanitis G, Kane JM, Correll CU, et al; American Society of Clinical Psychopharmacology, Pharmakopsychiatrie TTDMTFOTAFNU. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):19cs13169. doi: 10.4088/JCP.19cs13169

Issue
Current Psychiatry - 20(2)
Issue
Current Psychiatry - 20(2)
Page Number
8-13
Page Number
8-13
Publications
Publications
Topics
Article Type
Display Headline
Long-acting injectable antipsychotics during COVID-19
Display Headline
Long-acting injectable antipsychotics during COVID-19
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media

COVID-19 and patients with serious mental illness

Article Type
Changed
Thu, 08/26/2021 - 16:00
Display Headline
COVID-19 and patients with serious mental illness

“This whole thing is not about heroism. It’s about decency. It may seem a ridiculous idea, but the only way to fight the plague is with decency . ”

– Albert Camus, La Peste (1947)1

Severe acute respiratory syndrome (SARS), H1N1 swine flu, Ebola, Zika, and Middle East respiratory syndrome (MERS): the 21st century has already been witness to several serious infectious outbreaks and pandemics,2 but none has been as deadly and consequential as the current one. The ongoing SARS-coronavirus-2 (SARS-CoV-2) pandemic is shaping not only current psychiatric care but the future of psychiatry. Now that we are beyond the initial stages of the coronavirus disease 2019 (COVID-19) pandemic, when psychiatrists had a crash course in disaster psychiatry, our attention must shift to rebuilding and managing disillusionment and other psychological fallout of the intense early days.3

In this article, we offer guidance to psychiatrists caring for patients with serious mental illness (SMI) during the SARS-CoV-2 pandemic. Patients with SMI are easily forgotten as other issues (eg, preserving ICU capacity) overshadow the already historically neglected needs of this impoverished group.4 From both human and public-health perspectives, this inattention is a mistake. Assuring psychiatric stability is critically important to prevent the spread of COVID-19 in marginalized communities comprised of individuals who are poor, members of racial minorities, and others who already experience health disparities.5 Without controlling transmission in these groups, the pandemic will not be sufficiently contained.

We begin by highlighting general principles of pandemic management because caring for patients with SMI does not occur in a vacuum. Infectious outbreaks require not only helping those who need direct medical care because they are infected, but also managing populations that are at risk of getting infected, including health care and other essential workers.

Principles of pandemic management

Delivery of medical care during a pandemic differs from routine care. An effective disaster response requires collaboration and coordination among public-health, treatment, and emergency systems. Many institutions shift to an incident management system and crisis leadership, with clear lines of authority to coordinate responders and build medical surge capacity. Such a top-down leadership approach must plan and allow for the emergence of other credible leaders and for the restoration of people’s agency.

Unfortunately, adaptive capacity may be limited, especially in the public sector and psychiatric care system, where resources are already poor. Particularly early in a pandemic, services considered non-essential—which includes most psychiatric outpatient care—can become unavailable. A major effort is needed to prevent the psychiatric care system from contracting further, as happened during 9/11.6 Additionally, “essential” cannot be conflated with “emergent,” as can easily occur in extreme circumstances. Early and sustained efforts are required to ensure that patients with SMI who may be teetering on the edge of emergency status do not slip off that edge, especially when the emergency medical system is operating over capacity.

A comprehensive outbreak response must consider that a pandemic is not only a medical crisis but a mental health crisis and a communication emergency.7 Mental health clinicians need to provide accurate information and help patients cope with their fears.

Continue to: Psychological aspects of pandemics

 

 

Psychological aspects of pandemics. Previous infectious outbreaks have reaffirmed that mental health plays an outsized role during epidemics. Chaos, uncertainty, fear of death, and loss of income and housing cause prolonged stress and exact a psychological toll.

Adverse psychological impacts include expectable, normal reactions such as stress-induced anxiety or insomnia. In addition, new-onset psychiatric illnesses or exacerbations of existing ones may emerge.8 As disillusionment and demoralization appear in the wake of the acute phase, with persistently high unemployment, suicide prevention becomes an important goal.9

Pandemics lead to expectable behavioral responses (eg, increases in substance use and interpersonal conflict). Fear-based decisions may result in unhelpful behavior, such as hoarding medications (which may result in shortages) or dangerous, unsupervised use of unproven medications (eg, hydroxychloroquine). Trust is needed to accept public-health measures, and recommendations (eg, wearing masks) must be culturally informed to be credible and effective.

Because people are affected differently, at individual, cultural, and socioeconomic levels, they will view the situation differently. For many people, secondary stressors (eg, job loss) may be more disastrous than the primary medical event (ie, the pandemic). This distinction is critical because concrete financial help, not psychiatric care, is needed. Sometimes, even when a psychiatric disorder such as SMI or major neurocognitive disorder is present, the illusion of an acute decompensation can be created by the loss of social and structural supports that previously scaffolded a person’s life.

Mental illness prevention. Community mental-health surveillance is important to monitor for distress, psychiatric symptoms, health-risk behaviors, risk and safety perception, and preparedness. Clinicians must be ready to normalize expectable and temporary distress, while recognizing when that distress becomes pathological. This may be difficult in patients with SMI who often already have reduced stress tolerance or problem-based coping skills.10

Continue to: Psychological first aid...

 

 

Psychological first aid (PFA) is a standard intervention recommended by the World Health Organization for most individuals following a disaster; it is evidence-informed and has face validity.11 Intended to relieve distress by creating an environment that is safe, calm, and connected, PFA fosters self-efficacy and hope. While PFA is a form of universal prevention, it is not designed for patients with SMI, is not a psychiatric intervention, and is not provided by clinicians. Its principles, however, can easily be applied to patients with SMI to prevent distressing symptoms from becoming a relapse.

Communication. Good risk and crisis communication are critical because individual and population behavior will be governed by the perception of risk and fear, and not by facts. Failure to manage the “infodemic”7—with its misinformation, contradictory messages, and rumors—jeopardizes infection control if patients become paralyzed by uncertainty and fear. Scapegoating occurs easily during times of threat, and society must contain the parallel epidemic of xenophobia based on stigma and misinformation.12

Decision-making under uncertainty is not perfect and subject to revision as better information becomes available. Pointing this out to the public is delicate but essential to curtail skepticism and mistrust when policies are adjusted in response to new circumstances and knowledge.

Mistrust of an authority’s legitimacy and fear-based decisions lead to lack of cooperation with public-health measures, which can undermine an effective response to the pandemic. Travel restrictions or quarantine measures will not be followed if individuals question their importance. Like the general public, patients need education and clear communication to address their fear of contagion, dangers posed to family (and pets), and mistrust of authority and government. A lack of appreciation of the seriousness of the pandemic and individual responsibility may need to be addressed. Two important measures to accomplish this are steering patients to reputable sources of information and advising that they limit media exposure.

Resilience-building. Community and workplace resilience are important aspects of making it through a disaster as best as possible. Resilience is not innate and fixed; it must be deliberately built.13 Choosing an attitude of post-traumatic growth over the victim narrative is a helpful stance. Practicing self-care (rest, nutrition, exercise) and self-compassion (self-kindness, common humanity, mindfulness) is good advice for patients and caregivers alike.

Continue to: Workforce protection

 

 

Workforce protection. Compared to other disasters, infectious outbreaks disproportionally affect the medical community, and care delivery is at stake. While psychological and psychiatric needs may increase during a pandemic, services often contract, day programs and clinics close, teams are reduced to skeleton crews, and only emergency psychiatric care is available. Workforce protection is critical to avoid illness or simple absenteeism due to mistrust of protective measures.

Only a well-briefed, well-led, well-supported, and adequately resourced workforce is going to be effective in managing this public-health emergency. Burnout and moral injury are feared long-term consequences for health care workers that need to be proactively addressed.14 As opposed to other forms of disasters, managing your own fears about safety is important. Clinicians and their patients sit in the proverbial same boat.

Ethics. The anticipated need to ration life-saving care (eg, ventilators) has been at the forefront of ethical concerns.15 In psychiatry, the question of involuntary public-health interventions for uncooperative psychiatric patients sits uncomfortably between public-health ethics and human rights, and is an opportunity for collaboration with public-health and infectious-disease colleagues.

Redeployed clinicians and those working under substandard conditions may be concerned about civil liability due to a modified standard of care during a crisis. Some clinicians may ask if their duty to care must override their natural instinct to protect themselves. There is a lot of room for resentment in these circumstances. Redeployed or otherwise “conscripted” clinicians may resent administrators, especially those administering from the safety of their homes. Those “left behind” to work in potentially precarious circumstances may resent their absent colleagues. Moreover, these front-line clinicians may have been forced to make ethical decisions for which they were not prepared.16 Maintaining morale is far from trivial, not just during the pandemic, but afterward, when (and if) the entire workforce is reunited. All parties need to be mindful of how their actions and decisions impact and are perceived by others, both in the hospital and at home.

Managing patients with SMI during COVID-19

Patients with SMI are potentially hard hit by COVID-19 due to a “tragic” epidemiologic triad of agent-host-environment: SARS-CoV-2 is a highly infectious agent affecting patients with SMI who are vulnerable hosts in permissive environments (Figure).

‘Tragic’ epidemiologic triad for patients with SMI

Continue to: While not as infectious as measles...

 

 

While not as infectious as measles, COVID-19 is more infectious than the seasonal flu virus.17 It can lead to uncontrolled infection within a short period of time, particularly in enclosed settings. Outbreaks have occurred readily on cruise ships and aircraft carriers as well as in nursing homes, homeless shelters, prisons, and group homes.

Patients with SMI are vulnerable hosts because they have many of the medical risk factors18 that portend a poor prognosis if they become infected, including pre-existing lung conditions and heart disease19 as well as diabetes and obesity.20 Obesity likely creates a hyperinflammatory state and a decrease in vital capacity. Patient-related behavioral factors include poor early-symptom reporting and ineffective infection control.

Unfavorable social determinants of health include not only poverty but crowded housing that is a perfect incubator for COVID-19.

Priority treatment goals. The overarching goal during a pandemic is to keep patients with SMI in psychiatric treatment and prevent them from disengaging from care in the service of infection control. Urgent tasks include infection control, relapse prevention, and preventing treatment disengagement and loneliness.

Infection control. As trusted sources of information, psychiatrists can play an important role in infection control in several important ways:

  • educating patients about infection-control measures and public-health recommendations
  • helping patients understand what testing can accomplish and when to pursue it
  • encouraging protective health behaviors (eg, hand washing, mask wearing, physical distancing)
  • assessing patients’ risk appreciation
  • assessing for and addressing obstacles to implementing and complying with infection-control measures
  • explaining contact tracing
  • providing reassurance.

Continue to: Materials and explanations...

 

 

Materials and explanations must be adapted for patient understanding.

Patients with disorganization or cognitive disturbances may have difficulties cooperating or problem-solving. Patients with negative symptoms may be inappropriately unconcerned and also inaccurately report symptoms that suggest COVID-19. Acute psychosis or mania can prevent patients from complying with public-health efforts. Some measures may be difficult to implement if the means are simply not there (eg, physical distancing in a crowded apartment). Previously open settings (eg, group homes) have had to develop new mechanisms under the primacy of infection control. Inpatient units—traditionally places where community, shared healing, and group therapy are prized—have had to decrease maximum occupancy, limit the number of patients attending groups, and discourage or outrightly prohibit social interaction (eg, dining together).

Relapse prevention. Patients who take maintenance medications need to be supported. A manic or psychotic relapse during a pandemic puts patients at risk of acquiring and spreading COVID-19. “Treatment as prevention” is a slogan from human immunodeficiency virus (HIV) care that captures the importance of antiretroviral treatment to prevent medical complications from HIV, and also to reduce infecting other people. By analogy, psychiatric treatment for patients with SMI can prevent psychiatric instability and thereby control viral transmission. Avoiding sending psychiatric patients to a potentially stressed acute-care system is important.

Psychosocial support. Clinics need to ensure that patients continue to engage in care beyond medication-taking to proactively prevent psychiatric exacerbations. Healthful, resilience-building behaviors should be encouraged while monitoring and counseling against maladaptive ones (eg, increased substance use). Supporting patients emotionally and helping them solve problems are critical, particularly for those who are subjected to quarantine or isolation. Obviously, in these latter situations, outreach will be necessary and may require creative delivery systems and dedicated clinicians for patients who lack access to the technology necessary for virtual visits. Havens and Ghaemi21 have suggested that a good therapeutic alliance can be viewed as a mood stabilizer. Helping patients grieve losses (loved ones, jobs, sense of safety) may be an important part of support.

Even before COVID-19, loneliness was a major factor for patients with schizophrenia.22 A psychiatric clinic is one aspect of a person with SMI’s social network; during the initial phase of the pandemic, many clinics and treatment programs closed. Patients for whom clinics structure and anchor their activities are at high risk of disconnecting from treatment, staying at home, and becoming lonely.

Continue to: Caregivers are always important...

 

 

Caregivers are always important to SMI patients, but they may assume an even bigger role during this pandemic. Some patients may have moved in with a relative, after years of living on their own. In other cases, stable caregiver relationships may be disrupted due to COVID-19–related sickness in the caregiver; if not addressed, this can result in a patient’s clinical decompensation. Clinicians should take the opportunity to understand who a patient’s caregivers are (group home staff, families) and rekindle clinical contact with them. Relationships with caregivers that may have been on “autopilot” during normal times are opportunities for welcome support and guidance, to the benefit of both patients and caregivers.

Table 1 summarizes clinical tasks that need to be kept in mind when conducting clinic visits during COVID-19 in order to achieve the high-priority treatment goals of infection control, relapse prevention, and psychosocial support.

Clinical tasks for patients with SMI during the COVID-19 pandemic

Differential diagnosis. Neuropsychiatric syndromes have long been observed in influenza pandemics,23 due both to direct viral effects and to the effects of critical illness on the brain. Two core symptoms of COVID-19—anosmia and ageusia—suggest that COVID-19 can directly affect the brain. While neurologic manifestations are common,24 it remains unclear to what extent COVID-19 can directly “cause” psychiatric symptoms, or if such symptoms are the result of cytokines25 or other medical processes (eg, thromboembolism).26 Psychosis due to COVID-19 may, in some cases, represent a stress-related brief psychotic disorder.27

Hospitalized patients who have recovered from COVID-19 may have experienced prolonged sedation and severe delirium in an ICU.28 Complications such as posttraumatic stress disorder,29 hypoperfusion-related brain injuries, or other long-term cognitive difficulties may result. In previous flu epidemics, patients developed serious neurologic complications such as post-encephalitic Parkinson’s disease.30

Any person subjected to isolation or quarantine is at risk for psychiatric complications.31 Patients with SMI who live in group homes may be particularly susceptible to new rules, including no-visitor policies.

Continue to: Outpatients whose primary disorder...

 

 

Outpatients whose primary disorder is well controlled may, like anyone else, struggle with the effects of the pandemic. It is necessary to carefully differentiate non-specific symptoms associated with stress from the emergence of a new disorder resulting from stress.32 For some patients, grief or adjustment disorders should be considered. Prolonged stress and uncertainty may eventually lead to an exacerbation of a primary disorder, particularly if the situation (eg, financial loss) does not improve or worsens. Demoralization and suicidal thinking need to be monitored. Relapse or increased use of alcohol or other substances as a response to stress may also complicate the clinical picture.33 Last, smoking cessation as a major treatment goal in general should be re-emphasized and not ignored during the ongoing pandemic.34

Psychiatric symptoms in patients with SMI during the COVID-19 pandemic

Table 2 summarizes psychiatric symptoms that need to be considered when managing a patient with SMI during this pandemic.

Treatment tools

Psychopharmacology. Even though crisis-mode prescribing may be necessary, the safe use of psychotropics remains the goal of psychiatric prescribing. Access to medications becomes a larger consideration; for many patients, a 90-day supply may be indicated. Review of polypharmacy, including for pneumonia risk, should be undertaken. Preventing drooling (eg, from sedation, clozapine, extrapyramidal symptoms [EPS]) will decrease aspiration risk.

 

In general, treatment of psychiatric symptoms in a patient with COVID-19 follows usual guidelines. The best treatment for COVID-19 patients with delirium, however, remains to be established, particularly how to manage severe agitation.28 Pharmacodynamic and pharmacokinetic drug–drug interactions between psychotropics and antiviral treatments for COVID-19 (eg, QTc prolongation) can be expected and need to be reviewed.35 For stress-related anxiety, judicious pharmacotherapy can be helpful. Diazepam given at the earliest signs of a psychotic relapse may stave off a relapse for patients with schizophrenia.36 Even if permitted under relaxed prescribing rules during a public-health emergency, prescribing controlled substances without seeing patients in person requires additional thought. In some cases, adjusting the primary medication to buffer against stress may be preferred (eg, adjusting an antipsychotic in a patient on maintenance treatment for schizophrenia, particularly if a low-dose strategy is pursued).

Consensus statement on the use of clozapine during the COVID-19 pandemic

Clozapine requires registry-based prescribing and bloodwork (“no blood, no drug”). The use of clozapine during this public-health emergency has been made easier because of FDA guidance that allows clozapine to be dispensed without blood work if obtaining blood work is not possible (eg, a patient is quarantined) or can be accomplished only at substantial risk to patients and the population at large. Under certain conditions, clozapine can be dispensed safely and in a way that is consistent with infection prevention. Clozapine-treated patients admitted with COVID-19 should be monitored for clozapine toxicity and the clozapine dose adjusted.37 A consensus statement consistent with the FDA and clinical considerations for using clozapine during COVID-19 is summarized in Table 3.38

Continue to: Long-acting injectable antipsychotics...

 

 

Long-acting injectable antipsychotics (LAIs) pose a problem because they require in-person visits. Ideally, during a pandemic, patients should be seen in person as frequently as medically necessary but as infrequently as possible to limit exposure of both patients and staff. Table 4 provides some clinical recommendations on how to use LAIs during the pandemic.39

Use of long-acting injectable antipsychotics during the COVID-19 pandemic

Supportive psychotherapy may be the most important tool we have in helping patients with loss and uncertainty during these challenging months.40 Simply staying in contact with patients plays a major role in preventing care discontinuity. Even routine interactions have become stressful, with everyone wearing a mask that partially obscures the face. People with impaired hearing may find it even more difficult to understand you.

Education, problem-solving, and a directive, encouraging style are major tools of supportive psychotherapy to reduce symptoms and increase adaptive skills. Clarify that social distancing refers to physical, not emotional, distancing. The judicious and temporary use of anxiolytics is appropriate to reduce anxiety. Concrete help and problem-solving (eg, filling out forms) are examples of proactive crisis intervention.

Telepsychiatry emerged in the pandemic’s early days as the default mode of practice in order to limit in-person contacts.41 Like all new technology, telepsychiatry brings progress and peril.42 While it has gone surprisingly well for most, the “digital divide” does not afford all patients access to the needed technology. The long-term effectiveness and acceptance of telehealth remain to be seen. (Editor’s Note: For more about this topic, see “Telepsychiatry: What you need to know.” Current Psychiatry. 2020;19[6]:16-23.)

Lessons learned and outlook

Infectious outbreaks have historically inflicted long-term disruptions on societies and altered the course of history. However, each disaster is unique, and lessons from previous disasters may only partially apply.43 We do not yet know how this one will end, including how long it will take for the world’s economies to recover. If nothing else, the current public-health emergency has brought to the forefront what psychiatrists have always known: health disparities are partially responsible for different disease risks (in this case, the risk of getting infected with SARS-CoV-2).5 It may not be a coincidence that the Black Lives Matter movement is becoming a major impetus for social change at a time when the pandemic is exposing health-care inequalities.

Continue to: Some areas of the country...

 

 

Some areas of the country succeeded in reducing infections and limiting community spread, which ushered in an uneasy sense of normalcy even while the pandemic continues. At least for now, these locales can focus on rebuilding and preparing for expectable fluctuations in disease activity, including the arrival of the annual flu season on top of COVID-19.44 Recovery is not a return to the status quo ante but building stronger communities—“building back better.”45 Unless there is a continuum of care, shortcomings in one sector will have ripple effects through the entire system, particularly for psychiatric care for patients with SMI, which was inadequate before the pandemic.

Ensuring access to critical care was a priority during the pandemic’s early phase but came at the price of deferring other types of care, such as routine primary care; the coming months will see the downstream consequences of this approach,46 including for patients with SMI.

In the meantime, doing our job as clinicians, as Camus’s fictitious Dr. Bernard Rieux from the epigraph responds when asked how to define decency, may be the best we can do in these times. This includes contributing to and molding our field’s future and fostering a sense of agency in our patients and in ourselves. Major goals will be to preserve lessons learned, maintain flexibility, and avoid a return to unhelpful overregulation and payment models that do not reflect the flexible, person-centered care so important for patients with SMI.47

Bottom Line

During a pandemic, patients with serious mental illness may be easily forgotten as other issues overshadow the needs of this impoverished group. During a pandemic, the priority treatment goals for these patients are infection control, relapse prevention, and preventing treatment disengagement and loneliness. A pandemic requires changes in how patients with serious mental illness will receive psychopharmacology and psychotherapy.

Related Resources

Drug Brand Names

Clozapine • Clozaril
Diazepam • Valium
Hydroxychloroquine • Plaquenil

References

1. Camus A. La peste. Paris, France: Éditions Gallimard; 1947.
2. Huremovic´ D. Brief history of pandemics (pandemics throughout history). In: Huremovic´ D (ed). Psychiatry of pandemics: a mental health response to infection outbreak. Cham, Switzerland: Springer Nature Switzerland AG; 2019:7-35.
3. Substance Abuse and Mental Health Services Administration. Phases of disaster. https://www.samhsa.gov/dtac/recovering-disasters/phases-disaster. Updated June 17, 2020. Accessed August 7, 2020.
4. Geller J. COVID-19 and advocacy—the good and the unacceptable. Psychiatric News. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2020.5b13. Published May 7, 2020. Accessed August 7, 2020.
5. Webb Hooper M, Nápoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466-2467.
6. Sederer LI, Lanzara CB, Essock SM, et al. Lessons learned from the New York State mental health response to the September 11, 2001, attacks. Psychiatr Serv. 2011;62(9):1085-1089.
7. World Health Organization. Infodemic management – infodemiology. https://www.who.int/teams/risk-communication/infodemic-management. Accessed August 7, 2020.
8. Zhou J, Liu L, Xue P, et al. Mental health response to the COVID-19 outbreak in China. Am J Psychiatry. 2020;117(7):574-575.
9. Kawohl W, Nordt C. COVID-19, unemployment, and suicide. Lancet Psychiatry. 2020;7(5):389-390.
10. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. doi: 10.1016/S2215-0366(20)30090-0.
11. Minihan E, Gavin B, Kelly BD, et al. Covid-19, mental health and psychological first aid. Ir J Psychol Med. 2020:1-12.
12. Adja KYC, Golinelli D, Lenzi J, et al. Pandemics and social stigma: who’s next? Italy’s experience with COVID-19. Public Health. 2020;185:39-41.
13. Rosenberg AR. Cultivating deliberate resilience during the coronavirus disease 2019 pandemic [published online April 14, 2020]. JAMA Pediatr. doi: 10.1001/jamapediatrics.2020.1436.
14. Dean W, Talbot SG, Caplan A. Clarifying the language of clinician distress [published online January 31, 2020]. JAMA. doi: 10.1001/jama.2019.21576.
15. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049-2055.
16. Rosenbaum L. Facing Covid-19 in Italy - ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med. 2020;382(20):1873-1875.
17. Viceconte G, Petrosillo N. COVID-19 R0: magic number or conundrum? Infect Dis Rep. 2020;12(1):8516.
18. de Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15-22.
19. Chen R, Liang W, Jiang M, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158(1):97-105.
20. Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020;10(3):e12365. doi: 10.1111/cob.12365.
21. Havens LL, Ghaemi SN. Existential despair and bipolar disorder: the therapeutic alliance as a mood stabilizer. Am J Psychother. 2005;59(2):137-147.
22. Trémeau F, Antonius D, Malaspina D, et al. Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Res. 2016;246:211-217.
23. Menninger KA. Psychoses associated with influenza: I. General data: statistical analysis. JAMA. 1919;72(4):235-241.
24. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832. doi: 10.1016/j.jns.2020.116832.
25. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? [published online May 19, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.012.
26. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39.
27. Martin Jr. EB. Brief psychotic disorder triggered by fear of coronavirus? Psychiatric Times. https://www.psychiatrictimes.com/view/brief-psychotic-disorder-triggered-fear-coronavirus-small-case-series. Published May 8, 2020. Accessed August 7, 2020.
28. Sher Y, Rabkin B, Maldonado JR, et al. COVID-19-associated hyperactive intensive care unit delirium with proposed pathophysiology and treatment: a case report [published online May 19, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.007.
29. Wolters AE, Peelen LM, Welling MC, et al. Long-term mental health problems after delirium in the ICU. Crit Care Med. 2016;44(10):1808-1813.
30. Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med Infect Dis. 2008;6(3):114-124.
31. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912-920.
32. Maercker A, Brewin CR, Bryant RA, et al. Diagnosis and classification of disorders specifically associated with stress: proposals for ICD-11. World Psychiatry. 2013;12(3):198-206.
33. Ornell F, Moura HF, Scherer JN, et al. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry Res. 2020;289:113096. doi: 10.1016/j.psychres.2020.113096.
34. Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking [published online April 3, 2020]. Nicotine Tob Res. https://doi.org/10.1093/ntr/ntaa059.
35. Back D, Marzolini C, Hodge C, et al. COVID-19 treatment in patients with comorbidities: awareness of drug-drug interactions [published online May 8, 2020]. Br J Clin Pharmacol. doi: 10.1111/bcp.14358.
36. Carpenter WT Jr., Buchanan RW, Kirkpatrick B, et al. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry. 1999;156(2):299-303.
37. Dotson S, Hartvigsen N, Wesner T, et al. Clozapine toxicity in the setting of COVID-19 [published online May 30, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.025.
38. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45(3):222-223.
39. Schnitzer K, MacLaurin S, Freudenreich O. Long-acting injectable antipsychotics during the COVID-19 pandemic. Current Psychiatry. In press.
40. Winston A, Rosenthal RN, Pinsker H. Learning supportive psychotherapy: an illustrated guide. Washington, DC: American Psychiatric Publishing; 2012.
41. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681.
42. Jordan A, Dixon LB. Considerations for telepsychiatry service implementation in the era of COVID-19. Psychiatr Serv. 2020;71(6):643-644.
43. DePierro J, Lowe S, Katz C. Lessons learned from 9/11: mental health perspectives on the COVID-19 pandemic. Psychiatry Res. 2020;288:113024.
44. Hussain S. Immunization and vaccination. In: Huremovic´ D (ed). Psychiatry of pandemics: a mental health response to infection outbreak. Cham, Switzerland: Springer Nature Switzerland AG; 2019.
45. Epping-Jordan JE, van Ommeren M, Ashour HN, et al. Beyond the crisis: building back better mental health care in 10 emergency-affected areas using a longer-term perspective. Int J Ment Health Syst. 2015;9:15.
46. Rosenbaum L. The untold toll - the pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368-2371.
47. Bartels SJ, Baggett TP, Freudenreich O, et al. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness [published online June 3, 2020]. Psychiatr Serv. doi: 10.1176/appi.ps.202000244.

Article PDF
Author and Disclosure Information

Oliver Freudenreich, MD, FACLP
Co-Director, MGH Schizophrenia Clinical and Research Program
Associate Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Nicholas Kontos, MD, FACLP
Director, Fellowship in Consultation-Liaison Psychiatry
Assistant Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

John Querques, MD
Vice Chairman for Hospital Services
Department of Psychiatry
Tufts Medical Center
Associate Professor of Psychiatry
Tufts University School of Medicine
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received grant or research support from Alkermes, Avanir, Janssen, and Otsuka, and has served as a consultant to American Psychiatric Association, Alkermes, Janssen, Neurocrine, Novartis, and Roche. Dr. Kontos and Dr. Querques report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Issue
Current Psychiatry - 19(9)
Publications
Topics
Page Number
24-27,33-39
Sections
Author and Disclosure Information

Oliver Freudenreich, MD, FACLP
Co-Director, MGH Schizophrenia Clinical and Research Program
Associate Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Nicholas Kontos, MD, FACLP
Director, Fellowship in Consultation-Liaison Psychiatry
Assistant Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

John Querques, MD
Vice Chairman for Hospital Services
Department of Psychiatry
Tufts Medical Center
Associate Professor of Psychiatry
Tufts University School of Medicine
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received grant or research support from Alkermes, Avanir, Janssen, and Otsuka, and has served as a consultant to American Psychiatric Association, Alkermes, Janssen, Neurocrine, Novartis, and Roche. Dr. Kontos and Dr. Querques report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Author and Disclosure Information

Oliver Freudenreich, MD, FACLP
Co-Director, MGH Schizophrenia Clinical and Research Program
Associate Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Nicholas Kontos, MD, FACLP
Director, Fellowship in Consultation-Liaison Psychiatry
Assistant Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

John Querques, MD
Vice Chairman for Hospital Services
Department of Psychiatry
Tufts Medical Center
Associate Professor of Psychiatry
Tufts University School of Medicine
Boston, Massachusetts

Disclosures
Dr. Freudenreich has received grant or research support from Alkermes, Avanir, Janssen, and Otsuka, and has served as a consultant to American Psychiatric Association, Alkermes, Janssen, Neurocrine, Novartis, and Roche. Dr. Kontos and Dr. Querques report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Article PDF
Article PDF

“This whole thing is not about heroism. It’s about decency. It may seem a ridiculous idea, but the only way to fight the plague is with decency . ”

– Albert Camus, La Peste (1947)1

Severe acute respiratory syndrome (SARS), H1N1 swine flu, Ebola, Zika, and Middle East respiratory syndrome (MERS): the 21st century has already been witness to several serious infectious outbreaks and pandemics,2 but none has been as deadly and consequential as the current one. The ongoing SARS-coronavirus-2 (SARS-CoV-2) pandemic is shaping not only current psychiatric care but the future of psychiatry. Now that we are beyond the initial stages of the coronavirus disease 2019 (COVID-19) pandemic, when psychiatrists had a crash course in disaster psychiatry, our attention must shift to rebuilding and managing disillusionment and other psychological fallout of the intense early days.3

In this article, we offer guidance to psychiatrists caring for patients with serious mental illness (SMI) during the SARS-CoV-2 pandemic. Patients with SMI are easily forgotten as other issues (eg, preserving ICU capacity) overshadow the already historically neglected needs of this impoverished group.4 From both human and public-health perspectives, this inattention is a mistake. Assuring psychiatric stability is critically important to prevent the spread of COVID-19 in marginalized communities comprised of individuals who are poor, members of racial minorities, and others who already experience health disparities.5 Without controlling transmission in these groups, the pandemic will not be sufficiently contained.

We begin by highlighting general principles of pandemic management because caring for patients with SMI does not occur in a vacuum. Infectious outbreaks require not only helping those who need direct medical care because they are infected, but also managing populations that are at risk of getting infected, including health care and other essential workers.

Principles of pandemic management

Delivery of medical care during a pandemic differs from routine care. An effective disaster response requires collaboration and coordination among public-health, treatment, and emergency systems. Many institutions shift to an incident management system and crisis leadership, with clear lines of authority to coordinate responders and build medical surge capacity. Such a top-down leadership approach must plan and allow for the emergence of other credible leaders and for the restoration of people’s agency.

Unfortunately, adaptive capacity may be limited, especially in the public sector and psychiatric care system, where resources are already poor. Particularly early in a pandemic, services considered non-essential—which includes most psychiatric outpatient care—can become unavailable. A major effort is needed to prevent the psychiatric care system from contracting further, as happened during 9/11.6 Additionally, “essential” cannot be conflated with “emergent,” as can easily occur in extreme circumstances. Early and sustained efforts are required to ensure that patients with SMI who may be teetering on the edge of emergency status do not slip off that edge, especially when the emergency medical system is operating over capacity.

A comprehensive outbreak response must consider that a pandemic is not only a medical crisis but a mental health crisis and a communication emergency.7 Mental health clinicians need to provide accurate information and help patients cope with their fears.

Continue to: Psychological aspects of pandemics

 

 

Psychological aspects of pandemics. Previous infectious outbreaks have reaffirmed that mental health plays an outsized role during epidemics. Chaos, uncertainty, fear of death, and loss of income and housing cause prolonged stress and exact a psychological toll.

Adverse psychological impacts include expectable, normal reactions such as stress-induced anxiety or insomnia. In addition, new-onset psychiatric illnesses or exacerbations of existing ones may emerge.8 As disillusionment and demoralization appear in the wake of the acute phase, with persistently high unemployment, suicide prevention becomes an important goal.9

Pandemics lead to expectable behavioral responses (eg, increases in substance use and interpersonal conflict). Fear-based decisions may result in unhelpful behavior, such as hoarding medications (which may result in shortages) or dangerous, unsupervised use of unproven medications (eg, hydroxychloroquine). Trust is needed to accept public-health measures, and recommendations (eg, wearing masks) must be culturally informed to be credible and effective.

Because people are affected differently, at individual, cultural, and socioeconomic levels, they will view the situation differently. For many people, secondary stressors (eg, job loss) may be more disastrous than the primary medical event (ie, the pandemic). This distinction is critical because concrete financial help, not psychiatric care, is needed. Sometimes, even when a psychiatric disorder such as SMI or major neurocognitive disorder is present, the illusion of an acute decompensation can be created by the loss of social and structural supports that previously scaffolded a person’s life.

Mental illness prevention. Community mental-health surveillance is important to monitor for distress, psychiatric symptoms, health-risk behaviors, risk and safety perception, and preparedness. Clinicians must be ready to normalize expectable and temporary distress, while recognizing when that distress becomes pathological. This may be difficult in patients with SMI who often already have reduced stress tolerance or problem-based coping skills.10

Continue to: Psychological first aid...

 

 

Psychological first aid (PFA) is a standard intervention recommended by the World Health Organization for most individuals following a disaster; it is evidence-informed and has face validity.11 Intended to relieve distress by creating an environment that is safe, calm, and connected, PFA fosters self-efficacy and hope. While PFA is a form of universal prevention, it is not designed for patients with SMI, is not a psychiatric intervention, and is not provided by clinicians. Its principles, however, can easily be applied to patients with SMI to prevent distressing symptoms from becoming a relapse.

Communication. Good risk and crisis communication are critical because individual and population behavior will be governed by the perception of risk and fear, and not by facts. Failure to manage the “infodemic”7—with its misinformation, contradictory messages, and rumors—jeopardizes infection control if patients become paralyzed by uncertainty and fear. Scapegoating occurs easily during times of threat, and society must contain the parallel epidemic of xenophobia based on stigma and misinformation.12

Decision-making under uncertainty is not perfect and subject to revision as better information becomes available. Pointing this out to the public is delicate but essential to curtail skepticism and mistrust when policies are adjusted in response to new circumstances and knowledge.

Mistrust of an authority’s legitimacy and fear-based decisions lead to lack of cooperation with public-health measures, which can undermine an effective response to the pandemic. Travel restrictions or quarantine measures will not be followed if individuals question their importance. Like the general public, patients need education and clear communication to address their fear of contagion, dangers posed to family (and pets), and mistrust of authority and government. A lack of appreciation of the seriousness of the pandemic and individual responsibility may need to be addressed. Two important measures to accomplish this are steering patients to reputable sources of information and advising that they limit media exposure.

Resilience-building. Community and workplace resilience are important aspects of making it through a disaster as best as possible. Resilience is not innate and fixed; it must be deliberately built.13 Choosing an attitude of post-traumatic growth over the victim narrative is a helpful stance. Practicing self-care (rest, nutrition, exercise) and self-compassion (self-kindness, common humanity, mindfulness) is good advice for patients and caregivers alike.

Continue to: Workforce protection

 

 

Workforce protection. Compared to other disasters, infectious outbreaks disproportionally affect the medical community, and care delivery is at stake. While psychological and psychiatric needs may increase during a pandemic, services often contract, day programs and clinics close, teams are reduced to skeleton crews, and only emergency psychiatric care is available. Workforce protection is critical to avoid illness or simple absenteeism due to mistrust of protective measures.

Only a well-briefed, well-led, well-supported, and adequately resourced workforce is going to be effective in managing this public-health emergency. Burnout and moral injury are feared long-term consequences for health care workers that need to be proactively addressed.14 As opposed to other forms of disasters, managing your own fears about safety is important. Clinicians and their patients sit in the proverbial same boat.

Ethics. The anticipated need to ration life-saving care (eg, ventilators) has been at the forefront of ethical concerns.15 In psychiatry, the question of involuntary public-health interventions for uncooperative psychiatric patients sits uncomfortably between public-health ethics and human rights, and is an opportunity for collaboration with public-health and infectious-disease colleagues.

Redeployed clinicians and those working under substandard conditions may be concerned about civil liability due to a modified standard of care during a crisis. Some clinicians may ask if their duty to care must override their natural instinct to protect themselves. There is a lot of room for resentment in these circumstances. Redeployed or otherwise “conscripted” clinicians may resent administrators, especially those administering from the safety of their homes. Those “left behind” to work in potentially precarious circumstances may resent their absent colleagues. Moreover, these front-line clinicians may have been forced to make ethical decisions for which they were not prepared.16 Maintaining morale is far from trivial, not just during the pandemic, but afterward, when (and if) the entire workforce is reunited. All parties need to be mindful of how their actions and decisions impact and are perceived by others, both in the hospital and at home.

Managing patients with SMI during COVID-19

Patients with SMI are potentially hard hit by COVID-19 due to a “tragic” epidemiologic triad of agent-host-environment: SARS-CoV-2 is a highly infectious agent affecting patients with SMI who are vulnerable hosts in permissive environments (Figure).

‘Tragic’ epidemiologic triad for patients with SMI

Continue to: While not as infectious as measles...

 

 

While not as infectious as measles, COVID-19 is more infectious than the seasonal flu virus.17 It can lead to uncontrolled infection within a short period of time, particularly in enclosed settings. Outbreaks have occurred readily on cruise ships and aircraft carriers as well as in nursing homes, homeless shelters, prisons, and group homes.

Patients with SMI are vulnerable hosts because they have many of the medical risk factors18 that portend a poor prognosis if they become infected, including pre-existing lung conditions and heart disease19 as well as diabetes and obesity.20 Obesity likely creates a hyperinflammatory state and a decrease in vital capacity. Patient-related behavioral factors include poor early-symptom reporting and ineffective infection control.

Unfavorable social determinants of health include not only poverty but crowded housing that is a perfect incubator for COVID-19.

Priority treatment goals. The overarching goal during a pandemic is to keep patients with SMI in psychiatric treatment and prevent them from disengaging from care in the service of infection control. Urgent tasks include infection control, relapse prevention, and preventing treatment disengagement and loneliness.

Infection control. As trusted sources of information, psychiatrists can play an important role in infection control in several important ways:

  • educating patients about infection-control measures and public-health recommendations
  • helping patients understand what testing can accomplish and when to pursue it
  • encouraging protective health behaviors (eg, hand washing, mask wearing, physical distancing)
  • assessing patients’ risk appreciation
  • assessing for and addressing obstacles to implementing and complying with infection-control measures
  • explaining contact tracing
  • providing reassurance.

Continue to: Materials and explanations...

 

 

Materials and explanations must be adapted for patient understanding.

Patients with disorganization or cognitive disturbances may have difficulties cooperating or problem-solving. Patients with negative symptoms may be inappropriately unconcerned and also inaccurately report symptoms that suggest COVID-19. Acute psychosis or mania can prevent patients from complying with public-health efforts. Some measures may be difficult to implement if the means are simply not there (eg, physical distancing in a crowded apartment). Previously open settings (eg, group homes) have had to develop new mechanisms under the primacy of infection control. Inpatient units—traditionally places where community, shared healing, and group therapy are prized—have had to decrease maximum occupancy, limit the number of patients attending groups, and discourage or outrightly prohibit social interaction (eg, dining together).

Relapse prevention. Patients who take maintenance medications need to be supported. A manic or psychotic relapse during a pandemic puts patients at risk of acquiring and spreading COVID-19. “Treatment as prevention” is a slogan from human immunodeficiency virus (HIV) care that captures the importance of antiretroviral treatment to prevent medical complications from HIV, and also to reduce infecting other people. By analogy, psychiatric treatment for patients with SMI can prevent psychiatric instability and thereby control viral transmission. Avoiding sending psychiatric patients to a potentially stressed acute-care system is important.

Psychosocial support. Clinics need to ensure that patients continue to engage in care beyond medication-taking to proactively prevent psychiatric exacerbations. Healthful, resilience-building behaviors should be encouraged while monitoring and counseling against maladaptive ones (eg, increased substance use). Supporting patients emotionally and helping them solve problems are critical, particularly for those who are subjected to quarantine or isolation. Obviously, in these latter situations, outreach will be necessary and may require creative delivery systems and dedicated clinicians for patients who lack access to the technology necessary for virtual visits. Havens and Ghaemi21 have suggested that a good therapeutic alliance can be viewed as a mood stabilizer. Helping patients grieve losses (loved ones, jobs, sense of safety) may be an important part of support.

Even before COVID-19, loneliness was a major factor for patients with schizophrenia.22 A psychiatric clinic is one aspect of a person with SMI’s social network; during the initial phase of the pandemic, many clinics and treatment programs closed. Patients for whom clinics structure and anchor their activities are at high risk of disconnecting from treatment, staying at home, and becoming lonely.

Continue to: Caregivers are always important...

 

 

Caregivers are always important to SMI patients, but they may assume an even bigger role during this pandemic. Some patients may have moved in with a relative, after years of living on their own. In other cases, stable caregiver relationships may be disrupted due to COVID-19–related sickness in the caregiver; if not addressed, this can result in a patient’s clinical decompensation. Clinicians should take the opportunity to understand who a patient’s caregivers are (group home staff, families) and rekindle clinical contact with them. Relationships with caregivers that may have been on “autopilot” during normal times are opportunities for welcome support and guidance, to the benefit of both patients and caregivers.

Table 1 summarizes clinical tasks that need to be kept in mind when conducting clinic visits during COVID-19 in order to achieve the high-priority treatment goals of infection control, relapse prevention, and psychosocial support.

Clinical tasks for patients with SMI during the COVID-19 pandemic

Differential diagnosis. Neuropsychiatric syndromes have long been observed in influenza pandemics,23 due both to direct viral effects and to the effects of critical illness on the brain. Two core symptoms of COVID-19—anosmia and ageusia—suggest that COVID-19 can directly affect the brain. While neurologic manifestations are common,24 it remains unclear to what extent COVID-19 can directly “cause” psychiatric symptoms, or if such symptoms are the result of cytokines25 or other medical processes (eg, thromboembolism).26 Psychosis due to COVID-19 may, in some cases, represent a stress-related brief psychotic disorder.27

Hospitalized patients who have recovered from COVID-19 may have experienced prolonged sedation and severe delirium in an ICU.28 Complications such as posttraumatic stress disorder,29 hypoperfusion-related brain injuries, or other long-term cognitive difficulties may result. In previous flu epidemics, patients developed serious neurologic complications such as post-encephalitic Parkinson’s disease.30

Any person subjected to isolation or quarantine is at risk for psychiatric complications.31 Patients with SMI who live in group homes may be particularly susceptible to new rules, including no-visitor policies.

Continue to: Outpatients whose primary disorder...

 

 

Outpatients whose primary disorder is well controlled may, like anyone else, struggle with the effects of the pandemic. It is necessary to carefully differentiate non-specific symptoms associated with stress from the emergence of a new disorder resulting from stress.32 For some patients, grief or adjustment disorders should be considered. Prolonged stress and uncertainty may eventually lead to an exacerbation of a primary disorder, particularly if the situation (eg, financial loss) does not improve or worsens. Demoralization and suicidal thinking need to be monitored. Relapse or increased use of alcohol or other substances as a response to stress may also complicate the clinical picture.33 Last, smoking cessation as a major treatment goal in general should be re-emphasized and not ignored during the ongoing pandemic.34

Psychiatric symptoms in patients with SMI during the COVID-19 pandemic

Table 2 summarizes psychiatric symptoms that need to be considered when managing a patient with SMI during this pandemic.

Treatment tools

Psychopharmacology. Even though crisis-mode prescribing may be necessary, the safe use of psychotropics remains the goal of psychiatric prescribing. Access to medications becomes a larger consideration; for many patients, a 90-day supply may be indicated. Review of polypharmacy, including for pneumonia risk, should be undertaken. Preventing drooling (eg, from sedation, clozapine, extrapyramidal symptoms [EPS]) will decrease aspiration risk.

 

In general, treatment of psychiatric symptoms in a patient with COVID-19 follows usual guidelines. The best treatment for COVID-19 patients with delirium, however, remains to be established, particularly how to manage severe agitation.28 Pharmacodynamic and pharmacokinetic drug–drug interactions between psychotropics and antiviral treatments for COVID-19 (eg, QTc prolongation) can be expected and need to be reviewed.35 For stress-related anxiety, judicious pharmacotherapy can be helpful. Diazepam given at the earliest signs of a psychotic relapse may stave off a relapse for patients with schizophrenia.36 Even if permitted under relaxed prescribing rules during a public-health emergency, prescribing controlled substances without seeing patients in person requires additional thought. In some cases, adjusting the primary medication to buffer against stress may be preferred (eg, adjusting an antipsychotic in a patient on maintenance treatment for schizophrenia, particularly if a low-dose strategy is pursued).

Consensus statement on the use of clozapine during the COVID-19 pandemic

Clozapine requires registry-based prescribing and bloodwork (“no blood, no drug”). The use of clozapine during this public-health emergency has been made easier because of FDA guidance that allows clozapine to be dispensed without blood work if obtaining blood work is not possible (eg, a patient is quarantined) or can be accomplished only at substantial risk to patients and the population at large. Under certain conditions, clozapine can be dispensed safely and in a way that is consistent with infection prevention. Clozapine-treated patients admitted with COVID-19 should be monitored for clozapine toxicity and the clozapine dose adjusted.37 A consensus statement consistent with the FDA and clinical considerations for using clozapine during COVID-19 is summarized in Table 3.38

Continue to: Long-acting injectable antipsychotics...

 

 

Long-acting injectable antipsychotics (LAIs) pose a problem because they require in-person visits. Ideally, during a pandemic, patients should be seen in person as frequently as medically necessary but as infrequently as possible to limit exposure of both patients and staff. Table 4 provides some clinical recommendations on how to use LAIs during the pandemic.39

Use of long-acting injectable antipsychotics during the COVID-19 pandemic

Supportive psychotherapy may be the most important tool we have in helping patients with loss and uncertainty during these challenging months.40 Simply staying in contact with patients plays a major role in preventing care discontinuity. Even routine interactions have become stressful, with everyone wearing a mask that partially obscures the face. People with impaired hearing may find it even more difficult to understand you.

Education, problem-solving, and a directive, encouraging style are major tools of supportive psychotherapy to reduce symptoms and increase adaptive skills. Clarify that social distancing refers to physical, not emotional, distancing. The judicious and temporary use of anxiolytics is appropriate to reduce anxiety. Concrete help and problem-solving (eg, filling out forms) are examples of proactive crisis intervention.

Telepsychiatry emerged in the pandemic’s early days as the default mode of practice in order to limit in-person contacts.41 Like all new technology, telepsychiatry brings progress and peril.42 While it has gone surprisingly well for most, the “digital divide” does not afford all patients access to the needed technology. The long-term effectiveness and acceptance of telehealth remain to be seen. (Editor’s Note: For more about this topic, see “Telepsychiatry: What you need to know.” Current Psychiatry. 2020;19[6]:16-23.)

Lessons learned and outlook

Infectious outbreaks have historically inflicted long-term disruptions on societies and altered the course of history. However, each disaster is unique, and lessons from previous disasters may only partially apply.43 We do not yet know how this one will end, including how long it will take for the world’s economies to recover. If nothing else, the current public-health emergency has brought to the forefront what psychiatrists have always known: health disparities are partially responsible for different disease risks (in this case, the risk of getting infected with SARS-CoV-2).5 It may not be a coincidence that the Black Lives Matter movement is becoming a major impetus for social change at a time when the pandemic is exposing health-care inequalities.

Continue to: Some areas of the country...

 

 

Some areas of the country succeeded in reducing infections and limiting community spread, which ushered in an uneasy sense of normalcy even while the pandemic continues. At least for now, these locales can focus on rebuilding and preparing for expectable fluctuations in disease activity, including the arrival of the annual flu season on top of COVID-19.44 Recovery is not a return to the status quo ante but building stronger communities—“building back better.”45 Unless there is a continuum of care, shortcomings in one sector will have ripple effects through the entire system, particularly for psychiatric care for patients with SMI, which was inadequate before the pandemic.

Ensuring access to critical care was a priority during the pandemic’s early phase but came at the price of deferring other types of care, such as routine primary care; the coming months will see the downstream consequences of this approach,46 including for patients with SMI.

In the meantime, doing our job as clinicians, as Camus’s fictitious Dr. Bernard Rieux from the epigraph responds when asked how to define decency, may be the best we can do in these times. This includes contributing to and molding our field’s future and fostering a sense of agency in our patients and in ourselves. Major goals will be to preserve lessons learned, maintain flexibility, and avoid a return to unhelpful overregulation and payment models that do not reflect the flexible, person-centered care so important for patients with SMI.47

Bottom Line

During a pandemic, patients with serious mental illness may be easily forgotten as other issues overshadow the needs of this impoverished group. During a pandemic, the priority treatment goals for these patients are infection control, relapse prevention, and preventing treatment disengagement and loneliness. A pandemic requires changes in how patients with serious mental illness will receive psychopharmacology and psychotherapy.

Related Resources

Drug Brand Names

Clozapine • Clozaril
Diazepam • Valium
Hydroxychloroquine • Plaquenil

“This whole thing is not about heroism. It’s about decency. It may seem a ridiculous idea, but the only way to fight the plague is with decency . ”

– Albert Camus, La Peste (1947)1

Severe acute respiratory syndrome (SARS), H1N1 swine flu, Ebola, Zika, and Middle East respiratory syndrome (MERS): the 21st century has already been witness to several serious infectious outbreaks and pandemics,2 but none has been as deadly and consequential as the current one. The ongoing SARS-coronavirus-2 (SARS-CoV-2) pandemic is shaping not only current psychiatric care but the future of psychiatry. Now that we are beyond the initial stages of the coronavirus disease 2019 (COVID-19) pandemic, when psychiatrists had a crash course in disaster psychiatry, our attention must shift to rebuilding and managing disillusionment and other psychological fallout of the intense early days.3

In this article, we offer guidance to psychiatrists caring for patients with serious mental illness (SMI) during the SARS-CoV-2 pandemic. Patients with SMI are easily forgotten as other issues (eg, preserving ICU capacity) overshadow the already historically neglected needs of this impoverished group.4 From both human and public-health perspectives, this inattention is a mistake. Assuring psychiatric stability is critically important to prevent the spread of COVID-19 in marginalized communities comprised of individuals who are poor, members of racial minorities, and others who already experience health disparities.5 Without controlling transmission in these groups, the pandemic will not be sufficiently contained.

We begin by highlighting general principles of pandemic management because caring for patients with SMI does not occur in a vacuum. Infectious outbreaks require not only helping those who need direct medical care because they are infected, but also managing populations that are at risk of getting infected, including health care and other essential workers.

Principles of pandemic management

Delivery of medical care during a pandemic differs from routine care. An effective disaster response requires collaboration and coordination among public-health, treatment, and emergency systems. Many institutions shift to an incident management system and crisis leadership, with clear lines of authority to coordinate responders and build medical surge capacity. Such a top-down leadership approach must plan and allow for the emergence of other credible leaders and for the restoration of people’s agency.

Unfortunately, adaptive capacity may be limited, especially in the public sector and psychiatric care system, where resources are already poor. Particularly early in a pandemic, services considered non-essential—which includes most psychiatric outpatient care—can become unavailable. A major effort is needed to prevent the psychiatric care system from contracting further, as happened during 9/11.6 Additionally, “essential” cannot be conflated with “emergent,” as can easily occur in extreme circumstances. Early and sustained efforts are required to ensure that patients with SMI who may be teetering on the edge of emergency status do not slip off that edge, especially when the emergency medical system is operating over capacity.

A comprehensive outbreak response must consider that a pandemic is not only a medical crisis but a mental health crisis and a communication emergency.7 Mental health clinicians need to provide accurate information and help patients cope with their fears.

Continue to: Psychological aspects of pandemics

 

 

Psychological aspects of pandemics. Previous infectious outbreaks have reaffirmed that mental health plays an outsized role during epidemics. Chaos, uncertainty, fear of death, and loss of income and housing cause prolonged stress and exact a psychological toll.

Adverse psychological impacts include expectable, normal reactions such as stress-induced anxiety or insomnia. In addition, new-onset psychiatric illnesses or exacerbations of existing ones may emerge.8 As disillusionment and demoralization appear in the wake of the acute phase, with persistently high unemployment, suicide prevention becomes an important goal.9

Pandemics lead to expectable behavioral responses (eg, increases in substance use and interpersonal conflict). Fear-based decisions may result in unhelpful behavior, such as hoarding medications (which may result in shortages) or dangerous, unsupervised use of unproven medications (eg, hydroxychloroquine). Trust is needed to accept public-health measures, and recommendations (eg, wearing masks) must be culturally informed to be credible and effective.

Because people are affected differently, at individual, cultural, and socioeconomic levels, they will view the situation differently. For many people, secondary stressors (eg, job loss) may be more disastrous than the primary medical event (ie, the pandemic). This distinction is critical because concrete financial help, not psychiatric care, is needed. Sometimes, even when a psychiatric disorder such as SMI or major neurocognitive disorder is present, the illusion of an acute decompensation can be created by the loss of social and structural supports that previously scaffolded a person’s life.

Mental illness prevention. Community mental-health surveillance is important to monitor for distress, psychiatric symptoms, health-risk behaviors, risk and safety perception, and preparedness. Clinicians must be ready to normalize expectable and temporary distress, while recognizing when that distress becomes pathological. This may be difficult in patients with SMI who often already have reduced stress tolerance or problem-based coping skills.10

Continue to: Psychological first aid...

 

 

Psychological first aid (PFA) is a standard intervention recommended by the World Health Organization for most individuals following a disaster; it is evidence-informed and has face validity.11 Intended to relieve distress by creating an environment that is safe, calm, and connected, PFA fosters self-efficacy and hope. While PFA is a form of universal prevention, it is not designed for patients with SMI, is not a psychiatric intervention, and is not provided by clinicians. Its principles, however, can easily be applied to patients with SMI to prevent distressing symptoms from becoming a relapse.

Communication. Good risk and crisis communication are critical because individual and population behavior will be governed by the perception of risk and fear, and not by facts. Failure to manage the “infodemic”7—with its misinformation, contradictory messages, and rumors—jeopardizes infection control if patients become paralyzed by uncertainty and fear. Scapegoating occurs easily during times of threat, and society must contain the parallel epidemic of xenophobia based on stigma and misinformation.12

Decision-making under uncertainty is not perfect and subject to revision as better information becomes available. Pointing this out to the public is delicate but essential to curtail skepticism and mistrust when policies are adjusted in response to new circumstances and knowledge.

Mistrust of an authority’s legitimacy and fear-based decisions lead to lack of cooperation with public-health measures, which can undermine an effective response to the pandemic. Travel restrictions or quarantine measures will not be followed if individuals question their importance. Like the general public, patients need education and clear communication to address their fear of contagion, dangers posed to family (and pets), and mistrust of authority and government. A lack of appreciation of the seriousness of the pandemic and individual responsibility may need to be addressed. Two important measures to accomplish this are steering patients to reputable sources of information and advising that they limit media exposure.

Resilience-building. Community and workplace resilience are important aspects of making it through a disaster as best as possible. Resilience is not innate and fixed; it must be deliberately built.13 Choosing an attitude of post-traumatic growth over the victim narrative is a helpful stance. Practicing self-care (rest, nutrition, exercise) and self-compassion (self-kindness, common humanity, mindfulness) is good advice for patients and caregivers alike.

Continue to: Workforce protection

 

 

Workforce protection. Compared to other disasters, infectious outbreaks disproportionally affect the medical community, and care delivery is at stake. While psychological and psychiatric needs may increase during a pandemic, services often contract, day programs and clinics close, teams are reduced to skeleton crews, and only emergency psychiatric care is available. Workforce protection is critical to avoid illness or simple absenteeism due to mistrust of protective measures.

Only a well-briefed, well-led, well-supported, and adequately resourced workforce is going to be effective in managing this public-health emergency. Burnout and moral injury are feared long-term consequences for health care workers that need to be proactively addressed.14 As opposed to other forms of disasters, managing your own fears about safety is important. Clinicians and their patients sit in the proverbial same boat.

Ethics. The anticipated need to ration life-saving care (eg, ventilators) has been at the forefront of ethical concerns.15 In psychiatry, the question of involuntary public-health interventions for uncooperative psychiatric patients sits uncomfortably between public-health ethics and human rights, and is an opportunity for collaboration with public-health and infectious-disease colleagues.

Redeployed clinicians and those working under substandard conditions may be concerned about civil liability due to a modified standard of care during a crisis. Some clinicians may ask if their duty to care must override their natural instinct to protect themselves. There is a lot of room for resentment in these circumstances. Redeployed or otherwise “conscripted” clinicians may resent administrators, especially those administering from the safety of their homes. Those “left behind” to work in potentially precarious circumstances may resent their absent colleagues. Moreover, these front-line clinicians may have been forced to make ethical decisions for which they were not prepared.16 Maintaining morale is far from trivial, not just during the pandemic, but afterward, when (and if) the entire workforce is reunited. All parties need to be mindful of how their actions and decisions impact and are perceived by others, both in the hospital and at home.

Managing patients with SMI during COVID-19

Patients with SMI are potentially hard hit by COVID-19 due to a “tragic” epidemiologic triad of agent-host-environment: SARS-CoV-2 is a highly infectious agent affecting patients with SMI who are vulnerable hosts in permissive environments (Figure).

‘Tragic’ epidemiologic triad for patients with SMI

Continue to: While not as infectious as measles...

 

 

While not as infectious as measles, COVID-19 is more infectious than the seasonal flu virus.17 It can lead to uncontrolled infection within a short period of time, particularly in enclosed settings. Outbreaks have occurred readily on cruise ships and aircraft carriers as well as in nursing homes, homeless shelters, prisons, and group homes.

Patients with SMI are vulnerable hosts because they have many of the medical risk factors18 that portend a poor prognosis if they become infected, including pre-existing lung conditions and heart disease19 as well as diabetes and obesity.20 Obesity likely creates a hyperinflammatory state and a decrease in vital capacity. Patient-related behavioral factors include poor early-symptom reporting and ineffective infection control.

Unfavorable social determinants of health include not only poverty but crowded housing that is a perfect incubator for COVID-19.

Priority treatment goals. The overarching goal during a pandemic is to keep patients with SMI in psychiatric treatment and prevent them from disengaging from care in the service of infection control. Urgent tasks include infection control, relapse prevention, and preventing treatment disengagement and loneliness.

Infection control. As trusted sources of information, psychiatrists can play an important role in infection control in several important ways:

  • educating patients about infection-control measures and public-health recommendations
  • helping patients understand what testing can accomplish and when to pursue it
  • encouraging protective health behaviors (eg, hand washing, mask wearing, physical distancing)
  • assessing patients’ risk appreciation
  • assessing for and addressing obstacles to implementing and complying with infection-control measures
  • explaining contact tracing
  • providing reassurance.

Continue to: Materials and explanations...

 

 

Materials and explanations must be adapted for patient understanding.

Patients with disorganization or cognitive disturbances may have difficulties cooperating or problem-solving. Patients with negative symptoms may be inappropriately unconcerned and also inaccurately report symptoms that suggest COVID-19. Acute psychosis or mania can prevent patients from complying with public-health efforts. Some measures may be difficult to implement if the means are simply not there (eg, physical distancing in a crowded apartment). Previously open settings (eg, group homes) have had to develop new mechanisms under the primacy of infection control. Inpatient units—traditionally places where community, shared healing, and group therapy are prized—have had to decrease maximum occupancy, limit the number of patients attending groups, and discourage or outrightly prohibit social interaction (eg, dining together).

Relapse prevention. Patients who take maintenance medications need to be supported. A manic or psychotic relapse during a pandemic puts patients at risk of acquiring and spreading COVID-19. “Treatment as prevention” is a slogan from human immunodeficiency virus (HIV) care that captures the importance of antiretroviral treatment to prevent medical complications from HIV, and also to reduce infecting other people. By analogy, psychiatric treatment for patients with SMI can prevent psychiatric instability and thereby control viral transmission. Avoiding sending psychiatric patients to a potentially stressed acute-care system is important.

Psychosocial support. Clinics need to ensure that patients continue to engage in care beyond medication-taking to proactively prevent psychiatric exacerbations. Healthful, resilience-building behaviors should be encouraged while monitoring and counseling against maladaptive ones (eg, increased substance use). Supporting patients emotionally and helping them solve problems are critical, particularly for those who are subjected to quarantine or isolation. Obviously, in these latter situations, outreach will be necessary and may require creative delivery systems and dedicated clinicians for patients who lack access to the technology necessary for virtual visits. Havens and Ghaemi21 have suggested that a good therapeutic alliance can be viewed as a mood stabilizer. Helping patients grieve losses (loved ones, jobs, sense of safety) may be an important part of support.

Even before COVID-19, loneliness was a major factor for patients with schizophrenia.22 A psychiatric clinic is one aspect of a person with SMI’s social network; during the initial phase of the pandemic, many clinics and treatment programs closed. Patients for whom clinics structure and anchor their activities are at high risk of disconnecting from treatment, staying at home, and becoming lonely.

Continue to: Caregivers are always important...

 

 

Caregivers are always important to SMI patients, but they may assume an even bigger role during this pandemic. Some patients may have moved in with a relative, after years of living on their own. In other cases, stable caregiver relationships may be disrupted due to COVID-19–related sickness in the caregiver; if not addressed, this can result in a patient’s clinical decompensation. Clinicians should take the opportunity to understand who a patient’s caregivers are (group home staff, families) and rekindle clinical contact with them. Relationships with caregivers that may have been on “autopilot” during normal times are opportunities for welcome support and guidance, to the benefit of both patients and caregivers.

Table 1 summarizes clinical tasks that need to be kept in mind when conducting clinic visits during COVID-19 in order to achieve the high-priority treatment goals of infection control, relapse prevention, and psychosocial support.

Clinical tasks for patients with SMI during the COVID-19 pandemic

Differential diagnosis. Neuropsychiatric syndromes have long been observed in influenza pandemics,23 due both to direct viral effects and to the effects of critical illness on the brain. Two core symptoms of COVID-19—anosmia and ageusia—suggest that COVID-19 can directly affect the brain. While neurologic manifestations are common,24 it remains unclear to what extent COVID-19 can directly “cause” psychiatric symptoms, or if such symptoms are the result of cytokines25 or other medical processes (eg, thromboembolism).26 Psychosis due to COVID-19 may, in some cases, represent a stress-related brief psychotic disorder.27

Hospitalized patients who have recovered from COVID-19 may have experienced prolonged sedation and severe delirium in an ICU.28 Complications such as posttraumatic stress disorder,29 hypoperfusion-related brain injuries, or other long-term cognitive difficulties may result. In previous flu epidemics, patients developed serious neurologic complications such as post-encephalitic Parkinson’s disease.30

Any person subjected to isolation or quarantine is at risk for psychiatric complications.31 Patients with SMI who live in group homes may be particularly susceptible to new rules, including no-visitor policies.

Continue to: Outpatients whose primary disorder...

 

 

Outpatients whose primary disorder is well controlled may, like anyone else, struggle with the effects of the pandemic. It is necessary to carefully differentiate non-specific symptoms associated with stress from the emergence of a new disorder resulting from stress.32 For some patients, grief or adjustment disorders should be considered. Prolonged stress and uncertainty may eventually lead to an exacerbation of a primary disorder, particularly if the situation (eg, financial loss) does not improve or worsens. Demoralization and suicidal thinking need to be monitored. Relapse or increased use of alcohol or other substances as a response to stress may also complicate the clinical picture.33 Last, smoking cessation as a major treatment goal in general should be re-emphasized and not ignored during the ongoing pandemic.34

Psychiatric symptoms in patients with SMI during the COVID-19 pandemic

Table 2 summarizes psychiatric symptoms that need to be considered when managing a patient with SMI during this pandemic.

Treatment tools

Psychopharmacology. Even though crisis-mode prescribing may be necessary, the safe use of psychotropics remains the goal of psychiatric prescribing. Access to medications becomes a larger consideration; for many patients, a 90-day supply may be indicated. Review of polypharmacy, including for pneumonia risk, should be undertaken. Preventing drooling (eg, from sedation, clozapine, extrapyramidal symptoms [EPS]) will decrease aspiration risk.

 

In general, treatment of psychiatric symptoms in a patient with COVID-19 follows usual guidelines. The best treatment for COVID-19 patients with delirium, however, remains to be established, particularly how to manage severe agitation.28 Pharmacodynamic and pharmacokinetic drug–drug interactions between psychotropics and antiviral treatments for COVID-19 (eg, QTc prolongation) can be expected and need to be reviewed.35 For stress-related anxiety, judicious pharmacotherapy can be helpful. Diazepam given at the earliest signs of a psychotic relapse may stave off a relapse for patients with schizophrenia.36 Even if permitted under relaxed prescribing rules during a public-health emergency, prescribing controlled substances without seeing patients in person requires additional thought. In some cases, adjusting the primary medication to buffer against stress may be preferred (eg, adjusting an antipsychotic in a patient on maintenance treatment for schizophrenia, particularly if a low-dose strategy is pursued).

Consensus statement on the use of clozapine during the COVID-19 pandemic

Clozapine requires registry-based prescribing and bloodwork (“no blood, no drug”). The use of clozapine during this public-health emergency has been made easier because of FDA guidance that allows clozapine to be dispensed without blood work if obtaining blood work is not possible (eg, a patient is quarantined) or can be accomplished only at substantial risk to patients and the population at large. Under certain conditions, clozapine can be dispensed safely and in a way that is consistent with infection prevention. Clozapine-treated patients admitted with COVID-19 should be monitored for clozapine toxicity and the clozapine dose adjusted.37 A consensus statement consistent with the FDA and clinical considerations for using clozapine during COVID-19 is summarized in Table 3.38

Continue to: Long-acting injectable antipsychotics...

 

 

Long-acting injectable antipsychotics (LAIs) pose a problem because they require in-person visits. Ideally, during a pandemic, patients should be seen in person as frequently as medically necessary but as infrequently as possible to limit exposure of both patients and staff. Table 4 provides some clinical recommendations on how to use LAIs during the pandemic.39

Use of long-acting injectable antipsychotics during the COVID-19 pandemic

Supportive psychotherapy may be the most important tool we have in helping patients with loss and uncertainty during these challenging months.40 Simply staying in contact with patients plays a major role in preventing care discontinuity. Even routine interactions have become stressful, with everyone wearing a mask that partially obscures the face. People with impaired hearing may find it even more difficult to understand you.

Education, problem-solving, and a directive, encouraging style are major tools of supportive psychotherapy to reduce symptoms and increase adaptive skills. Clarify that social distancing refers to physical, not emotional, distancing. The judicious and temporary use of anxiolytics is appropriate to reduce anxiety. Concrete help and problem-solving (eg, filling out forms) are examples of proactive crisis intervention.

Telepsychiatry emerged in the pandemic’s early days as the default mode of practice in order to limit in-person contacts.41 Like all new technology, telepsychiatry brings progress and peril.42 While it has gone surprisingly well for most, the “digital divide” does not afford all patients access to the needed technology. The long-term effectiveness and acceptance of telehealth remain to be seen. (Editor’s Note: For more about this topic, see “Telepsychiatry: What you need to know.” Current Psychiatry. 2020;19[6]:16-23.)

Lessons learned and outlook

Infectious outbreaks have historically inflicted long-term disruptions on societies and altered the course of history. However, each disaster is unique, and lessons from previous disasters may only partially apply.43 We do not yet know how this one will end, including how long it will take for the world’s economies to recover. If nothing else, the current public-health emergency has brought to the forefront what psychiatrists have always known: health disparities are partially responsible for different disease risks (in this case, the risk of getting infected with SARS-CoV-2).5 It may not be a coincidence that the Black Lives Matter movement is becoming a major impetus for social change at a time when the pandemic is exposing health-care inequalities.

Continue to: Some areas of the country...

 

 

Some areas of the country succeeded in reducing infections and limiting community spread, which ushered in an uneasy sense of normalcy even while the pandemic continues. At least for now, these locales can focus on rebuilding and preparing for expectable fluctuations in disease activity, including the arrival of the annual flu season on top of COVID-19.44 Recovery is not a return to the status quo ante but building stronger communities—“building back better.”45 Unless there is a continuum of care, shortcomings in one sector will have ripple effects through the entire system, particularly for psychiatric care for patients with SMI, which was inadequate before the pandemic.

Ensuring access to critical care was a priority during the pandemic’s early phase but came at the price of deferring other types of care, such as routine primary care; the coming months will see the downstream consequences of this approach,46 including for patients with SMI.

In the meantime, doing our job as clinicians, as Camus’s fictitious Dr. Bernard Rieux from the epigraph responds when asked how to define decency, may be the best we can do in these times. This includes contributing to and molding our field’s future and fostering a sense of agency in our patients and in ourselves. Major goals will be to preserve lessons learned, maintain flexibility, and avoid a return to unhelpful overregulation and payment models that do not reflect the flexible, person-centered care so important for patients with SMI.47

Bottom Line

During a pandemic, patients with serious mental illness may be easily forgotten as other issues overshadow the needs of this impoverished group. During a pandemic, the priority treatment goals for these patients are infection control, relapse prevention, and preventing treatment disengagement and loneliness. A pandemic requires changes in how patients with serious mental illness will receive psychopharmacology and psychotherapy.

Related Resources

Drug Brand Names

Clozapine • Clozaril
Diazepam • Valium
Hydroxychloroquine • Plaquenil

References

1. Camus A. La peste. Paris, France: Éditions Gallimard; 1947.
2. Huremovic´ D. Brief history of pandemics (pandemics throughout history). In: Huremovic´ D (ed). Psychiatry of pandemics: a mental health response to infection outbreak. Cham, Switzerland: Springer Nature Switzerland AG; 2019:7-35.
3. Substance Abuse and Mental Health Services Administration. Phases of disaster. https://www.samhsa.gov/dtac/recovering-disasters/phases-disaster. Updated June 17, 2020. Accessed August 7, 2020.
4. Geller J. COVID-19 and advocacy—the good and the unacceptable. Psychiatric News. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2020.5b13. Published May 7, 2020. Accessed August 7, 2020.
5. Webb Hooper M, Nápoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466-2467.
6. Sederer LI, Lanzara CB, Essock SM, et al. Lessons learned from the New York State mental health response to the September 11, 2001, attacks. Psychiatr Serv. 2011;62(9):1085-1089.
7. World Health Organization. Infodemic management – infodemiology. https://www.who.int/teams/risk-communication/infodemic-management. Accessed August 7, 2020.
8. Zhou J, Liu L, Xue P, et al. Mental health response to the COVID-19 outbreak in China. Am J Psychiatry. 2020;117(7):574-575.
9. Kawohl W, Nordt C. COVID-19, unemployment, and suicide. Lancet Psychiatry. 2020;7(5):389-390.
10. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. doi: 10.1016/S2215-0366(20)30090-0.
11. Minihan E, Gavin B, Kelly BD, et al. Covid-19, mental health and psychological first aid. Ir J Psychol Med. 2020:1-12.
12. Adja KYC, Golinelli D, Lenzi J, et al. Pandemics and social stigma: who’s next? Italy’s experience with COVID-19. Public Health. 2020;185:39-41.
13. Rosenberg AR. Cultivating deliberate resilience during the coronavirus disease 2019 pandemic [published online April 14, 2020]. JAMA Pediatr. doi: 10.1001/jamapediatrics.2020.1436.
14. Dean W, Talbot SG, Caplan A. Clarifying the language of clinician distress [published online January 31, 2020]. JAMA. doi: 10.1001/jama.2019.21576.
15. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049-2055.
16. Rosenbaum L. Facing Covid-19 in Italy - ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med. 2020;382(20):1873-1875.
17. Viceconte G, Petrosillo N. COVID-19 R0: magic number or conundrum? Infect Dis Rep. 2020;12(1):8516.
18. de Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15-22.
19. Chen R, Liang W, Jiang M, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158(1):97-105.
20. Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020;10(3):e12365. doi: 10.1111/cob.12365.
21. Havens LL, Ghaemi SN. Existential despair and bipolar disorder: the therapeutic alliance as a mood stabilizer. Am J Psychother. 2005;59(2):137-147.
22. Trémeau F, Antonius D, Malaspina D, et al. Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Res. 2016;246:211-217.
23. Menninger KA. Psychoses associated with influenza: I. General data: statistical analysis. JAMA. 1919;72(4):235-241.
24. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832. doi: 10.1016/j.jns.2020.116832.
25. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? [published online May 19, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.012.
26. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39.
27. Martin Jr. EB. Brief psychotic disorder triggered by fear of coronavirus? Psychiatric Times. https://www.psychiatrictimes.com/view/brief-psychotic-disorder-triggered-fear-coronavirus-small-case-series. Published May 8, 2020. Accessed August 7, 2020.
28. Sher Y, Rabkin B, Maldonado JR, et al. COVID-19-associated hyperactive intensive care unit delirium with proposed pathophysiology and treatment: a case report [published online May 19, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.007.
29. Wolters AE, Peelen LM, Welling MC, et al. Long-term mental health problems after delirium in the ICU. Crit Care Med. 2016;44(10):1808-1813.
30. Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med Infect Dis. 2008;6(3):114-124.
31. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912-920.
32. Maercker A, Brewin CR, Bryant RA, et al. Diagnosis and classification of disorders specifically associated with stress: proposals for ICD-11. World Psychiatry. 2013;12(3):198-206.
33. Ornell F, Moura HF, Scherer JN, et al. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry Res. 2020;289:113096. doi: 10.1016/j.psychres.2020.113096.
34. Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking [published online April 3, 2020]. Nicotine Tob Res. https://doi.org/10.1093/ntr/ntaa059.
35. Back D, Marzolini C, Hodge C, et al. COVID-19 treatment in patients with comorbidities: awareness of drug-drug interactions [published online May 8, 2020]. Br J Clin Pharmacol. doi: 10.1111/bcp.14358.
36. Carpenter WT Jr., Buchanan RW, Kirkpatrick B, et al. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry. 1999;156(2):299-303.
37. Dotson S, Hartvigsen N, Wesner T, et al. Clozapine toxicity in the setting of COVID-19 [published online May 30, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.025.
38. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45(3):222-223.
39. Schnitzer K, MacLaurin S, Freudenreich O. Long-acting injectable antipsychotics during the COVID-19 pandemic. Current Psychiatry. In press.
40. Winston A, Rosenthal RN, Pinsker H. Learning supportive psychotherapy: an illustrated guide. Washington, DC: American Psychiatric Publishing; 2012.
41. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681.
42. Jordan A, Dixon LB. Considerations for telepsychiatry service implementation in the era of COVID-19. Psychiatr Serv. 2020;71(6):643-644.
43. DePierro J, Lowe S, Katz C. Lessons learned from 9/11: mental health perspectives on the COVID-19 pandemic. Psychiatry Res. 2020;288:113024.
44. Hussain S. Immunization and vaccination. In: Huremovic´ D (ed). Psychiatry of pandemics: a mental health response to infection outbreak. Cham, Switzerland: Springer Nature Switzerland AG; 2019.
45. Epping-Jordan JE, van Ommeren M, Ashour HN, et al. Beyond the crisis: building back better mental health care in 10 emergency-affected areas using a longer-term perspective. Int J Ment Health Syst. 2015;9:15.
46. Rosenbaum L. The untold toll - the pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368-2371.
47. Bartels SJ, Baggett TP, Freudenreich O, et al. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness [published online June 3, 2020]. Psychiatr Serv. doi: 10.1176/appi.ps.202000244.

References

1. Camus A. La peste. Paris, France: Éditions Gallimard; 1947.
2. Huremovic´ D. Brief history of pandemics (pandemics throughout history). In: Huremovic´ D (ed). Psychiatry of pandemics: a mental health response to infection outbreak. Cham, Switzerland: Springer Nature Switzerland AG; 2019:7-35.
3. Substance Abuse and Mental Health Services Administration. Phases of disaster. https://www.samhsa.gov/dtac/recovering-disasters/phases-disaster. Updated June 17, 2020. Accessed August 7, 2020.
4. Geller J. COVID-19 and advocacy—the good and the unacceptable. Psychiatric News. https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2020.5b13. Published May 7, 2020. Accessed August 7, 2020.
5. Webb Hooper M, Nápoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466-2467.
6. Sederer LI, Lanzara CB, Essock SM, et al. Lessons learned from the New York State mental health response to the September 11, 2001, attacks. Psychiatr Serv. 2011;62(9):1085-1089.
7. World Health Organization. Infodemic management – infodemiology. https://www.who.int/teams/risk-communication/infodemic-management. Accessed August 7, 2020.
8. Zhou J, Liu L, Xue P, et al. Mental health response to the COVID-19 outbreak in China. Am J Psychiatry. 2020;117(7):574-575.
9. Kawohl W, Nordt C. COVID-19, unemployment, and suicide. Lancet Psychiatry. 2020;7(5):389-390.
10. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. doi: 10.1016/S2215-0366(20)30090-0.
11. Minihan E, Gavin B, Kelly BD, et al. Covid-19, mental health and psychological first aid. Ir J Psychol Med. 2020:1-12.
12. Adja KYC, Golinelli D, Lenzi J, et al. Pandemics and social stigma: who’s next? Italy’s experience with COVID-19. Public Health. 2020;185:39-41.
13. Rosenberg AR. Cultivating deliberate resilience during the coronavirus disease 2019 pandemic [published online April 14, 2020]. JAMA Pediatr. doi: 10.1001/jamapediatrics.2020.1436.
14. Dean W, Talbot SG, Caplan A. Clarifying the language of clinician distress [published online January 31, 2020]. JAMA. doi: 10.1001/jama.2019.21576.
15. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049-2055.
16. Rosenbaum L. Facing Covid-19 in Italy - ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med. 2020;382(20):1873-1875.
17. Viceconte G, Petrosillo N. COVID-19 R0: magic number or conundrum? Infect Dis Rep. 2020;12(1):8516.
18. de Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15-22.
19. Chen R, Liang W, Jiang M, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158(1):97-105.
20. Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020;10(3):e12365. doi: 10.1111/cob.12365.
21. Havens LL, Ghaemi SN. Existential despair and bipolar disorder: the therapeutic alliance as a mood stabilizer. Am J Psychother. 2005;59(2):137-147.
22. Trémeau F, Antonius D, Malaspina D, et al. Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Res. 2016;246:211-217.
23. Menninger KA. Psychoses associated with influenza: I. General data: statistical analysis. JAMA. 1919;72(4):235-241.
24. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832. doi: 10.1016/j.jns.2020.116832.
25. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? [published online May 19, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.012.
26. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39.
27. Martin Jr. EB. Brief psychotic disorder triggered by fear of coronavirus? Psychiatric Times. https://www.psychiatrictimes.com/view/brief-psychotic-disorder-triggered-fear-coronavirus-small-case-series. Published May 8, 2020. Accessed August 7, 2020.
28. Sher Y, Rabkin B, Maldonado JR, et al. COVID-19-associated hyperactive intensive care unit delirium with proposed pathophysiology and treatment: a case report [published online May 19, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.007.
29. Wolters AE, Peelen LM, Welling MC, et al. Long-term mental health problems after delirium in the ICU. Crit Care Med. 2016;44(10):1808-1813.
30. Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med Infect Dis. 2008;6(3):114-124.
31. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912-920.
32. Maercker A, Brewin CR, Bryant RA, et al. Diagnosis and classification of disorders specifically associated with stress: proposals for ICD-11. World Psychiatry. 2013;12(3):198-206.
33. Ornell F, Moura HF, Scherer JN, et al. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry Res. 2020;289:113096. doi: 10.1016/j.psychres.2020.113096.
34. Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking [published online April 3, 2020]. Nicotine Tob Res. https://doi.org/10.1093/ntr/ntaa059.
35. Back D, Marzolini C, Hodge C, et al. COVID-19 treatment in patients with comorbidities: awareness of drug-drug interactions [published online May 8, 2020]. Br J Clin Pharmacol. doi: 10.1111/bcp.14358.
36. Carpenter WT Jr., Buchanan RW, Kirkpatrick B, et al. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry. 1999;156(2):299-303.
37. Dotson S, Hartvigsen N, Wesner T, et al. Clozapine toxicity in the setting of COVID-19 [published online May 30, 2020]. Psychosomatics. doi: 10.1016/j.psym.2020.05.025.
38. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45(3):222-223.
39. Schnitzer K, MacLaurin S, Freudenreich O. Long-acting injectable antipsychotics during the COVID-19 pandemic. Current Psychiatry. In press.
40. Winston A, Rosenthal RN, Pinsker H. Learning supportive psychotherapy: an illustrated guide. Washington, DC: American Psychiatric Publishing; 2012.
41. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681.
42. Jordan A, Dixon LB. Considerations for telepsychiatry service implementation in the era of COVID-19. Psychiatr Serv. 2020;71(6):643-644.
43. DePierro J, Lowe S, Katz C. Lessons learned from 9/11: mental health perspectives on the COVID-19 pandemic. Psychiatry Res. 2020;288:113024.
44. Hussain S. Immunization and vaccination. In: Huremovic´ D (ed). Psychiatry of pandemics: a mental health response to infection outbreak. Cham, Switzerland: Springer Nature Switzerland AG; 2019.
45. Epping-Jordan JE, van Ommeren M, Ashour HN, et al. Beyond the crisis: building back better mental health care in 10 emergency-affected areas using a longer-term perspective. Int J Ment Health Syst. 2015;9:15.
46. Rosenbaum L. The untold toll - the pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368-2371.
47. Bartels SJ, Baggett TP, Freudenreich O, et al. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness [published online June 3, 2020]. Psychiatr Serv. doi: 10.1176/appi.ps.202000244.

Issue
Current Psychiatry - 19(9)
Issue
Current Psychiatry - 19(9)
Page Number
24-27,33-39
Page Number
24-27,33-39
Publications
Publications
Topics
Article Type
Display Headline
COVID-19 and patients with serious mental illness
Display Headline
COVID-19 and patients with serious mental illness
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media